



Clinical trial results:

A long-term, randomised, double-blind, placebo-controlled, multinational, multi-centre trial to evaluate cardiovascular and other long-term outcomes with semaglutide in subjects with type 2 diabetes

Summary

| | |
|--------------------------|----------------------|
| EudraCT number | 2012-002839-28 |
| Trial protocol | GB ES BG DE DK PL IT |
| Global end of trial date | 15 March 2016 |

Results information

| | |
|--------------------------------|---------------|
| Result version number | v1 (current) |
| This version publication date | 31 March 2017 |
| First version publication date | 31 March 2017 |

Trial information

Trial identification

| | |
|-----------------------|-------------|
| Sponsor protocol code | NN9535-3744 |
|-----------------------|-------------|

Additional study identifiers

| | |
|------------------------------------|-----------------|
| ISRCTN number | - |
| ClinicalTrials.gov id (NCT number) | NCT01720446 |
| WHO universal trial number (UTN) | U1111-1131-7227 |

Notes:

Sponsors

| | |
|------------------------------|--|
| Sponsor organisation name | Novo Nordisk A/S |
| Sponsor organisation address | Novo Allé, Bagsvaerd, Denmark, 2880 |
| Public contact | Global Clinical Registry (GCR, 1452), Novo Nordisk A/S, clinicaltrials@novonordisk.com |
| Scientific contact | Global Clinical Registry (GCR, 1452), Novo Nordisk A/S, clinicaltrials@novonordisk.com |

Notes:

Paediatric regulatory details

| | |
|--|----|
| Is trial part of an agreed paediatric investigation plan (PIP) | No |
| Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial? | No |
| Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial? | No |

Notes:

Results analysis stage

| | |
|--|-----------------|
| Analysis stage | Final |
| Date of interim/final analysis | 24 October 2016 |
| Is this the analysis of the primary completion data? | Yes |
| Primary completion date | 15 March 2016 |
| Global end of trial reached? | Yes |
| Global end of trial date | 15 March 2016 |
| Was the trial ended prematurely? | No |

Notes:

General information about the trial

Main objective of the trial:

To confirm that treatment with semaglutide does not result in an unacceptable increase in cardiovascular risk as compared to placebo in adults with type 2 diabetes. This is done by demonstrating that the upper limit of the two-sided 95% confidence interval (CI) of the hazard ratio for semaglutide versus placebo is less than 1.8 when comparing time to first occurrence of a major adverse cardiovascular event (MACE).

Protection of trial subjects:

The trial was conducted in accordance with the Declaration of Helsinki, ICH Good Clinical Practice, EN ISO 14155 Part 1 and 2 and FDA 21 CFR 312.120.

Background therapy:

All participating subjects received the best standard-of-care in addition to the trial products and, to the extent possible, achieved optimal glycaemic control according to local standards (additional glucose lowering medications could be added to the anti-diabetic regimen at the discretion of investigator).

Evidence for comparator:

Not applicable

| | |
|---|------------------|
| Actual start date of recruitment | 21 February 2013 |
| Long term follow-up planned | No |
| Independent data monitoring committee (IDMC) involvement? | Yes |

Notes:

Population of trial subjects

Subjects enrolled per country

| | |
|--------------------------------------|---------------------|
| Country: Number of subjects enrolled | Argentina: 166 |
| Country: Number of subjects enrolled | Australia: 111 |
| Country: Number of subjects enrolled | Bulgaria: 101 |
| Country: Number of subjects enrolled | Brazil: 105 |
| Country: Number of subjects enrolled | Canada: 138 |
| Country: Number of subjects enrolled | Germany: 85 |
| Country: Number of subjects enrolled | Denmark: 66 |
| Country: Number of subjects enrolled | Algeria: 95 |
| Country: Number of subjects enrolled | Spain: 85 |
| Country: Number of subjects enrolled | United Kingdom: 117 |
| Country: Number of subjects enrolled | Israel: 100 |
| Country: Number of subjects enrolled | Italy: 80 |
| Country: Number of subjects enrolled | Mexico: 165 |
| Country: Number of subjects enrolled | Malaysia: 70 |
| Country: Number of subjects enrolled | Poland: 98 |

| | |
|--------------------------------------|-------------------------|
| Country: Number of subjects enrolled | Russian Federation: 294 |
| Country: Number of subjects enrolled | Thailand: 74 |
| Country: Number of subjects enrolled | Turkey: 128 |
| Country: Number of subjects enrolled | Taiwan: 82 |
| Country: Number of subjects enrolled | United States: 1137 |
| Worldwide total number of subjects | 3297 |
| EEA total number of subjects | 632 |

Notes:

| Subjects enrolled per age group | |
|---|------|
| In utero | 0 |
| Preterm newborn - gestational age < 37 wk | 0 |
| Newborns (0-27 days) | 0 |
| Infants and toddlers (28 days-23 months) | 0 |
| Children (2-11 years) | 0 |
| Adolescents (12-17 years) | 0 |
| Adults (18-64 years) | 1699 |
| From 65 to 84 years | 1578 |
| 85 years and over | 20 |

Subject disposition

Recruitment

Recruitment details:

The trial was conducted at 229 sites in 20 countries. Country (sites): Algeria (4), Argentina (7), Australia (8), Brazil (8), Bulgaria (5), Canada (13), Denmark (5), Germany (7), Israel (6), Italy (6), Malaysia (6), Mexico (9), Poland (5), Russia (11), Spain (6), Taiwan (4), Thailand (5), Turkey (10), United Kingdom (8) and United States (96).

Pre-assignment

Screening details:

The trial population was subjects with T2D with inadequate glycaemic control ($HbA1c \geq 7\%$) at high CV risk. The trial included subjects ≥ 50 years of age at screening with clinical evidence of CV disease and subjects ≥ 60 years of age at screening with subclinical evidence of CV disease.

Period 1

| | |
|------------------------------|--------------------------------|
| Period 1 title | Overall Study (overall period) |
| Is this the baseline period? | Yes |
| Allocation method | Randomised - controlled |
| Blinding used | Double blind |
| Roles blinded | Investigator, Monitor, Subject |

Arms

| | |
|------------------------------|--------------------|
| Are arms mutually exclusive? | Yes |
| Arm title | Semaglutide 0.5 mg |

Arm description:

Subjects received once-weekly dose of semaglutide 0.5 mg as an add-on to their standard-of-care treatment. Injections were administered subcutaneously in the thigh, abdomen or upper arm, at any time of day irrespective of meals. The injections were to be administered on the same weekday during the trial. Semaglutide was initiated at a dose of 0.25 mg and was escalated (doubled) to 0.5 mg after 4 weeks. Hence the target dose of 0.5 mg was achieved after 4 weeks of treatment. Each subject was treated for 104 weeks.

| | |
|--|--|
| Arm type | Experimental |
| Investigational medicinal product name | Semaglutide |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Solution for injection in pre-filled pen |
| Routes of administration | Subcutaneous use |

Dosage and administration details:

Semaglutide solution for injection (1.34 mg/mL in a 1.5 mL pre-filled PDS290 pen-injector) was administered in doses of 0.5 mg once-weekly as subcutaneous (s.c.) injections either in the thigh, abdomen or upper arm, at any time of day irrespective of meals. Subjects started with doses of 0.25 mg semaglutide. After 4 weeks of treatment, the dose was escalated (doubled). Hence, the target dose of 0.5 mg was achieved after 4 weeks of treatment.

| | |
|------------------|--------------------|
| Arm title | Semaglutide 1.0 mg |
|------------------|--------------------|

Arm description:

Subjects received once-weekly dose of semaglutide 1.0 mg as an add-on to their standard-of-care treatment. Injections were administered subcutaneously in the thigh, abdomen or upper arm, at any time of day irrespective of meals. The injections were to be administered on the same weekday during the trial. Semaglutide was initiated at a dose of 0.25 mg and was escalated (doubled) to 0.5 mg after 4 weeks. Hence the target dose of 1.0 mg was achieved after 8 weeks of treatment. Each subject was treated for 104 weeks.

| | |
|----------|--------------|
| Arm type | Experimental |
|----------|--------------|

| | |
|--|--|
| Investigational medicinal product name | Semaglutide |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Solution for injection in pre-filled pen |
| Routes of administration | Subcutaneous use |

Dosage and administration details:

Semaglutide solution for injection (1.34 mg/mL in a 1.5 mL pre-filled PDS290 pen-injector) was administered in doses of 1.0 mg once-weekly as subcutaneous (s.c.) injections either in the thigh, abdomen or upper arm, at any time of day irrespective of meals. Subjects started with doses of 0.25 mg semaglutide. After 4 weeks of treatment, the dose was escalated (doubled). Hence, the target dose of 1.0 mg was achieved after 8 weeks of treatment.

| | |
|------------------|----------------|
| Arm title | Placebo 0.5 mg |
|------------------|----------------|

Arm description:

Subjects received once-weekly dose of placebo 0.5 mg as an add-on to their standard-of-care treatment. Injections were administered subcutaneously in the thigh, abdomen or upper arm, at any time of day irrespective of meals. The injections were to be administered on the same weekday during the trial. Semaglutide was initiated at a dose of 0.25 mg and was escalated (doubled) to 0.5 mg after 4 weeks. Hence the target dose of 0.5 mg was achieved after 4 weeks of treatment. Each subject was treated for 104 weeks.

| | |
|--|--|
| Arm type | Placebo |
| Investigational medicinal product name | Placebo |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Solution for injection in pre-filled pen |
| Routes of administration | Subcutaneous use |

Dosage and administration details:

The composition of the placebo corresponded to that of semaglutide drug product but with absence of the active pharmaceutical ingredient. Placebo solution for injection (1.34 mg/mL in a 1.5 mL pre-filled PDS290 pen-injector) was administered in doses of 0.5 mg once-weekly as subcutaneous (s.c.) injections either in the thigh, abdomen or upper arm, at any time of day irrespective of meals. Subjects started with doses of 0.25 mg semaglutide. After 4 weeks of treatment, the dose was escalated (doubled). Hence, the target dose of 0.5 mg was achieved after 4 weeks of treatment.

| | |
|------------------|----------------|
| Arm title | Placebo 1.0 mg |
|------------------|----------------|

Arm description:

Subjects received once-weekly dose of placebo 1.0 mg as an add-on to their standard-of-care treatment. Injections were administered subcutaneously in the thigh, abdomen or upper arm, at any time of day irrespective of meals. The injections were to be administered on the same weekday during the trial. Semaglutide was initiated at a dose of 0.25 mg and was escalated (doubled) to 0.5 mg after 4 weeks. Hence the target dose of 1.0 mg was achieved after 8 weeks of treatment. Each subject was treated for 104 weeks.

| | |
|--|--|
| Arm type | Placebo |
| Investigational medicinal product name | Placebo |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Solution for injection in pre-filled pen |
| Routes of administration | Subcutaneous use |

Dosage and administration details:

The composition of the placebo corresponded to that of semaglutide drug product but with absence of the active pharmaceutical ingredient. Placebo solution for injection (1.34 mg/mL in a 1.5 mL pre-filled PDS290 pen-injector) was administered in doses of 1.0 mg once-weekly as subcutaneous (s.c.) injections either in the thigh, abdomen or upper arm, at any time of day irrespective of meals. Subjects started with doses of 0.25 mg semaglutide. After 4 weeks of treatment, the dose was escalated (doubled). Hence, target dose of 1.0 mg was achieved after 8 weeks of treatment.

| Number of subjects in period 1 | Semaglutide 0.5 mg | Semaglutide 1.0 mg | Placebo 0.5 mg |
|---------------------------------------|--------------------|--------------------|----------------|
| Started | 826 | 822 | 824 |
| Completed | 812 | 811 | 804 |
| Not completed | 14 | 11 | 20 |
| Consent withdrawn by subject | 2 | 5 | 4 |
| Lost to follow-up | 12 | 6 | 16 |

| Number of subjects in period 1 | Placebo 1.0 mg |
|---------------------------------------|----------------|
| Started | 825 |
| Completed | 805 |
| Not completed | 20 |
| Consent withdrawn by subject | 4 |
| Lost to follow-up | 16 |

Baseline characteristics

Reporting groups

| | |
|--|--------------------|
| Reporting group title | Semaglutide 0.5 mg |
| Reporting group description: | |
| Subjects received once-weekly dose of semaglutide 0.5 mg as an add-on to their standard-of-care treatment. Injections were administered subcutaneously in the thigh, abdomen or upper arm, at any time of day irrespective of meals. The injections were to be administered on the same weekday during the trial. Semaglutide was initiated at a dose of 0.25 mg and was escalated (doubled) to 0.5 mg after 4 weeks. Hence the target dose of 0.5 mg was achieved after 4 weeks of treatment. Each subject was treated for 104 weeks. | |
| Reporting group title | Semaglutide 1.0 mg |
| Reporting group description: | |
| Subjects received once-weekly dose of semaglutide 1.0 mg as an add-on to their standard-of-care treatment. Injections were administered subcutaneously in the thigh, abdomen or upper arm, at any time of day irrespective of meals. The injections were to be administered on the same weekday during the trial. Semaglutide was initiated at a dose of 0.25 mg and was escalated (doubled) to 0.5 mg after 4 weeks. Hence the target dose of 1.0 mg was achieved after 8 weeks of treatment. Each subject was treated for 104 weeks. | |
| Reporting group title | Placebo 0.5 mg |
| Reporting group description: | |
| Subjects received once-weekly dose of placebo 0.5 mg as an add-on to their standard-of-care treatment. Injections were administered subcutaneously in the thigh, abdomen or upper arm, at any time of day irrespective of meals. The injections were to be administered on the same weekday during the trial. Semaglutide was initiated at a dose of 0.25 mg and was escalated (doubled) to 0.5 mg after 4 weeks. Hence the target dose of 0.5 mg was achieved after 4 weeks of treatment. Each subject was treated for 104 weeks. | |
| Reporting group title | Placebo 1.0 mg |
| Reporting group description: | |
| Subjects received once-weekly dose of placebo 1.0 mg as an add-on to their standard-of-care treatment. Injections were administered subcutaneously in the thigh, abdomen or upper arm, at any time of day irrespective of meals. The injections were to be administered on the same weekday during the trial. Semaglutide was initiated at a dose of 0.25 mg and was escalated (doubled) to 0.5 mg after 4 weeks. Hence the target dose of 1.0 mg was achieved after 8 weeks of treatment. Each subject was treated for 104 weeks. | |

| Reporting group values | Semaglutide 0.5 mg | Semaglutide 1.0 mg | Placebo 0.5 mg |
|---|--------------------|--------------------|----------------|
| Number of subjects | 826 | 822 | 824 |
| Age Categorical Units: Subjects | | | |
| Adults (18-64 years) | 440 | 415 | 419 |
| From 65-84 years | 383 | 400 | 399 |
| 85 years and over | 3 | 7 | 6 |
| Age Continuous Units: years | | | |
| arithmetic mean | 64.6 | 64.7 | 64.8 |
| standard deviation | ± 7.3 | ± 7.1 | ± 7.6 |
| Gender Categorical Units: Subjects | | | |
| Female | 331 | 304 | 342 |
| Male | 495 | 518 | 482 |
| Glycosylated haemoglobin Units: percentage of glycosylated haemoglobin | | | |
| arithmetic mean | 8.67 | 8.73 | 8.7 |

| | | | |
|---|-----------------|------------------|------------------|
| standard deviation | ± 1.39 | ± 1.51 | ± 1.49 |
| Fasting plasma glucose Units: mg/dL | | | |
| arithmetic mean | 185.4 | 182.9 | 185.8 |
| standard deviation | ± 66.09 | ± 68.04 | ± 68.23 |
| Body weight Units: kg | | | |
| arithmetic mean | 91.8 | 92.86 | 91.83 |
| standard deviation | ± 20.25 | ± 21.05 | ± 20.35 |
| LDL-cholesterol Units: mg/dL | | | |
| arithmetic mean | 89.62 | 89.72 | 89.01 |
| standard deviation | ± 39.08 | ± 34.49 | ± 38.35 |
| HDL-cholesterol Units: mg/dL | | | |
| arithmetic mean | 45.92 | 44.97 | 45.82 |
| standard deviation | ± 13 | ± 12.42 | ± 12.92 |
| Total cholesterol Units: mg/dL | | | |
| geometric mean | 165.38 | 164.96 | 164.38 |
| full range (min-max) | 65.25 to 632.43 | 79.54 to 562.16 | 70.27 to 378.38 |
| Triglycerides Units: mg/dL | | | |
| geometric mean | 163.66 | 158.93 | 162.3 |
| full range (min-max) | 27.59 to 1913.5 | 10.68 to 3378.44 | 30.26 to 1438.24 |
| Free fatty acids Units: mmol/L | | | |
| geometric mean | 0.83 | 0.8 | 0.83 |
| full range (min-max) | 0.04 to 3.82 | 0.04 to 4.2 | 0.04 to 3.34 |
| Systolic blood pressure Units: mmHg | | | |
| arithmetic mean | 136.1 | 135.8 | 135.8 |
| standard deviation | ± 17.97 | ± 16.98 | ± 16.16 |
| Diastolic blood pressure Units: mmHg | | | |
| arithmetic mean | 77.1 | 76.88 | 77.54 |
| standard deviation | ± 9.78 | ± 10.21 | ± 9.85 |
| Pulse rate Units: beats/min | | | |
| arithmetic mean | 72.69 | 71.53 | 72.01 |
| standard deviation | ± 11.22 | ± 10.86 | ± 10.62 |

| | | | |
|------------------------------------|----------------|-------|--|
| Reporting group values | Placebo 1.0 mg | Total | |
| Number of subjects | 825 | 3297 | |
| Age Categorical Units: Subjects | | | |
| Adults (18-64 years) | 425 | 1699 | |
| From 65-84 years | 396 | 1578 | |
| 85 years and over | 4 | 20 | |

| | | | |
|---|---------------------------|------|--|
| Age Continuous Units: years arithmetic mean standard deviation | 64.4 ± 7.5 | - | |
| Gender Categorical Units: Subjects | | | |
| Female | 318 | 1295 | |
| Male | 507 | 2002 | |
| Glycosylated haemoglobin Units: percentage of glycosylated haemoglobin arithmetic mean standard deviation | 8.7 ± 1.45 | - | |
| Fasting plasma glucose Units: mg/dL arithmetic mean standard deviation | 184.6 ± 63.08 | - | |
| Body weight Units: kg arithmetic mean standard deviation | 91.9 ± 20.75 | - | |
| LDL-cholesterol Units: mg/dL arithmetic mean standard deviation | 91.14 ± 37.9 | - | |
| HDL-cholesterol Units: mg/dL arithmetic mean standard deviation | 44.61 ± 12.26 | - | |
| Total cholesterol Units: mg/dL geometric mean full range (min-max) | 165.97 64.86 to 537.07 | - | |
| Triglycerides Units: mg/dL geometric mean full range (min-max) | 163 35.6 to 2435.93 | - | |
| Free fatty acids Units: mmol/L geometric mean full range (min-max) | 0.81 0.04 to 4.22 | - | |
| Systolic blood pressure Units: mmHg arithmetic mean standard deviation | 134.8 ± 17.45 | - | |
| Diastolic blood pressure Units: mmHg arithmetic mean standard deviation | 76.66 ± 10.21 | - | |
| Pulse rate Units: beats/min arithmetic mean | 71.95 | | |

| | | | |
|--------------------|---------|---|--|
| standard deviation | ± 10.92 | - | |
|--------------------|---------|---|--|

Subject analysis sets

| | |
|----------------------------|---------------|
| Subject analysis set title | Semaglutide |
| Subject analysis set type | Full analysis |

Subject analysis set description:

Subjects received once-weekly dose of semaglutide 0.5 mg or 1.0 mg as an add-on to their standard-of-care treatment. Injections were administered subcutaneously in the thigh, abdomen or upper arm, at any time of day irrespective of meals. The injections were to be administered on the same weekday during the trial. Semaglutide was initiated at a dose of 0.25 mg and was escalated (doubled) to 0.5 mg after 4 weeks. Hence the target dose of 0.5 mg was achieved after 4 weeks of treatment and the target dose of 1.0 mg was achieved after 8 weeks of treatment. Each subject was treated for 104 weeks.

| | |
|----------------------------|---------------|
| Subject analysis set title | Placebo |
| Subject analysis set type | Full analysis |

Subject analysis set description:

Subjects received once-weekly dose of placebo 0.5 mg or 1.0 mg as an add-on to their standard-of-care treatment. Injections were administered subcutaneously in the thigh, abdomen or upper arm, at any time of day irrespective of meals. The injections were to be administered on the same weekday during the trial. Placebo was initiated at a dose of 0.25 mg and was escalated (doubled) to 0.5 mg after 4 weeks. Hence the target dose of 0.5 mg was achieved after 4 weeks of treatment and the target dose of 1.0 mg was achieved after 8 weeks of treatment. Each subject was treated for 104 weeks.

| Reporting group values | Semaglutide | Placebo | |
|---|-------------|---------|--|
| Number of subjects | 1648 | 1649 | |
| Age Categorical Units: Subjects | | | |
| Adults (18-64 years) | | | |
| From 65-84 years | | | |
| 85 years and over | | | |
| Age Continuous Units: years | | | |
| arithmetic mean | 64.7 | 64.6 | |
| standard deviation | ± 7.2 | ± 7.5 | |
| Gender Categorical Units: Subjects | | | |
| Female | | | |
| Male | | | |
| Glycosylated haemoglobin Units: percentage of glycosylated haemoglobin | | | |
| arithmetic mean | | | |
| standard deviation | ± | ± | |
| Fasting plasma glucose Units: mg/dL | | | |
| arithmetic mean | | | |
| standard deviation | ± | ± | |
| Body weight Units: kg | | | |
| arithmetic mean | | | |
| standard deviation | ± | ± | |
| LDL-cholesterol | | | |

| | | | |
|--|-------|-------|--|
| Units: mg/dL arithmetic mean standard deviation | \pm | \pm | |
| HDL-cholesterol Units: mg/dL arithmetic mean standard deviation | \pm | \pm | |
| Total cholesterol Units: mg/dL geometric mean full range (min-max) | | | |
| Triglycerides Units: mg/dL geometric mean full range (min-max) | | | |
| Free fatty acids Units: mmol/L geometric mean full range (min-max) | | | |
| Systolic blood pressure Units: mmHg arithmetic mean standard deviation | \pm | \pm | |
| Diastolic blood pressure Units: mmHg arithmetic mean standard deviation | \pm | \pm | |
| Pulse rate Units: beats/min arithmetic mean standard deviation | \pm | \pm | |

End points

End points reporting groups

| | |
|-----------------------|--------------------|
| Reporting group title | Semaglutide 0.5 mg |
|-----------------------|--------------------|

Reporting group description:

Subjects received once-weekly dose of semaglutide 0.5 mg as an add-on to their standard-of-care treatment. Injections were administered subcutaneously in the thigh, abdomen or upper arm, at any time of day irrespective of meals. The injections were to be administered on the same weekday during the trial. Semaglutide was initiated at a dose of 0.25 mg and was escalated (doubled) to 0.5 mg after 4 weeks. Hence the target dose of 0.5 mg was achieved after 4 weeks of treatment. Each subject was treated for 104 weeks.

| | |
|-----------------------|--------------------|
| Reporting group title | Semaglutide 1.0 mg |
|-----------------------|--------------------|

Reporting group description:

Subjects received once-weekly dose of semaglutide 1.0 mg as an add-on to their standard-of-care treatment. Injections were administered subcutaneously in the thigh, abdomen or upper arm, at any time of day irrespective of meals. The injections were to be administered on the same weekday during the trial. Semaglutide was initiated at a dose of 0.25 mg and was escalated (doubled) to 0.5 mg after 4 weeks. Hence the target dose of 1.0 mg was achieved after 8 weeks of treatment. Each subject was treated for 104 weeks.

| | |
|-----------------------|----------------|
| Reporting group title | Placebo 0.5 mg |
|-----------------------|----------------|

Reporting group description:

Subjects received once-weekly dose of placebo 0.5 mg as an add-on to their standard-of-care treatment. Injections were administered subcutaneously in the thigh, abdomen or upper arm, at any time of day irrespective of meals. The injections were to be administered on the same weekday during the trial. Semaglutide was initiated at a dose of 0.25 mg and was escalated (doubled) to 0.5 mg after 4 weeks. Hence the target dose of 0.5 mg was achieved after 4 weeks of treatment. Each subject was treated for 104 weeks.

| | |
|-----------------------|----------------|
| Reporting group title | Placebo 1.0 mg |
|-----------------------|----------------|

Reporting group description:

Subjects received once-weekly dose of placebo 1.0 mg as an add-on to their standard-of-care treatment. Injections were administered subcutaneously in the thigh, abdomen or upper arm, at any time of day irrespective of meals. The injections were to be administered on the same weekday during the trial. Semaglutide was initiated at a dose of 0.25 mg and was escalated (doubled) to 0.5 mg after 4 weeks. Hence the target dose of 1.0 mg was achieved after 8 weeks of treatment. Each subject was treated for 104 weeks.

| | |
|----------------------------|-------------|
| Subject analysis set title | Semaglutide |
|----------------------------|-------------|

| | |
|---------------------------|---------------|
| Subject analysis set type | Full analysis |
|---------------------------|---------------|

Subject analysis set description:

Subjects received once-weekly dose of semaglutide 0.5 mg or 1.0 mg as an add-on to their standard-of-care treatment. Injections were administered subcutaneously in the thigh, abdomen or upper arm, at any time of day irrespective of meals. The injections were to be administered on the same weekday during the trial. Semaglutide was initiated at a dose of 0.25 mg and was escalated (doubled) to 0.5 mg after 4 weeks. Hence the target dose of 0.5 mg was achieved after 4 weeks of treatment and the target dose of 1.0 mg was achieved after 8 weeks of treatment. Each subject was treated for 104 weeks.

| | |
|----------------------------|---------|
| Subject analysis set title | Placebo |
|----------------------------|---------|

| | |
|---------------------------|---------------|
| Subject analysis set type | Full analysis |
|---------------------------|---------------|

Subject analysis set description:

Subjects received once-weekly dose of placebo 0.5 mg or 1.0 mg as an add-on to their standard-of-care treatment. Injections were administered subcutaneously in the thigh, abdomen or upper arm, at any time of day irrespective of meals. The injections were to be administered on the same weekday during the trial. Placebo was initiated at a dose of 0.25 mg and was escalated (doubled) to 0.5 mg after 4 weeks. Hence the target dose of 0.5 mg was achieved after 4 weeks of treatment and the target dose of 1.0 mg was achieved after 8 weeks of treatment. Each subject was treated for 104 weeks.

Primary: Time from randomisation to first occurrence of a MACE, defined as cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke.

| | |
|-----------------|---|
| End point title | Time from randomisation to first occurrence of a MACE, defined as cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke. |
|-----------------|---|

End point description:

Proportion of subjects experiencing a first event of a MACE, defined as cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke.

| | |
|----------------|---------|
| End point type | Primary |
|----------------|---------|

End point timeframe:

Time from randomisation to first occurrence of an expanded composite cardiovascular outcome.

| End point values | Semaglutide | Placebo | | |
|-------------------------------|----------------------|----------------------|--|--|
| Subject group type | Subject analysis set | Subject analysis set | | |
| Number of subjects analysed | 1648 | 1649 | | |
| Units: proportion of subjects | | | | |
| number (not applicable) | 6.6 | 8.9 | | |

Statistical analyses

| | |
|----------------------------|-----------------|
| Statistical analysis title | Non-Inferiority |
|----------------------------|-----------------|

Statistical analysis description:

The primary endpoint was analysed using a stratified Cox proportional hazards model with treatment group (semaglutide, placebo) as fixed factor. Assuming the same population MACE risk for the semaglutide and placebo groups (i.e., the population HR equals 1), a total minimum of 122 events were needed in order to have at least 90% power to ascertain that the upper two-sided 95% confidence limit for the HR was less than 1.8.

| | |
|---|-------------------------|
| Comparison groups | Semaglutide v Placebo |
| Number of subjects included in analysis | 3297 |
| Analysis specification | Pre-specified |
| Analysis type | non-inferiority |
| P-value | < 0.0001 ^[1] |
| Method | Regression, Cox |
| Parameter estimate | Hazard ratio (HR) |
| Point estimate | 0.74 |
| Confidence interval | |
| level | 95 % |
| sides | 2-sided |
| lower limit | 0.58 |
| upper limit | 0.95 |

Notes:

[1] - The 'p-value' is for the two-sided Wald test of non-inferiority with limit 1.8.

| | |
|----------------------------|-------------|
| Statistical analysis title | Superiority |
|----------------------------|-------------|

Statistical analysis description:

A post hoc analysis of superiority of semaglutide versus placebo was performed based on the pre-specified Cox proportional hazard analysis using the two-sided Wald test of no difference, with treatment (semaglutide, placebo) as fixed factor and stratified by all possible combinations of the three stratification factors used in the randomisation procedure (in total 9 levels).

| | |
|-------------------|-----------------------|
| Comparison groups | Semaglutide v Placebo |
|-------------------|-----------------------|

| | |
|---|-------------------------|
| Number of subjects included in analysis | 3297 |
| Analysis specification | Post-hoc |
| Analysis type | superiority |
| P-value | = 0.0167 ^[2] |
| Method | Regression, Cox |
| Parameter estimate | Hazard ratio (HR) |
| Point estimate | 0.74 |
| Confidence interval | |
| level | 95 % |
| sides | 2-sided |
| lower limit | 0.58 |
| upper limit | 0.95 |

Notes:

[2] - The 'p-value' is for the two-sided Wald test of no difference.

Secondary: Time from randomisation to first occurrence of an expanded composite cardiovascular outcome.

| | |
|-----------------|--|
| End point title | Time from randomisation to first occurrence of an expanded composite cardiovascular outcome. |
|-----------------|--|

End point description:

Subjects experiencing first occurrence of an expanded composite CV outcome (defined as either MACE, revascularisation [coronary and peripheral], unstable angina requiring hospitalisation or hospitalisation for heart failure).

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Time from randomisation up to end of follow-up (scheduled at week 109)

| End point values | Semaglutide | Placebo | | |
|------------------------------|----------------------|----------------------|--|--|
| Subject group type | Subject analysis set | Subject analysis set | | |
| Number of subjects analysed | 1648 | 1649 | | |
| Units: proportion of subject | | | | |
| number (not applicable) | 12.1 | 16 | | |

Statistical analyses

| | |
|----------------------------|---|
| Statistical analysis title | Analysis for an expanded composite CV outcome |
|----------------------------|---|

Statistical analysis description:

Analysis was done by Cox proportional hazards model with treatment (semaglutide; placebo) as a fixed factor and stratified by all possible combinations of the three stratification factors used in the randomisation procedure (in total 9 levels).

| | |
|-------------------|-----------------------|
| Comparison groups | Semaglutide v Placebo |
|-------------------|-----------------------|

| | |
|---|-------------------|
| Number of subjects included in analysis | 3297 |
| Analysis specification | Pre-specified |
| Analysis type | other |
| P-value | = 0.0016 |
| Method | Regression, Cox |
| Parameter estimate | Hazard ratio (HR) |
| Point estimate | 0.74 |
| Confidence interval | |
| level | 95 % |
| sides | 2-sided |
| lower limit | 0.62 |
| upper limit | 0.89 |

Secondary: Time from randomisation to each individual component of the expanded composite cardiovascular outcome

| | |
|------------------------|---|
| End point title | Time from randomisation to each individual component of the expanded composite cardiovascular outcome |
| End point description: | Subjects experiencing an event onset for each individual component of the expanded composite cardiovascular outcomes (defined as either MACE, revascularisation [coronary and peripheral], unstable angina requiring hospitalisation or hospitalisation for heart failure). |
| End point type | Secondary |
| End point timeframe: | Time from randomisation up to end of Follow-up (scheduled at week 109) |

| End point values | Semaglutide | Placebo | | |
|-----------------------------------|----------------------|----------------------|--|--|
| Subject group type | Subject analysis set | Subject analysis set | | |
| Number of subjects analysed | 1648 | 1649 | | |
| Units: proportion of subjects | | | | |
| number (not applicable) | | | | |
| Cardiovascular death | 1.6 | 1.9 | | |
| Non-fatal MI | 2.5 | 3.7 | | |
| Non-fatal Stroke | 1.5 | 2.7 | | |
| Revascularisation | 2.6 | 4.2 | | |
| UAP requiring hospitalisation | 1.1 | 1.3 | | |
| Hospitalisation for heart failure | 2.7 | 2.4 | | |

Statistical analyses

| | |
|-----------------------------------|---|
| Statistical analysis title | Analysis for cardiovascular death |
| Statistical analysis description: | Analysis for CV death was done by Cox proportional hazards model with treatment (semaglutide; placebo) as a fixed factor and stratified by all possible combinations of the three stratification factors used in the randomisation procedure (in total 9 levels). |
| Comparison groups | Semaglutide v Placebo |

| | |
|---|-------------------|
| Number of subjects included in analysis | 3297 |
| Analysis specification | Pre-specified |
| Analysis type | other |
| P-value | = 0.9181 |
| Method | Regression, Cox |
| Parameter estimate | Hazard ratio (HR) |
| Point estimate | 0.98 |
| Confidence interval | |
| level | 95 % |
| sides | 2-sided |
| lower limit | 0.65 |
| upper limit | 1.48 |

| | |
|-----------------------------------|--|
| Statistical analysis title | Analysis for non-fatal myocardial infarction |
|-----------------------------------|--|

Statistical analysis description:

Analysis for non-fatal myocardial infarction was done by Cox proportional hazards model with treatment (semaglutide; placebo) as a fixed factor and stratified by all possible combinations of the three stratification factors used in the randomisation procedure (in total 9 levels).

| | |
|---|-----------------------|
| Comparison groups | Semaglutide v Placebo |
| Number of subjects included in analysis | 3297 |
| Analysis specification | Pre-specified |
| Analysis type | other |
| P-value | = 0.1194 |
| Method | Regression, Cox |
| Parameter estimate | Hazard ratio (HR) |
| Point estimate | 0.74 |
| Confidence interval | |
| level | 95 % |
| sides | 2-sided |
| lower limit | 0.51 |
| upper limit | 1.08 |

| | |
|-----------------------------------|-------------------------------|
| Statistical analysis title | Analysis for non-fatal stroke |
|-----------------------------------|-------------------------------|

Statistical analysis description:

Analysis for non-fatal stroke was done by Cox proportional hazards model with treatment (semaglutide; placebo) as a fixed factor and stratified by all possible combinations of the three stratification factors used in the randomisation procedure (in total 9 levels).

| | |
|---|-----------------------|
| Comparison groups | Semaglutide v Placebo |
| Number of subjects included in analysis | 3297 |
| Analysis specification | Pre-specified |
| Analysis type | other |
| P-value | = 0.0438 |
| Method | Regression, Cox |
| Parameter estimate | Hazard ratio (HR) |
| Point estimate | 0.61 |

| | |
|---------------------|---------|
| Confidence interval | |
| level | 95 % |
| sides | 2-sided |
| lower limit | 0.38 |
| upper limit | 0.99 |

| | |
|-----------------------------------|--------------------------------|
| Statistical analysis title | Analysis for revascularisation |
|-----------------------------------|--------------------------------|

Statistical analysis description:

Analysis for revascularisation was done by Cox proportional hazards model with treatment (semaglutide; placebo) as a fixed factor and stratified by all possible combinations of the three stratification factors used in the randomisation procedure (in total 9 levels).

| | |
|---|-----------------------|
| Comparison groups | Semaglutide v Placebo |
| Number of subjects included in analysis | 3297 |
| Analysis specification | Pre-specified |
| Analysis type | other |
| P-value | = 0.0027 |
| Method | Regression, Cox |
| Parameter estimate | Hazard ratio (HR) |
| Point estimate | 0.65 |
| Confidence interval | |
| level | 95 % |
| sides | 2-sided |
| lower limit | 0.5 |
| upper limit | 0.86 |

| | |
|-----------------------------------|---|
| Statistical analysis title | Analysis for UA requiring hospitalisation |
|-----------------------------------|---|

Statistical analysis description:

Analysis for 'unstable angina requiring hospitalisation' was done by Cox proportional hazards model with treatment (semaglutide; placebo) as a fixed factor and stratified by all possible combinations of the three stratification factors used in the randomisation procedure (in total 9 levels).

| | |
|---|-----------------------|
| Comparison groups | Semaglutide v Placebo |
| Number of subjects included in analysis | 3297 |
| Analysis specification | Pre-specified |
| Analysis type | other |
| P-value | = 0.4914 |
| Method | Regression, Cox |
| Parameter estimate | Hazard ratio (HR) |
| Point estimate | 0.82 |
| Confidence interval | |
| level | 95 % |
| sides | 2-sided |
| lower limit | 0.47 |
| upper limit | 1.44 |

| | |
|-----------------------------------|--|
| Statistical analysis title | Analysis for hospitalisation for heart failure |
|-----------------------------------|--|

Statistical analysis description:

Analysis for hospitalisation for heart failure was done by Cox proportional hazards model with treatment (semaglutide; placebo) as a fixed factor and stratified by all possible combinations of the three stratification factors used in the randomisation procedure (in total 9 levels).

| | |
|---|-----------------------|
| Comparison groups | Semaglutide v Placebo |
| Number of subjects included in analysis | 3297 |
| Analysis specification | Pre-specified |
| Analysis type | other |
| P-value | = 0.5735 |
| Method | Regression, Cox |
| Parameter estimate | Hazard ratio (HR) |
| Point estimate | 1.11 |
| Confidence interval | |
| level | 95 % |
| sides | 2-sided |
| lower limit | 0.77 |
| upper limit | 1.61 |

Secondary: Time from randomisation to first occurrence of all-cause death, non-fatal MI, or non-fatal stroke

| | |
|-----------------|---|
| End point title | Time from randomisation to first occurrence of all-cause death, non-fatal MI, or non-fatal stroke |
|-----------------|---|

End point description:

Proportion of subjects experiencing a first occurrence of all-cause death, non-fatal MI, or non-fatal stroke.

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Time from randomisation up to end of follow-up (scheduled at week 109)

| End point values | Semaglutide | Placebo | | |
|-------------------------------|----------------------|----------------------|--|--|
| Subject group type | Subject analysis set | Subject analysis set | | |
| Number of subjects analysed | 1648 | 1649 | | |
| Units: proportion of subjects | | | | |
| number (not applicable) | 7.4 | 9.6 | | |

Statistical analyses

| | |
|-----------------------------------|----------|
| Statistical analysis title | Analysis |
|-----------------------------------|----------|

Statistical analysis description:

Analysis for all-cause death, non-fatal MI or non-fatal stroke was done by Cox proportional hazards model with treatment (semaglutide; placebo) as a fixed factor and stratified by all possible combinations of the three stratification factors used in the randomisation procedure (in total 9 levels).

| | |
|-------------------|-----------------------|
| Comparison groups | Semaglutide v Placebo |
|-------------------|-----------------------|

| | |
|---|-------------------|
| Number of subjects included in analysis | 3297 |
| Analysis specification | Pre-specified |
| Analysis type | other |
| P-value | = 0.0292 |
| Method | Regression, Cox |
| Parameter estimate | Hazard ratio (HR) |
| Point estimate | 0.77 |
| Confidence interval | |
| level | 95 % |
| sides | 2-sided |
| lower limit | 0.61 |
| upper limit | 0.97 |

Secondary: Change from baseline to last assessment in the trial in other treatment outcomes: glycosylated haemoglobin (HbA1c)

| | |
|------------------------|--|
| End point title | Change from baseline to last assessment in the trial in other treatment outcomes: glycosylated haemoglobin (HbA1c) |
| End point description: | Estimated mean change from baseline in glycosylated haemoglobin (HbA1c) to last assessment in the trial during the treatment period. |
| End point type | Secondary |
| End point timeframe: | Week 0, up to week 104 |

| End point values | Semaglutide 0.5 mg | Semaglutide 1.0 mg | Placebo 0.5 mg | Placebo 1.0 mg |
|---|--------------------|--------------------|-----------------|-----------------|
| Subject group type | Reporting group | Reporting group | Reporting group | Reporting group |
| Number of subjects analysed | 826 | 822 | 824 | 825 |
| Units: percentage of glycosylated haemoglobin | | | | |
| least squares mean (standard error) | -1.09 (± 0.05) | -1.41 (± 0.05) | -0.44 (± 0.05) | -0.36 (± 0.05) |

Statistical analyses

| | |
|---|--|
| Statistical analysis title | Analysis for HbA1c |
| Statistical analysis description: | Analysis was done using a mixed model for repeated measurements with treatment (4 levels) and stratification (9 levels) as fixed factors and baseline value as covariate, all nested within visit. |
| Comparison groups | Semaglutide 0.5 mg v Placebo 0.5 mg |
| Number of subjects included in analysis | 1650 |
| Analysis specification | Pre-specified |
| Analysis type | other |
| P-value | < 0.0001 |
| Method | Mixed models analysis |
| Parameter estimate | Treatment difference |
| Point estimate | -0.66 |

| | |
|---------------------|---------|
| Confidence interval | |
| level | 95 % |
| sides | 2-sided |
| lower limit | -0.8 |
| upper limit | -0.52 |

| | |
|-----------------------------------|--------------------|
| Statistical analysis title | Analysis for HbA1c |
|-----------------------------------|--------------------|

Statistical analysis description:

Analysis was done using a mixed model for repeated measurements with treatment (4 levels) and stratification (9 levels) as fixed factors and baseline value as covariate, all nested within visit.

| | |
|---|-------------------------------------|
| Comparison groups | Semaglutide 1.0 mg v Placebo 1.0 mg |
| Number of subjects included in analysis | 1647 |
| Analysis specification | Pre-specified |
| Analysis type | other |
| P-value | = 0.0001 |
| Method | Mixed models analysis |
| Parameter estimate | Treatment difference |
| Point estimate | -1.05 |
| Confidence interval | |
| level | 95 % |
| sides | 2-sided |
| lower limit | -1.19 |
| upper limit | -0.91 |

Secondary: Secondary: Change from baseline to last assessment in the trial in other treatment outcomes: fasting plasma glucose

| | |
|-----------------|---|
| End point title | Secondary: Change from baseline to last assessment in the trial in other treatment outcomes: fasting plasma glucose |
|-----------------|---|

End point description:

Estimated mean change from baseline to last assessment in fasting plasma glucose in the trial during the treatment period.

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Week 0, up to week 104

| End point values | Semaglutide 0.5 mg | Semaglutide 1.0 mg | Placebo 0.5 mg | Placebo 1.0 mg |
|-------------------------------------|--------------------|--------------------|-----------------|-----------------|
| Subject group type | Reporting group | Reporting group | Reporting group | Reporting group |
| Number of subjects analysed | 826 | 822 | 824 | 825 |
| Units: mg/dL | | | | |
| least squares mean (standard error) | -1.75 (± 0.12) | -2.11 (± 0.12) | -1.02 (± 0.12) | -0.88 (± 0.12) |

Statistical analyses

| Statistical analysis title | Analysis for FPG |
|--|-------------------------------------|
| Statistical analysis description: | |
| Analysis was done using a mixed model for repeated measurements with treatment (4 levels) and stratification (9 levels) as fixed factors and baseline value as covariate, all nested within visit. | |
| Comparison groups | Semaglutide 0.5 mg v Placebo 0.5 mg |
| Number of subjects included in analysis | 1650 |
| Analysis specification | Pre-specified |
| Analysis type | other |
| P-value | < 0.0001 |
| Method | Mixed models analysis |
| Parameter estimate | Treatment difference |
| Point estimate | -0.72 |
| Confidence interval | |
| level | 95 % |
| sides | 2-sided |
| lower limit | -1.06 |
| upper limit | -0.38 |

| Statistical analysis title | Analysis for FPG |
|--|-------------------------------------|
| Statistical analysis description: | |
| Analysis was done using a mixed model for repeated measurements with treatment (4 levels) and stratification (9 levels) as fixed factors and baseline value as covariate, all nested within visit. | |
| Comparison groups | Semaglutide 1.0 mg v Placebo 1.0 mg |
| Number of subjects included in analysis | 1647 |
| Analysis specification | Pre-specified |
| Analysis type | other |
| P-value | < 0.0001 |
| Method | Mixed models analysis |
| Parameter estimate | Treatment difference |
| Point estimate | -1.22 |
| Confidence interval | |
| level | 95 % |
| sides | 2-sided |
| lower limit | -1.56 |
| upper limit | -0.88 |

Secondary: Change from baseline to last assessment in the trial in other treatment outcomes: body weight

| | |
|---|--|
| End point title | Change from baseline to last assessment in the trial in other treatment outcomes: body weight ^[3] |
| End point description: | |
| Estimated mean change from baseline to last assessment in body weight in the trial during the treatment period. | |
| End point type | Secondary |
| End point timeframe: | |
| Week 0, up to week 104 | |

Notes:

[3] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period. Justification: The data for the two placebo arms are pooled for analysis and thus there are only 3 arms for this endpoint instead of four.

| End point values | Semaglutide 0.5 mg | Semaglutide 1.0 mg | Placebo | |
|-------------------------------------|-----------------------|-----------------------|----------------------|--|
| Subject group type | Reporting group | Reporting group | Subject analysis set | |
| Number of subjects analysed | 826 | 822 | 1649 | |
| Units: kg | | | | |
| least squares mean (standard error) | -3.57 (± 0.21) | -4.88 (± 0.22) | -0.62 (± 0.15) | |

Statistical analyses

| Statistical analysis title | Analysis for body weight |
|----------------------------|--------------------------|
|----------------------------|--------------------------|

Statistical analysis description:

Analysis was done using a mixed model for repeated measurements with treatment (4 levels) and stratification (9 levels) as fixed factors and baseline value as covariate, all nested within visit.

| | |
|---|------------------------------|
| Comparison groups | Semaglutide 0.5 mg v Placebo |
| Number of subjects included in analysis | 2475 |
| Analysis specification | Pre-specified |
| Analysis type | other |
| P-value | < 0.0001 |
| Method | Mixed models analysis |
| Parameter estimate | Treatment difference |
| Point estimate | -2.95 |
| Confidence interval | |
| level | 95 % |
| sides | 2-sided |
| lower limit | -3.47 |
| upper limit | -2.44 |

| Statistical analysis title | Analysis for body weight |
|----------------------------|--------------------------|
|----------------------------|--------------------------|

Statistical analysis description:

Analysis was done using a mixed model for repeated measurements with treatment (4 levels) and stratification (9 levels) as fixed factors and baseline value as covariate, all nested within visit.

| | |
|---|------------------------------|
| Comparison groups | Semaglutide 1.0 mg v Placebo |
| Number of subjects included in analysis | 2471 |
| Analysis specification | Pre-specified |
| Analysis type | other |
| P-value | < 0.0001 |
| Method | Mixed models analysis |
| Parameter estimate | treatment difference |
| Point estimate | -4.27 |

| | |
|---------------------|---------|
| Confidence interval | |
| level | 95 % |
| sides | 2-sided |
| lower limit | -4.78 |
| upper limit | -3.75 |

Secondary: Change from baseline to last assessment in the trial in other treatment outcomes: lipid profile

| | |
|---|---|
| End point title | Change from baseline to last assessment in the trial in other treatment outcomes: lipid profile |
| End point description: Estimated ratio to baseline at week 104 during the treatment period in lipid profile (total cholesterol, HDL cholesterol, LDL cholesterol and triglycerides). | |
| End point type | Secondary |
| End point timeframe: Week 0, up to week 104 | |

| End point values | Semaglutide 0.5 mg | Semaglutide 1.0 mg | Placebo 0.5 mg | Placebo 1.0 mg |
|-------------------------------------|--------------------|--------------------|-----------------|-----------------|
| Subject group type | Reporting group | Reporting group | Reporting group | Reporting group |
| Number of subjects analysed | 826 | 822 | 824 | 825 |
| Units: mg/dL | | | | |
| least squares mean (standard error) | | | | |
| Total cholesterol | 0.97 (± 0.01) | 0.97 (± 0.01) | 1 (± 0.01) | 0.99 (± 0.01) |
| HDL-Cholesterol | 0.99 (± 0.01) | 1.01 (± 0.01) | 0.99 (± 0.01) | 0.97 (± 0.01) |
| LDL-Cholesterol | 0.97 (± 0.01) | 0.98 (± 0.01) | 1.01 (± 0.01) | 0.99 (± 0.01) |
| Triglycerides | 0.93 (± 0.01) | 0.92 (± 0.01) | 0.96 (± 0.01) | 0.98 (± 0.01) |

Statistical analyses

| | |
|---|-------------------------------------|
| Statistical analysis title | Analysis for total cholesterol |
| Statistical analysis description: Analysis for total cholesterol was done using a mixed model for repeated measurements with treatment (4 levels) and stratification (9 levels) as fixed factors and baseline value as covariate, all nested within visit. The response and its baseline value were log-transformed before analysis. | |
| Comparison groups | Semaglutide 0.5 mg v Placebo 0.5 mg |
| Number of subjects included in analysis | 1650 |
| Analysis specification | Pre-specified |
| Analysis type | other |
| P-value | = 0.0149 |
| Method | Mixed models analysis |
| Parameter estimate | Treatment difference |
| Point estimate | 0.97 |

| | |
|---------------------|---------|
| Confidence interval | |
| level | 95 % |
| sides | 2-sided |
| lower limit | 0.95 |
| upper limit | 1 |

| | |
|-----------------------------------|--------------------------------|
| Statistical analysis title | Analysis for total cholesterol |
|-----------------------------------|--------------------------------|

Statistical analysis description:

Analysis for total cholesterol was done using a mixed model for repeated measurements with treatment (4 levels) and stratification (9 levels) as fixed factors and baseline value as covariate, all nested within visit. The response and its baseline value were log-transformed before analysis.

| | |
|---|-------------------------------------|
| Comparison groups | Semaglutide 1.0 mg v Placebo 1.0 mg |
| Number of subjects included in analysis | 1647 |
| Analysis specification | Pre-specified |
| Analysis type | other |
| P-value | = 0.258 |
| Method | Mixed models analysis |
| Parameter estimate | Treatment ratio |
| Point estimate | 0.99 |
| Confidence interval | |
| level | 95 % |
| sides | 2-sided |
| lower limit | 0.97 |
| upper limit | 1.01 |

| | |
|-----------------------------------|------------------------------|
| Statistical analysis title | Analysis for HDL-cholesterol |
|-----------------------------------|------------------------------|

Statistical analysis description:

Analysis for HDL-cholesterol was done using a mixed model for repeated measurements with treatment (4 levels) and stratification (9 levels) as fixed factors and baseline value as covariate, all nested within visit.

| | |
|---|-------------------------------------|
| Comparison groups | Semaglutide 0.5 mg v Placebo 0.5 mg |
| Number of subjects included in analysis | 1650 |
| Analysis specification | Pre-specified |
| Analysis type | other |
| P-value | = 0.8106 |
| Method | Mixed models analysis |
| Parameter estimate | Treatment ratio |
| Point estimate | 1 |
| Confidence interval | |
| level | 95 % |
| sides | 2-sided |
| lower limit | 0.99 |
| upper limit | 1.02 |

| | |
|-----------------------------------|------------------------------|
| Statistical analysis title | Analysis for HDL cholesterol |
|-----------------------------------|------------------------------|

Statistical analysis description:

Analysis for HDL-cholesterol was done using a mixed model for repeated measurements with treatment (4 levels) and stratification (9 levels) as fixed factors and baseline value as covariate, all nested within visit.

| | |
|---|-------------------------------------|
| Comparison groups | Semaglutide 1.0 mg v Placebo 1.0 mg |
| Number of subjects included in analysis | 1647 |
| Analysis specification | Pre-specified |
| Analysis type | other |
| P-value | < 0.0001 |
| Method | Mixed models analysis |
| Parameter estimate | Treatment ratio |
| Point estimate | 1.04 |
| Confidence interval | |
| level | 95 % |
| sides | 2-sided |
| lower limit | 0.99 |
| upper limit | 1.06 |

Statistical analysis title

Analysis for LDL-cholesterol

Statistical analysis description:

Analysis for LDL-cholesterol was done using a mixed model for repeated measurements with treatment (4 levels) and stratification (9 levels) as fixed factors and baseline value as covariate, all nested within visit.

| | |
|---|-------------------------------------|
| Comparison groups | Semaglutide 0.5 mg v Placebo 0.5 mg |
| Number of subjects included in analysis | 1650 |
| Analysis specification | Pre-specified |
| Analysis type | other |
| P-value | = 0.0185 |
| Method | Mixed models analysis |
| Parameter estimate | Treatment ratio |
| Point estimate | 0.96 |
| Confidence interval | |
| level | 95 % |
| sides | 2-sided |
| lower limit | 0.93 |
| upper limit | 0.99 |

Statistical analysis title

Analysis for LDL-cholesterol

Statistical analysis description:

Analysis for LDL-cholesterol was done using a mixed model for repeated measurements with treatment (4 levels) and stratification (9 levels) as fixed factors and baseline value as covariate, all nested within visit.

| | |
|-------------------|-------------------------------------|
| Comparison groups | Semaglutide 1.0 mg v Placebo 1.0 mg |
|-------------------|-------------------------------------|

| | |
|---|-----------------------|
| Number of subjects included in analysis | 1647 |
| Analysis specification | Pre-specified |
| Analysis type | other |
| P-value | = 0.5996 |
| Method | Mixed models analysis |
| Parameter estimate | Treatment ratio |
| Point estimate | 0.99 |
| Confidence interval | |
| level | 95 % |
| sides | 2-sided |
| lower limit | 0.96 |
| upper limit | 1.03 |

| | |
|-----------------------------------|----------------------------|
| Statistical analysis title | Analysis for triglycerides |
|-----------------------------------|----------------------------|

Statistical analysis description:

Analysis for triglycerides was done using a mixed model for repeated measurements with treatment (4 levels) and stratification (9 levels) as fixed factors and baseline value as covariate, all nested within visit.

| | |
|---|-------------------------------------|
| Comparison groups | Semaglutide 0.5 mg v Placebo 0.5 mg |
| Number of subjects included in analysis | 1650 |
| Analysis specification | Pre-specified |
| Analysis type | other |
| P-value | = 0.1833 |
| Method | Mixed models analysis |
| Parameter estimate | Treatment ratio |
| Point estimate | 0.97 |
| Confidence interval | |
| level | 95 % |
| sides | 2-sided |
| lower limit | 0.93 |
| upper limit | 1.01 |

| | |
|-----------------------------------|----------------------------|
| Statistical analysis title | Analysis for triglycerides |
|-----------------------------------|----------------------------|

Statistical analysis description:

Analysis for triglycerides was done using a mixed model for repeated measurements with treatment (4 levels) and stratification (9 levels) as fixed factors and baseline value as covariate, all nested within visit.

| | |
|---|-------------------------------------|
| Comparison groups | Semaglutide 1.0 mg v Placebo 1.0 mg |
| Number of subjects included in analysis | 1647 |
| Analysis specification | Pre-specified |
| Analysis type | other |
| P-value | = 0.0009 |
| Method | Mixed models analysis |
| Parameter estimate | Treatment ratio |
| Point estimate | 0.93 |

| | |
|---------------------|---------|
| Confidence interval | |
| level | 95 % |
| sides | 2-sided |
| lower limit | 0.89 |
| upper limit | 0.97 |

Secondary: Change from baseline to last assessment in the trial in other treatment outcomes: lipid profile (free fatty acids)

| | |
|--|--|
| End point title | Change from baseline to last assessment in the trial in other treatment outcomes: lipid profile (free fatty acids) |
| End point description: Estimated mean change from baseline to last assessment in the trial during the treatment period in vital signs (pulse rate). | |
| End point type | Secondary |
| End point timeframe: Week 0, up to week 104 | |

| End point values | Semaglutide 0.5 mg | Semaglutide 1.0 mg | Placebo 0.5 mg | Placebo 1.0 mg |
|-------------------------------------|--------------------|--------------------|-----------------|-----------------|
| Subject group type | Reporting group | Reporting group | Reporting group | Reporting group |
| Number of subjects analysed | 826 | 822 | 824 | 825 |
| Units: mmol/L | | | | |
| least squares mean (standard error) | 0.95 (± 0.02) | 0.91 (± 0.01) | 0.96 (± 0.02) | 0.99 (± 0.02) |

Statistical analyses

| | |
|--|-------------------------------------|
| Statistical analysis title | Analysis for free fatty acids |
| Statistical analysis description: Analysis for free fatty acids was done using a mixed model for repeated measurements with treatment (4 levels) and stratification (9 levels) as fixed factors and baseline value as covariate, all nested within visit. | |
| Comparison groups | Semaglutide 0.5 mg v Placebo 0.5 mg |
| Number of subjects included in analysis | 1650 |
| Analysis specification | Pre-specified |
| Analysis type | other |
| P-value | = 0.7796 |
| Method | Mixed models analysis |
| Parameter estimate | Treatment ratio |
| Point estimate | 0.99 |
| Confidence interval | |
| level | 95 % |
| sides | 2-sided |
| lower limit | 0.95 |
| upper limit | 1.04 |

| | |
|--|-------------------------------------|
| Statistical analysis title | Analysis for free fatty acids |
| Statistical analysis description: Analysis for free fatty acids was done using a mixed model for repeated measurements with treatment (4 levels) and stratification (9 levels) as fixed factors and baseline value as covariate, all nested within visit. | |
| Comparison groups | Semaglutide 1.0 mg v Placebo 1.0 mg |
| Number of subjects included in analysis | 1647 |
| Analysis specification | Pre-specified |
| Analysis type | other |
| P-value | = 0.0003 |
| Method | Mixed models analysis |
| Parameter estimate | Treatment ratio |
| Point estimate | 0.92 |
| Confidence interval | |
| level | 95 % |
| sides | 2-sided |
| lower limit | 0.88 |
| upper limit | 0.96 |

Secondary: Change from baseline to last assessment in the trial in other treatment outcomes: urinary albumin to creatinine ratio

| | |
|---|---|
| End point title | Change from baseline to last assessment in the trial in other treatment outcomes: urinary albumin to creatinine ratio |
| End point description: Estimated ratio to baseline in urinary albumin to creatinine ratio at week 104 during the treatment period. | |
| End point type | Secondary |
| End point timeframe: Week 0, up to week 104 | |

| End point values | Semaglutide 0.5 mg | Semaglutide 1.0 mg | Placebo 0.5 mg | Placebo 1.0 mg |
|-------------------------------------|--------------------|--------------------|-----------------|-----------------|
| Subject group type | Reporting group | Reporting group | Reporting group | Reporting group |
| Number of subjects analysed | 826 | 822 | 824 | 825 |
| Units: mg/g | | | | |
| least squares mean (standard error) | 1.02 (± 0.05) | 0.91 (± 0.05) | 1.32 (± 0.07) | 1.29 (± 0.06) |

Statistical analyses

| | |
|--|--|
| Statistical analysis title | Analysis for urinary albumin to creatinine ratio |
| Statistical analysis description: Analysis for urinary albumin to creatinine ration was done using a mixed model for repeated | |

measurements with treatment (4 levels) and stratification (9 levels) as fixed factors and baseline value as covariate, all nested within visit. The response and its baseline value were log-transformed before analysis.

| | |
|---|-------------------------------------|
| Comparison groups | Semaglutide 0.5 mg v Placebo 0.5 mg |
| Number of subjects included in analysis | 1650 |
| Analysis specification | Pre-specified |
| Analysis type | other |
| P-value | = 0.0003 |
| Method | Mixed models analysis |
| Parameter estimate | Treatment ratio |
| Point estimate | 0.78 |
| Confidence interval | |
| level | 95 % |
| sides | 2-sided |
| lower limit | 0.68 |
| upper limit | 0.89 |

| | |
|-----------------------------------|--|
| Statistical analysis title | Analysis for urinary albumin to creatinine ratio |
|-----------------------------------|--|

Statistical analysis description:

Analysis for urinary albumin to creatinine ration was donne using a mixed model for repeated measurements with treatment (4 levels) and stratification (9 levels) as fixed factors and baseline value as covariate, all nested within visit. The response and its baseline value were log-transformed before analysis.

| | |
|---|-------------------------------------|
| Comparison groups | Semaglutide 1.0 mg v Placebo 1.0 mg |
| Number of subjects included in analysis | 1647 |
| Analysis specification | Pre-specified |
| Analysis type | other |
| P-value | < 0.0001 |
| Method | Mixed models analysis |
| Parameter estimate | Treatment ratio |
| Point estimate | 0.71 |
| Confidence interval | |
| level | 95 % |
| sides | 2-sided |
| lower limit | 0.62 |
| upper limit | 0.81 |

Secondary: Change from baseline to last assessment in the trial in other treatment outcomes: vital signs

| | |
|-----------------|---|
| End point title | Change from baseline to last assessment in the trial in other treatment outcomes: vital signs |
|-----------------|---|

End point description:

Estimated mean change from baseline to last assessment in the trial during the treatment period in vital signs (diastolic blood pressure and systolic blood pressure).

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Week 0, up to week 104

| End point values | Semaglutide 0.5 mg | Semaglutide 1.0 mg | Placebo 0.5 mg | Placebo 1.0 mg |
|-------------------------------------|---------------------|---------------------|---------------------|---------------------|
| Subject group type | Reporting group | Reporting group | Reporting group | Reporting group |
| Number of subjects analysed | 826 | 822 | 824 | 825 |
| Units: mmHg | | | | |
| least squares mean (standard error) | | | | |
| Diastolic blood pressure (mmHg) | -1.37 (\pm 0.32) | -1.57 (\pm 0.32) | -1.42 (\pm 0.32) | -1.71 (\pm 0.32) |
| Systolic blood pressure (mmHg) | -3.44 (\pm 0.54) | -5.37 (\pm 0.54) | -2.17 (\pm 0.54) | -2.78 (\pm 0.54) |

Statistical analyses

| Statistical analysis title | Analysis for diastolic blood pressure |
|---|---------------------------------------|
| Statistical analysis description: | |
| Analysis for diastolic blood pressure was done using a mixed model for repeated measurements with treatment (4 levels) and stratification (9 levels) as fixed factors and baseline value as covariate, all nested within visit. | |
| Comparison groups | Semaglutide 0.5 mg v Placebo 0.5 mg |
| Number of subjects included in analysis | 1650 |
| Analysis specification | Pre-specified |
| Analysis type | other |
| P-value | = 0.9205 |
| Method | Mixed models analysis |
| Parameter estimate | Treatment ratio |
| Point estimate | 0.04 |
| Confidence interval | |
| level | 95 % |
| sides | 2-sided |
| lower limit | -0.83 |
| upper limit | 0.92 |

| Statistical analysis title | Analysis for diastolic blood pressure |
|---|---------------------------------------|
| Statistical analysis description: | |
| Analysis for diastolic blood pressure was done using a mixed model for repeated measurements with treatment (4 levels) and stratification (9 levels) as fixed factors and baseline value as covariate, all nested within visit. | |
| Comparison groups | Semaglutide 1.0 mg v Placebo 1.0 mg |
| Number of subjects included in analysis | 1647 |
| Analysis specification | Pre-specified |
| Analysis type | other |
| P-value | = 0.7477 |
| Method | Mixed models analysis |
| Parameter estimate | Treatment difference |
| Point estimate | 0.14 |

| | |
|---------------------|---------|
| Confidence interval | |
| level | 95 % |
| sides | 2-sided |
| lower limit | -0.74 |
| upper limit | 1.03 |

| | |
|-----------------------------------|--------------------------------------|
| Statistical analysis title | Analysis for systolic blood pressure |
|-----------------------------------|--------------------------------------|

Statistical analysis description:

Analysis for systolic blood pressure was done using a mixed model for repeated measurements with treatment (4 levels) and stratification (9 levels) as fixed factors and baseline value as covariate, all nested within visit.

| | |
|---|-------------------------------------|
| Comparison groups | Semaglutide 0.5 mg v Placebo 0.5 mg |
| Number of subjects included in analysis | 1650 |
| Analysis specification | Pre-specified |
| Analysis type | other |
| P-value | = 0.0976 |
| Method | Mixed models analysis |
| Parameter estimate | Treatment difference |
| Point estimate | -1.27 |
| Confidence interval | |
| level | 95 % |
| sides | 2-sided |
| lower limit | -2.77 |
| upper limit | 0.23 |

| | |
|-----------------------------------|--------------------------------------|
| Statistical analysis title | Analysis for systolic blood pressure |
|-----------------------------------|--------------------------------------|

Statistical analysis description:

Analysis for systolic blood pressure was done using a mixed model for repeated measurements with treatment (4 levels) and stratification (9 levels) as fixed factors and baseline value as covariate, all nested within visit.

| | |
|---|-------------------------------------|
| Comparison groups | Semaglutide 1.0 mg v Placebo 1.0 mg |
| Number of subjects included in analysis | 1647 |
| Analysis specification | Pre-specified |
| Analysis type | other |
| P-value | = 0.0008 |
| Method | Mixed models analysis |
| Parameter estimate | Treatment difference |
| Point estimate | -2.59 |
| Confidence interval | |
| level | 95 % |
| sides | 2-sided |
| lower limit | -4.09 |
| upper limit | -1.08 |

Secondary: Change from baseline to last assessment in the trial in other treatment

outcomes: vital signs (pulse rate)

| | |
|-----------------|--|
| End point title | Change from baseline to last assessment in the trial in other treatment outcomes: vital signs (pulse rate) |
|-----------------|--|

End point description:

Estimated mean change from baseline to last assessment in the trial during the treatment period in vital signs (pulse rate).

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Week 0, up to week 104

| End point values | Semaglutide 0.5 mg | Semaglutide 1.0 mg | Placebo 0.5 mg | Placebo 1.0 mg |
|-------------------------------------|--------------------|--------------------|--------------------|---------------------|
| Subject group type | Reporting group | Reporting group | Reporting group | Reporting group |
| Number of subjects analysed | 826 | 822 | 824 | 825 |
| Units: beats/min | | | | |
| least squares mean (standard error) | 2.12 (\pm 0.34) | 2.41 (\pm 0.34) | 0.09 (\pm 0.34) | -0.07 (\pm 0.34) |

Statistical analyses

| | |
|-----------------------------------|-------------------------|
| Statistical analysis title | Analysis for pulse rate |
|-----------------------------------|-------------------------|

Statistical analysis description:

Analysis for pulse rate was done using a mixed model for repeated measurements with treatment (4 levels) and stratification (9 levels) as fixed factors and baseline value as covariate, all nested within visit.

| | |
|---|-------------------------------------|
| Comparison groups | Semaglutide 0.5 mg v Placebo 0.5 mg |
| Number of subjects included in analysis | 1650 |
| Analysis specification | Pre-specified |
| Analysis type | other |
| P-value | < 0.0001 |
| Method | Mixed models analysis |
| Parameter estimate | Treatment difference |
| Point estimate | 2.02 |
| Confidence interval | |
| level | 95 % |
| sides | 2-sided |
| lower limit | 1.07 |
| upper limit | 2.98 |

| | |
|-----------------------------------|-------------------------|
| Statistical analysis title | Analysis for pulse rate |
|-----------------------------------|-------------------------|

Statistical analysis description:

Analysis for pulse rate was done using a mixed model for repeated measurements with treatment (4 levels) and stratification (9 levels) as fixed factors and baseline value as covariate, all nested within visit.

| | |
|-------------------|-------------------------------------|
| Comparison groups | Semaglutide 1.0 mg v Placebo 1.0 mg |
|-------------------|-------------------------------------|

| | |
|---|-----------------------|
| Number of subjects included in analysis | 1647 |
| Analysis specification | Pre-specified |
| Analysis type | other |
| P-value | < 0.0001 |
| Method | Mixed models analysis |
| Parameter estimate | Treatment difference |
| Point estimate | 2.47 |
| Confidence interval | |
| level | 95 % |
| sides | 2-sided |
| lower limit | 1.52 |
| upper limit | 3.43 |

Secondary: Incidence during the trial in other treatment outcomes: hypoglycaemic events

| | |
|--|--|
| End point title | Incidence during the trial in other treatment outcomes: hypoglycaemic events |
| End point description: | |
| Rates (event rate per 100 exposure years) of severe or blood glucose confirmed symptomatic hypoglycaemia defined as an episode that was severe according to the ADA classification or BG confirmed by a PG value <3.1 mmol/L (56 mg/dL) with symptoms consistent with hypoglycaemia. | |
| End point type | Secondary |
| End point timeframe: | |
| Week 0 - 109 | |

| End point values | Semaglutide 0.5 mg | Semaglutide 1.0 mg | Placebo 0.5 mg | Placebo 1.0 mg |
|--|--------------------|--------------------|-----------------|-----------------|
| Subject group type | Reporting group | Reporting group | Reporting group | Reporting group |
| Number of subjects analysed | 826 | 822 | 824 | 825 |
| Units: Event rate per 100 exposure years | | | | |
| number (not applicable) | 37.5 | 36.2 | 35.3 | 39.7 |

Statistical analyses

No statistical analyses for this end point

Secondary: Incidence during the trial in other treatment outcomes: adverse events

| | |
|---|--|
| End point title | Incidence during the trial in other treatment outcomes: adverse events |
| End point description: | |
| Rates (event rate per 100 years of exposure) of treatment emergent adverse events during the treatment period (weeks 0-109) | |
| End point type | Secondary |
| End point timeframe: | |
| Weeks 0-109 | |

| End point values | Semaglutide 0.5 mg | Semaglutide 1.0 mg | Placebo 0.5 mg | Placebo 1.0 mg |
|---|--------------------|--------------------|-----------------|-----------------|
| Subject group type | Reporting group | Reporting group | Reporting group | Reporting group |
| Number of subjects analysed | 826 | 822 | 824 | 825 |
| Units: Event rate per 100 years of exposure | | | | |
| number (not applicable) | 330.5 | 337 | 317.4 | 298.3 |

Statistical analyses

No statistical analyses for this end point

Secondary: Occurrence during the trial in other treatment outcomes: anti-semaglutide antibodies

| | |
|-----------------|---|
| End point title | Occurrence during the trial in other treatment outcomes: anti-semaglutide antibodies ^[4] |
|-----------------|---|

End point description:

The proportion of subjects that tested positive for anti-semaglutide antibodies at any time point post-baseline during the trial, from week 0 to week 109.

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Weeks 0-109

Notes:

[4] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period. Justification: There will not be any antibody data for the two placebo arms. Thus the data is presented for only the 2 semaglutide arms for this endpoint.

| End point values | Semaglutide 0.5 mg | Semaglutide 1.0 mg | | |
|-------------------------------|--------------------|--------------------|--|--|
| Subject group type | Reporting group | Reporting group | | |
| Number of subjects analysed | 826 | 822 | | |
| Units: proportion of subjects | | | | |
| number (not applicable) | 1.4 | 2.3 | | |

Statistical analyses

No statistical analyses for this end point

Secondary: Change from baseline to last assessment in the trial in other treatment outcomes: patient reported outcome (PRO)

| | |
|-----------------|--|
| End point title | Change from baseline to last assessment in the trial in other treatment outcomes: patient reported outcome (PRO) |
|-----------------|--|

End point description:

Estimated mean change from baseline to last assessment in the trial in patient reported outcomes (PRO). PRO questionnaire measured the individual overall health related quality of life namely bodily pain, general health, mental component summary, mental health, physical component summary,

physical functioning, role-emotional, role-physical, social functioning and vitality. The PRO scores were transformed to a 0–100 scale with higher scores indicating greater health related quality of life.

| | |
|------------------------|-----------|
| End point type | Secondary |
| End point timeframe: | |
| Week 0, up to week 104 | |

| End point values | Semaglutide 0.5 mg | Semaglutide 1.0 mg | Placebo 0.5 mg | Placebo 1.0 mg |
|-------------------------------------|--------------------|--------------------|-----------------|-----------------|
| Subject group type | Reporting group | Reporting group | Reporting group | Reporting group |
| Number of subjects analysed | 826 | 822 | 824 | 825 |
| Units: Score | | | | |
| least squares mean (standard error) | | | | |
| Bodily pain | 0.66 (± 0.35) | 1.82 (± 0.35) | 0.16 (± 0.35) | 0.35 (± 0.35) |
| General health | 1.66 (± 0.29) | 2.55 (± 0.29) | 0.78 (± 0.29) | 1.13 (± 0.3) |
| Mental component summary | 0 (± 0.35) | 0.86 (± 0.35) | -0.17 (± 0.35) | -0.11 (± 0.35) |
| Mental health | 0.48 (± 0.33) | 1.08 (± 0.33) | -0.14 (± 0.33) | -0.31 (± 0.33) |
| Physical component summary | 0.76 (± 0.28) | 1.74 (± 0.28) | 0.07 (± 0.28) | 0.35 (± 0.28) |
| Physical functioning | 0.42 (± 0.32) | 1.12 (± 0.32) | -0.38 (± 0.32) | -0.37 (± 0.33) |
| Role-emotional | 0.17 (± 0.42) | 0.89 (± 0.42) | -0.36 (± 0.42) | -0.05 (± 0.42) |
| Role-physical | 0.39 (± 0.34) | 1.18 (± 0.35) | -0.33 (± 0.35) | 0.03 (± 0.35) |
| Social functioning | -0.25 (± 0.35) | 0.97 (± 0.35) | -0.2 (± 0.36) | -0.17 (± 0.36) |
| Vitality | 0.29 (± 0.31) | 1.55 (± 0.31) | -0.04 (± 0.31) | 0.35 (± 0.31) |

Statistical analyses

| | |
|--|-------------------------------------|
| Statistical analysis title | Analysis for bodily pain |
| Statistical analysis description: | |
| Analysis for bodily pain was done using a mixed model for repeated measurements with treatment (4 levels) and stratification (9 levels) as fixed factors and baseline value as covariate, all nested within visit. | |
| Comparison groups | Semaglutide 0.5 mg v Placebo 0.5 mg |
| Number of subjects included in analysis | 1650 |
| Analysis specification | Pre-specified |
| Analysis type | other |
| P-value | = 0.3171 |
| Method | Mixed models analysis |
| Parameter estimate | Treatment difference |
| Point estimate | 0.5 |
| Confidence interval | |
| level | 95 % |
| sides | 2-sided |
| lower limit | -0.48 |
| upper limit | 1.47 |

| | |
|-----------------------------------|--------------------------|
| Statistical analysis title | Analysis for bodily pain |
|-----------------------------------|--------------------------|

Statistical analysis description:

Analysis for bodily pain was done using a mixed model for repeated measurements with treatment (4 levels) and stratification (9 levels) as fixed factors and baseline value as covariate, all nested within visit.

| | |
|---|-------------------------------------|
| Comparison groups | Semaglutide 1.0 mg v Placebo 1.0 mg |
| Number of subjects included in analysis | 1647 |
| Analysis specification | Pre-specified |
| Analysis type | other |
| P-value | = 0.0031 |
| Method | Mixed models analysis |
| Parameter estimate | Treatment difference |
| Point estimate | 1.47 |
| Confidence interval | |
| level | 95 % |
| sides | 2-sided |
| lower limit | 0.5 |
| upper limit | 2.45 |

Statistical analysis title

Analysis for general health

Statistical analysis description:

Analysis for general health was done using a mixed model for repeated measurements with treatment (4 levels) and stratification (9 levels) as fixed factors and baseline value as covariate, all nested within visit.

| | |
|---|-------------------------------------|
| Comparison groups | Semaglutide 0.5 mg v Placebo 0.5 mg |
| Number of subjects included in analysis | 1650 |
| Analysis specification | Pre-specified |
| Analysis type | other |
| P-value | = 0.035 |
| Method | Mixed models analysis |
| Parameter estimate | Treatment difference |
| Point estimate | 0.87 |
| Confidence interval | |
| level | 95 % |
| sides | 2-sided |
| lower limit | 0.06 |
| upper limit | 1.69 |

Statistical analysis title

Analysis for general health

Statistical analysis description:

Analysis for general health was done using a mixed model for repeated measurements with treatment (4 levels) and stratification (9 levels) as fixed factors and baseline value as covariate, all nested within visit.

| | |
|-------------------|-------------------------------------|
| Comparison groups | Semaglutide 1.0 mg v Placebo 1.0 mg |
|-------------------|-------------------------------------|

| | |
|---|-----------------------|
| Number of subjects included in analysis | 1647 |
| Analysis specification | Pre-specified |
| Analysis type | other |
| P-value | = 0.0007 |
| Method | Mixed models analysis |
| Parameter estimate | Treatment difference |
| Point estimate | 1.42 |
| Confidence interval | |
| level | 95 % |
| sides | 2-sided |
| lower limit | 0.6 |
| upper limit | 2.24 |

| | |
|-----------------------------------|---------------------------------------|
| Statistical analysis title | Analysis for mental component summary |
|-----------------------------------|---------------------------------------|

Statistical analysis description:

Analysis for mental component summary was done using a mixed model for repeated measurements with treatment (4 levels) and stratification (9 levels) as fixed factors and baseline value as covariate, all nested within visit.

| | |
|---|-------------------------------------|
| Comparison groups | Semaglutide 0.5 mg v Placebo 0.5 mg |
| Number of subjects included in analysis | 1650 |
| Analysis specification | Pre-specified |
| Analysis type | other |
| P-value | = 0.7277 |
| Method | Mixed models analysis |
| Parameter estimate | Treatment difference |
| Point estimate | 0.17 |
| Confidence interval | |
| level | 95 % |
| sides | 2-sided |
| lower limit | -0.79 |
| upper limit | 1.13 |

| | |
|-----------------------------------|---------------------------------------|
| Statistical analysis title | Analysis for mental component summary |
|-----------------------------------|---------------------------------------|

Statistical analysis description:

Analysis for mental component summary was done using a mixed model for repeated measurements with treatment (4 levels) and stratification (9 levels) as fixed factors and baseline value as covariate, all nested within visit.

| | |
|---|-------------------------------------|
| Comparison groups | Semaglutide 1.0 mg v Placebo 1.0 mg |
| Number of subjects included in analysis | 1647 |
| Analysis specification | Pre-specified |
| Analysis type | other |
| P-value | = 0.0489 |
| Method | Mixed models analysis |
| Parameter estimate | Treatment difference |
| Point estimate | 0.97 |

| | |
|---------------------|---------|
| Confidence interval | |
| level | 95 % |
| sides | 2-sided |
| lower limit | 0 |
| upper limit | 1.94 |

| | |
|-----------------------------------|----------------------------|
| Statistical analysis title | Analysis for mental health |
|-----------------------------------|----------------------------|

Statistical analysis description:

Analysis for mental health was done using a mixed model for repeated measurements with treatment (4 levels) and stratification (9 levels) as fixed factors and baseline value as covariate, all nested within visit.

| | |
|---|-------------------------------------|
| Comparison groups | Semaglutide 0.5 mg v Placebo 0.5 mg |
| Number of subjects included in analysis | 1650 |
| Analysis specification | Pre-specified |
| Analysis type | other |
| P-value | = 0.186 |
| Method | Mixed models analysis |
| Parameter estimate | Treatment difference |
| Point estimate | 0.61 |
| Confidence interval | |
| level | 95 % |
| sides | 2-sided |
| lower limit | -0.3 |
| upper limit | 1.53 |

| | |
|-----------------------------------|----------------------------|
| Statistical analysis title | Analysis for mental health |
|-----------------------------------|----------------------------|

Statistical analysis description:

Analysis for mental health was done using a mixed model for repeated measurements with treatment (4 levels) and stratification (9 levels) as fixed factors and baseline value as covariate, all nested within visit.

| | |
|---|-------------------------------------|
| Comparison groups | Semaglutide 1.0 mg v Placebo 1.0 mg |
| Number of subjects included in analysis | 1647 |
| Analysis specification | Pre-specified |
| Analysis type | other |
| P-value | = 0.0029 |
| Method | Mixed models analysis |
| Parameter estimate | Treatment difference |
| Point estimate | 1.39 |
| Confidence interval | |
| level | 95 % |
| sides | 2-sided |
| lower limit | 0.48 |
| upper limit | 2.31 |

| | |
|-----------------------------------|---|
| Statistical analysis title | Analysis for physical component summary |
|-----------------------------------|---|

Statistical analysis description:

Analysis for physical component summary was done using a mixed model for repeated measurements with treatment (4 levels) and stratification (9 levels) as fixed factors and baseline value as covariate, all nested within visit.

| | |
|---|-------------------------------------|
| Comparison groups | Semaglutide 0.5 mg v Placebo 0.5 mg |
| Number of subjects included in analysis | 1650 |
| Analysis specification | Pre-specified |
| Analysis type | other |
| P-value | = 0.0833 |
| Method | Mixed models analysis |
| Parameter estimate | Treatment difference |
| Point estimate | 0.68 |
| Confidence interval | |
| level | 95 % |
| sides | 2-sided |
| lower limit | -0.09 |
| upper limit | 1.45 |

Statistical analysis title

Analysis for physical component summary

Statistical analysis description:

Analysis for physical component summary was done using a mixed model for repeated measurements with treatment (4 levels) and stratification (9 levels) as fixed factors and baseline value as covariate, all nested within visit.

| | |
|---|-------------------------------------|
| Comparison groups | Semaglutide 1.0 mg v Placebo 1.0 mg |
| Number of subjects included in analysis | 1647 |
| Analysis specification | Pre-specified |
| Analysis type | other |
| P-value | = 0.0004 |
| Method | Mixed models analysis |
| Parameter estimate | Treatment difference |
| Point estimate | 1.4 |
| Confidence interval | |
| level | 95 % |
| sides | 2-sided |
| lower limit | 0.62 |
| upper limit | 2.17 |

Statistical analysis title

Analysis for physical functioning

Statistical analysis description:

Analysis for physical functioning was done using a mixed model for repeated measurements with treatment (4 levels) and stratification (9 levels) as fixed factors and baseline value as covariate, all nested within visit.

| | |
|-------------------|-------------------------------------|
| Comparison groups | Semaglutide 0.5 mg v Placebo 0.5 mg |
|-------------------|-------------------------------------|

| | |
|---|-----------------------|
| Number of subjects included in analysis | 1650 |
| Analysis specification | Pre-specified |
| Analysis type | other |
| P-value | = 0.0799 |
| Method | Mixed models analysis |
| Parameter estimate | Treatment difference |
| Point estimate | 0.8 |
| Confidence interval | |
| level | 95 % |
| sides | 2-sided |
| lower limit | -0.1 |
| upper limit | 1.69 |

| | |
|-----------------------------------|-----------------------------------|
| Statistical analysis title | Analysis for physical functioning |
|-----------------------------------|-----------------------------------|

Statistical analysis description:

Analysis for physical functioning was done using a mixed model for repeated measurements with treatment (4 levels) and stratification (9 levels) as fixed factors and baseline value as covariate, all nested within visit.

| | |
|---|-------------------------------------|
| Comparison groups | Semaglutide 1.0 mg v Placebo 1.0 mg |
| Number of subjects included in analysis | 1647 |
| Analysis specification | Pre-specified |
| Analysis type | other |
| P-value | = 0.0011 |
| Method | Mixed models analysis |
| Parameter estimate | Treatment difference |
| Point estimate | 1.5 |
| Confidence interval | |
| level | 95 % |
| sides | 2-sided |
| lower limit | 0.6 |
| upper limit | 2.4 |

| | |
|-----------------------------------|-----------------------------|
| Statistical analysis title | Analysis for role emotional |
|-----------------------------------|-----------------------------|

Statistical analysis description:

Analysis for role emotional was done using a mixed model for repeated measurements with treatment (4 levels) and stratification (9 levels) as fixed factors and baseline value as covariate, all nested within visit.

| | |
|---|-------------------------------------|
| Comparison groups | Semaglutide 0.5 mg v Placebo 0.5 mg |
| Number of subjects included in analysis | 1650 |
| Analysis specification | Pre-specified |
| Analysis type | other |
| P-value | = 0.1431 |
| Method | Mixed models analysis |
| Parameter estimate | Treatment difference |
| Point estimate | 0.53 |

| | |
|---------------------|---------|
| Confidence interval | |
| level | 95 % |
| sides | 2-sided |
| lower limit | -0.63 |
| upper limit | 1.68 |

| | |
|-----------------------------------|-----------------------------|
| Statistical analysis title | Analysis for role emotional |
|-----------------------------------|-----------------------------|

Statistical analysis description:

Analysis for role emotional was done using a mixed model for repeated measurements with treatment (4 levels) and stratification (9 levels) as fixed factors and baseline value as covariate, all nested within visit.

| | |
|---|-------------------------------------|
| Comparison groups | Semaglutide 1.0 mg v Placebo 1.0 mg |
| Number of subjects included in analysis | 1647 |
| Analysis specification | Pre-specified |
| Analysis type | other |
| P-value | = 0.1136 |
| Method | Mixed models analysis |
| Parameter estimate | Treatment difference |
| Point estimate | 0.94 |
| Confidence interval | |
| level | 95 % |
| sides | 2-sided |
| lower limit | -0.22 |
| upper limit | 2.1 |

| | |
|-----------------------------------|----------------------------|
| Statistical analysis title | Analysis for role physical |
|-----------------------------------|----------------------------|

Statistical analysis description:

Analysis for role physical was done using a mixed model for repeated measurements with treatment (4 levels) and stratification (9 levels) as fixed factors and baseline value as covariate, all nested within visit.

| | |
|---|-------------------------------------|
| Comparison groups | Semaglutide 0.5 mg v Placebo 0.5 mg |
| Number of subjects included in analysis | 1650 |
| Analysis specification | Pre-specified |
| Analysis type | other |
| P-value | = 0.1431 |
| Method | Mixed models analysis |
| Parameter estimate | treatment difference |
| Point estimate | 0.72 |
| Confidence interval | |
| level | 95 % |
| sides | 2-sided |
| lower limit | -0.24 |
| upper limit | 1.67 |

| | |
|-----------------------------------|----------------------------|
| Statistical analysis title | Analysis for role physical |
|-----------------------------------|----------------------------|

Statistical analysis description:

Analysis for role physical was done using a mixed model for repeated measurements with treatment (4 levels) and stratification (9 levels) as fixed factors and baseline value as covariate, all nested within visit.

| | |
|---|-------------------------------------|
| Comparison groups | Semaglutide 1.0 mg v Placebo 1.0 mg |
| Number of subjects included in analysis | 1647 |
| Analysis specification | Pre-specified |
| Analysis type | other |
| P-value | = 0.0197 |
| Method | Mixed models analysis |
| Parameter estimate | Treatment difference |
| Point estimate | 1.14 |
| Confidence interval | |
| level | 95 % |
| sides | 2-sided |
| lower limit | 0.18 |
| upper limit | 2.11 |

Statistical analysis title

Analysis for social functioning

Statistical analysis description:

Analysis for social functioning was done using a mixed model for repeated measurements with treatment (4 levels) and stratification (9 levels) as fixed factors and baseline value as covariate, all nested within visit.

| | |
|---|-------------------------------------|
| Comparison groups | Semaglutide 0.5 mg v Placebo 0.5 mg |
| Number of subjects included in analysis | 1650 |
| Analysis specification | Pre-specified |
| Analysis type | other |
| P-value | = 0.9223 |
| Method | Mixed models analysis |
| Parameter estimate | Treatment difference |
| Point estimate | -0.05 |
| Confidence interval | |
| level | 95 % |
| sides | 2-sided |
| lower limit | -1.03 |
| upper limit | 0.93 |

Statistical analysis title

Analysis for social functioning

Statistical analysis description:

Analysis for social functioning was done using a mixed model for repeated measurements with treatment (4 levels) and stratification (9 levels) as fixed factors and baseline value as covariate, all nested within visit.

| | |
|-------------------|-------------------------------------|
| Comparison groups | Semaglutide 1.0 mg v Placebo 1.0 mg |
|-------------------|-------------------------------------|

| | |
|---|-----------------------|
| Number of subjects included in analysis | 1647 |
| Analysis specification | Pre-specified |
| Analysis type | other |
| P-value | = 0.0237 |
| Method | Mixed models analysis |
| Parameter estimate | Treatment difference |
| Point estimate | 1.14 |
| Confidence interval | |
| level | 95 % |
| sides | 2-sided |
| lower limit | 0.15 |
| upper limit | 2.13 |

| | |
|-----------------------------------|-----------------------|
| Statistical analysis title | Analysis for vitality |
|-----------------------------------|-----------------------|

Statistical analysis description:

Analysis for vitality was done using a mixed model for repeated measurements with treatment (4 levels) and stratification (9 levels) as fixed factors and baseline value as covariate, all nested within visit.

| | |
|---|-------------------------------------|
| Comparison groups | Semaglutide 0.5 mg v Placebo 0.5 mg |
| Number of subjects included in analysis | 1650 |
| Analysis specification | Pre-specified |
| Analysis type | other |
| P-value | = 0.4523 |
| Method | Mixed models analysis |
| Parameter estimate | Treatment difference |
| Point estimate | 0.33 |
| Confidence interval | |
| level | 95 % |
| sides | 2-sided |
| lower limit | -0.53 |
| upper limit | 1.19 |

| | |
|-----------------------------------|-----------------------|
| Statistical analysis title | Analysis for vitality |
|-----------------------------------|-----------------------|

Statistical analysis description:

Analysis for vitality was done using a mixed model for repeated measurements with treatment (4 levels) and stratification (9 levels) as fixed factors and baseline value as covariate, all nested within visit.

| | |
|---|-------------------------------------|
| Comparison groups | Semaglutide 1.0 mg v Placebo 1.0 mg |
| Number of subjects included in analysis | 1647 |
| Analysis specification | Pre-specified |
| Analysis type | other |
| P-value | = 0.0064 |
| Method | Mixed models analysis |
| Parameter estimate | Treatment difference |
| Point estimate | 1.2 |

| | |
|---------------------|---------|
| Confidence interval | |
| level | 95 % |
| sides | 2-sided |
| lower limit | 0.34 |
| upper limit | 2.07 |

Adverse events

Adverse events information

Timeframe for reporting adverse events:

Adverse events from the first trial-related activity after the subject had signed the informed consent (week -2) until the end of the posttreatment follow-up period (week 109).

Adverse event reporting additional description:

Safety was assessed using the full analysis set which includes all randomised subjects. Subjects contribute to the evaluation as randomised.

| | |
|-----------------|------------|
| Assessment type | Systematic |
|-----------------|------------|

Dictionary used

| | |
|-----------------|--------|
| Dictionary name | MedDRA |
|-----------------|--------|

| | |
|--------------------|----|
| Dictionary version | 18 |
|--------------------|----|

Reporting groups

| | |
|-----------------------|-------------|
| Reporting group title | Sema 0.5 mg |
|-----------------------|-------------|

Reporting group description: -

| | |
|-----------------------|-------------|
| Reporting group title | Sema 1.0 mg |
|-----------------------|-------------|

Reporting group description: -

| | |
|-----------------------|----------------|
| Reporting group title | Placebo 0.5 mg |
|-----------------------|----------------|

Reporting group description: -

| | |
|-----------------------|----------------|
| Reporting group title | Placebo 1.0 mg |
|-----------------------|----------------|

Reporting group description: -

| Serious adverse events | Sema 0.5 mg | Sema 1.0 mg | Placebo 0.5 mg |
|---|--------------------|--------------------|--------------------|
| Total subjects affected by serious adverse events | | | |
| subjects affected / exposed | 289 / 826 (34.99%) | 276 / 822 (33.58%) | 329 / 824 (39.93%) |
| number of deaths (all causes) | 30 | 32 | 32 |
| number of deaths resulting from adverse events | 3 | 3 | 2 |
| Neoplasms benign, malignant and unspecified (incl cysts and polyps) | | | |
| Acute lymphocytic leukaemia | | | |
| subjects affected / exposed | 0 / 826 (0.00%) | 0 / 822 (0.00%) | 0 / 824 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Acute myeloid leukaemia | | | |
| subjects affected / exposed | 0 / 826 (0.00%) | 0 / 822 (0.00%) | 1 / 824 (0.12%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| Adenocarcinoma gastric | | | |

| | | | |
|---|-----------------|-----------------|-----------------|
| subjects affected / exposed | 2 / 826 (0.24%) | 0 / 822 (0.00%) | 0 / 824 (0.00%) |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Adenocarcinoma of colon | | | |
| subjects affected / exposed | 1 / 826 (0.12%) | 0 / 822 (0.00%) | 2 / 824 (0.24%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 2 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Adenocarcinoma pancreas | | | |
| subjects affected / exposed | 0 / 826 (0.00%) | 0 / 822 (0.00%) | 1 / 824 (0.12%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Anaplastic astrocytoma | | | |
| subjects affected / exposed | 0 / 826 (0.00%) | 0 / 822 (0.00%) | 0 / 824 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| B-cell lymphoma | | | |
| subjects affected / exposed | 0 / 826 (0.00%) | 1 / 822 (0.12%) | 1 / 824 (0.12%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| B-cell small lymphocytic lymphoma | | | |
| subjects affected / exposed | 0 / 826 (0.00%) | 0 / 822 (0.00%) | 1 / 824 (0.12%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Basal cell carcinoma | | | |
| subjects affected / exposed | 1 / 826 (0.12%) | 1 / 822 (0.12%) | 1 / 824 (0.12%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 1 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Benign lymph node neoplasm | | | |
| subjects affected / exposed | 1 / 826 (0.12%) | 0 / 822 (0.00%) | 0 / 824 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Benign neoplasm of thyroid gland | | | |

| | | | |
|---|-----------------|-----------------|-----------------|
| subjects affected / exposed | 0 / 826 (0.00%) | 0 / 822 (0.00%) | 0 / 824 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Bladder neoplasm | | | |
| subjects affected / exposed | 0 / 826 (0.00%) | 0 / 822 (0.00%) | 0 / 824 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Bladder papilloma | | | |
| subjects affected / exposed | 0 / 826 (0.00%) | 1 / 822 (0.12%) | 0 / 824 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Bladder transitional cell carcinoma | | | |
| subjects affected / exposed | 0 / 826 (0.00%) | 1 / 822 (0.12%) | 2 / 824 (0.24%) |
| occurrences causally related to treatment / all | 0 / 0 | 1 / 1 | 0 / 2 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Bladder transitional cell carcinoma recurrent | | | |
| subjects affected / exposed | 0 / 826 (0.00%) | 0 / 822 (0.00%) | 0 / 824 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Bladder transitional cell carcinoma stage II | | | |
| subjects affected / exposed | 0 / 826 (0.00%) | 1 / 822 (0.12%) | 0 / 824 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Bone cancer metastatic | | | |
| subjects affected / exposed | 0 / 826 (0.00%) | 1 / 822 (0.12%) | 0 / 824 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Brain neoplasm | | | |
| subjects affected / exposed | 0 / 826 (0.00%) | 1 / 822 (0.12%) | 0 / 824 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Breast cancer | | | |

| | | | |
|---|-----------------|-----------------|-----------------|
| subjects affected / exposed | 1 / 826 (0.12%) | 1 / 822 (0.12%) | 0 / 824 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Breast cancer in situ | | | |
| subjects affected / exposed | 0 / 826 (0.00%) | 1 / 822 (0.12%) | 0 / 824 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Breast cancer stage III | | | |
| subjects affected / exposed | 0 / 826 (0.00%) | 0 / 822 (0.00%) | 0 / 824 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Bronchial carcinoma | | | |
| subjects affected / exposed | 0 / 826 (0.00%) | 0 / 822 (0.00%) | 1 / 824 (0.12%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Cholangiocarcinoma | | | |
| subjects affected / exposed | 0 / 826 (0.00%) | 1 / 822 (0.12%) | 1 / 824 (0.12%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 2 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| Cholesteatoma | | | |
| subjects affected / exposed | 0 / 826 (0.00%) | 1 / 822 (0.12%) | 1 / 824 (0.12%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Chondroma | | | |
| subjects affected / exposed | 0 / 826 (0.00%) | 1 / 822 (0.12%) | 0 / 824 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Choroid melanoma | | | |
| subjects affected / exposed | 1 / 826 (0.12%) | 0 / 822 (0.00%) | 0 / 824 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Chronic lymphocytic leukaemia | | | |

| | | | |
|---|-----------------|-----------------|-----------------|
| subjects affected / exposed | 0 / 826 (0.00%) | 1 / 822 (0.12%) | 1 / 824 (0.12%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Clear cell renal cell carcinoma | | | |
| subjects affected / exposed | 0 / 826 (0.00%) | 0 / 822 (0.00%) | 0 / 824 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Colon adenoma | | | |
| subjects affected / exposed | 0 / 826 (0.00%) | 4 / 822 (0.49%) | 0 / 824 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 4 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Colon cancer | | | |
| subjects affected / exposed | 0 / 826 (0.00%) | 1 / 822 (0.12%) | 1 / 824 (0.12%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Colon cancer metastatic | | | |
| subjects affected / exposed | 0 / 826 (0.00%) | 0 / 822 (0.00%) | 0 / 824 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Colon neoplasm | | | |
| subjects affected / exposed | 0 / 826 (0.00%) | 0 / 822 (0.00%) | 1 / 824 (0.12%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Colorectal cancer | | | |
| subjects affected / exposed | 0 / 826 (0.00%) | 0 / 822 (0.00%) | 1 / 824 (0.12%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Endometrial adenocarcinoma | | | |
| subjects affected / exposed | 0 / 826 (0.00%) | 0 / 822 (0.00%) | 1 / 824 (0.12%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Endometrial sarcoma | | | |

| | | | |
|--|-----------------|-----------------|-----------------|
| subjects affected / exposed | 0 / 826 (0.00%) | 0 / 822 (0.00%) | 0 / 824 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Extranodal marginal zone B-cell lymphoma (MALT type) | | | |
| subjects affected / exposed | 1 / 826 (0.12%) | 0 / 822 (0.00%) | 0 / 824 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Gallbladder adenocarcinoma | | | |
| subjects affected / exposed | 0 / 826 (0.00%) | 0 / 822 (0.00%) | 1 / 824 (0.12%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| Gastric cancer | | | |
| subjects affected / exposed | 1 / 826 (0.12%) | 0 / 822 (0.00%) | 0 / 824 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Glomus tumour | | | |
| subjects affected / exposed | 0 / 826 (0.00%) | 1 / 822 (0.12%) | 0 / 824 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Growth hormone-producing pituitary tumour | | | |
| subjects affected / exposed | 0 / 826 (0.00%) | 1 / 822 (0.12%) | 0 / 824 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Hepatic adenoma | | | |
| subjects affected / exposed | 0 / 826 (0.00%) | 0 / 822 (0.00%) | 1 / 824 (0.12%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 1 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Hepatic cancer | | | |
| subjects affected / exposed | 1 / 826 (0.12%) | 0 / 822 (0.00%) | 1 / 824 (0.12%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Invasive breast carcinoma | | | |

| | | | |
|---|-----------------|-----------------|-----------------|
| subjects affected / exposed | 0 / 826 (0.00%) | 0 / 822 (0.00%) | 1 / 824 (0.12%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Invasive ductal breast carcinoma | | | |
| subjects affected / exposed | 0 / 826 (0.00%) | 2 / 822 (0.24%) | 1 / 824 (0.12%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 2 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Laryngeal squamous cell carcinoma | | | |
| subjects affected / exposed | 1 / 826 (0.12%) | 0 / 822 (0.00%) | 0 / 824 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Lip neoplasm malignant stage unspecified | | | |
| subjects affected / exposed | 1 / 826 (0.12%) | 0 / 822 (0.00%) | 0 / 824 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Lung adenocarcinoma | | | |
| subjects affected / exposed | 0 / 826 (0.00%) | 1 / 822 (0.12%) | 1 / 824 (0.12%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Lung adenocarcinoma stage 0 | | | |
| subjects affected / exposed | 0 / 826 (0.00%) | 1 / 822 (0.12%) | 0 / 824 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Lung adenocarcinoma stage IV | | | |
| subjects affected / exposed | 0 / 826 (0.00%) | 1 / 822 (0.12%) | 0 / 824 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| Lung carcinoma cell type unspecified stage IV | | | |
| subjects affected / exposed | 0 / 826 (0.00%) | 1 / 822 (0.12%) | 0 / 824 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| Lung neoplasm | | | |

| | | | |
|---|-----------------|-----------------|-----------------|
| subjects affected / exposed | 0 / 826 (0.00%) | 1 / 822 (0.12%) | 0 / 824 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 1 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Lung neoplasm malignant | | | |
| subjects affected / exposed | 1 / 826 (0.12%) | 0 / 822 (0.00%) | 1 / 824 (0.12%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| Malignant melanoma | | | |
| subjects affected / exposed | 1 / 826 (0.12%) | 0 / 822 (0.00%) | 0 / 824 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Metastases to bone | | | |
| subjects affected / exposed | 0 / 826 (0.00%) | 1 / 822 (0.12%) | 0 / 824 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Metastases to central nervous system | | | |
| subjects affected / exposed | 0 / 826 (0.00%) | 1 / 822 (0.12%) | 0 / 824 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| Metastases to liver | | | |
| subjects affected / exposed | 1 / 826 (0.12%) | 0 / 822 (0.00%) | 0 / 824 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| Metastases to lung | | | |
| subjects affected / exposed | 1 / 826 (0.12%) | 0 / 822 (0.00%) | 0 / 824 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Metastases to lymph nodes | | | |
| subjects affected / exposed | 1 / 826 (0.12%) | 0 / 822 (0.00%) | 0 / 824 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Metastatic gastric cancer | | | |

| | | | |
|---|-----------------|-----------------|-----------------|
| subjects affected / exposed | 1 / 826 (0.12%) | 0 / 822 (0.00%) | 0 / 824 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| Neoplasm of appendix | | | |
| subjects affected / exposed | 0 / 826 (0.00%) | 1 / 822 (0.12%) | 0 / 824 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Non-small cell lung cancer | | | |
| subjects affected / exposed | 0 / 826 (0.00%) | 0 / 822 (0.00%) | 0 / 824 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Ovarian epithelial cancer | | | |
| subjects affected / exposed | 1 / 826 (0.12%) | 0 / 822 (0.00%) | 0 / 824 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| Ovarian germ cell teratoma benign | | | |
| subjects affected / exposed | 1 / 826 (0.12%) | 0 / 822 (0.00%) | 0 / 824 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Pancreatic carcinoma | | | |
| subjects affected / exposed | 0 / 826 (0.00%) | 0 / 822 (0.00%) | 0 / 824 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Pancreatic carcinoma metastatic | | | |
| subjects affected / exposed | 0 / 826 (0.00%) | 0 / 822 (0.00%) | 1 / 824 (0.12%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 1 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 1 / 1 |
| Pancreatic carcinoma stage IV | | | |
| subjects affected / exposed | 0 / 826 (0.00%) | 1 / 822 (0.12%) | 0 / 824 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| Papillary thyroid cancer | | | |

| | | | |
|---|-----------------|-----------------|-----------------|
| subjects affected / exposed | 0 / 826 (0.00%) | 0 / 822 (0.00%) | 1 / 824 (0.12%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 1 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Paraganglion neoplasm | | | |
| subjects affected / exposed | 1 / 826 (0.12%) | 0 / 822 (0.00%) | 0 / 824 (0.00%) |
| occurrences causally related to treatment / all | 1 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Parathyroid tumour benign | | | |
| subjects affected / exposed | 0 / 826 (0.00%) | 1 / 822 (0.12%) | 2 / 824 (0.24%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 2 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Phaeochromocytoma | | | |
| subjects affected / exposed | 1 / 826 (0.12%) | 0 / 822 (0.00%) | 0 / 824 (0.00%) |
| occurrences causally related to treatment / all | 1 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Plasma cell myeloma | | | |
| subjects affected / exposed | 0 / 826 (0.00%) | 0 / 822 (0.00%) | 0 / 824 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Prostate cancer | | | |
| subjects affected / exposed | 3 / 826 (0.36%) | 3 / 822 (0.36%) | 4 / 824 (0.49%) |
| occurrences causally related to treatment / all | 0 / 3 | 0 / 3 | 0 / 4 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Prostate cancer metastatic | | | |
| subjects affected / exposed | 0 / 826 (0.00%) | 1 / 822 (0.12%) | 0 / 824 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Prostate cancer recurrent | | | |
| subjects affected / exposed | 0 / 826 (0.00%) | 0 / 822 (0.00%) | 0 / 824 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Prostate cancer stage I | | | |

| | | | |
|---|-----------------|-----------------|-----------------|
| subjects affected / exposed | 0 / 826 (0.00%) | 0 / 822 (0.00%) | 0 / 824 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Prostate cancer stage III | | | |
| subjects affected / exposed | 0 / 826 (0.00%) | 0 / 822 (0.00%) | 0 / 824 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Rectal cancer | | | |
| subjects affected / exposed | 0 / 826 (0.00%) | 1 / 822 (0.12%) | 1 / 824 (0.12%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Renal cancer metastatic | | | |
| subjects affected / exposed | 1 / 826 (0.12%) | 0 / 822 (0.00%) | 0 / 824 (0.00%) |
| occurrences causally related to treatment / all | 1 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Renal cancer stage I | | | |
| subjects affected / exposed | 0 / 826 (0.00%) | 0 / 822 (0.00%) | 0 / 824 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Renal cell carcinoma | | | |
| subjects affected / exposed | 0 / 826 (0.00%) | 1 / 822 (0.12%) | 0 / 824 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| Small cell lung cancer | | | |
| subjects affected / exposed | 0 / 826 (0.00%) | 2 / 822 (0.24%) | 2 / 824 (0.24%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 2 | 1 / 2 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 2 | 0 / 0 |
| Squamous cell carcinoma | | | |
| subjects affected / exposed | 0 / 826 (0.00%) | 1 / 822 (0.12%) | 0 / 824 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Squamous cell carcinoma of lung | | | |

| | | | |
|---|-----------------|-----------------|-----------------|
| subjects affected / exposed | 0 / 826 (0.00%) | 0 / 822 (0.00%) | 0 / 824 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Squamous cell carcinoma of skin | | | |
| subjects affected / exposed | 0 / 826 (0.00%) | 1 / 822 (0.12%) | 0 / 824 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Thyroid cancer metastatic | | | |
| subjects affected / exposed | 0 / 826 (0.00%) | 1 / 822 (0.12%) | 0 / 824 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| Thyroid neoplasm | | | |
| subjects affected / exposed | 0 / 826 (0.00%) | 1 / 822 (0.12%) | 1 / 824 (0.12%) |
| occurrences causally related to treatment / all | 0 / 0 | 1 / 1 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Transitional cell carcinoma | | | |
| subjects affected / exposed | 1 / 826 (0.12%) | 0 / 822 (0.00%) | 0 / 824 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Ureteric cancer | | | |
| subjects affected / exposed | 0 / 826 (0.00%) | 1 / 822 (0.12%) | 0 / 824 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Uterine leiomyoma | | | |
| subjects affected / exposed | 0 / 826 (0.00%) | 2 / 822 (0.24%) | 0 / 824 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 2 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Vascular disorders | | | |
| Aortic aneurysm | | | |
| subjects affected / exposed | 1 / 826 (0.12%) | 2 / 822 (0.24%) | 0 / 824 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 2 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Aortic dissection | | | |

| | | | |
|---|-----------------|-----------------|-----------------|
| subjects affected / exposed | 0 / 826 (0.00%) | 0 / 822 (0.00%) | 0 / 824 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Aortic stenosis | | | |
| subjects affected / exposed | 2 / 826 (0.24%) | 0 / 822 (0.00%) | 1 / 824 (0.12%) |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Arterial insufficiency | | | |
| subjects affected / exposed | 0 / 826 (0.00%) | 0 / 822 (0.00%) | 1 / 824 (0.12%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Circulatory collapse | | | |
| subjects affected / exposed | 1 / 826 (0.12%) | 0 / 822 (0.00%) | 0 / 824 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Deep vein thrombosis | | | |
| subjects affected / exposed | 1 / 826 (0.12%) | 1 / 822 (0.12%) | 0 / 824 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Extremity necrosis | | | |
| subjects affected / exposed | 1 / 826 (0.12%) | 0 / 822 (0.00%) | 0 / 824 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Femoral artery aneurysm | | | |
| subjects affected / exposed | 0 / 826 (0.00%) | 1 / 822 (0.12%) | 0 / 824 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Femoral artery occlusion | | | |
| subjects affected / exposed | 1 / 826 (0.12%) | 2 / 822 (0.24%) | 0 / 824 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 2 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Haematoma | | | |

| | | | |
|---|-----------------|-----------------|-----------------|
| subjects affected / exposed | 1 / 826 (0.12%) | 0 / 822 (0.00%) | 0 / 824 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Hypertension | | | |
| subjects affected / exposed | 1 / 826 (0.12%) | 1 / 822 (0.12%) | 3 / 824 (0.36%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 1 | 0 / 3 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Hypertensive crisis | | | |
| subjects affected / exposed | 3 / 826 (0.36%) | 1 / 822 (0.12%) | 0 / 824 (0.00%) |
| occurrences causally related to treatment / all | 0 / 3 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Hypertensive emergency | | | |
| subjects affected / exposed | 4 / 826 (0.48%) | 0 / 822 (0.00%) | 0 / 824 (0.00%) |
| occurrences causally related to treatment / all | 1 / 4 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Hypotension | | | |
| subjects affected / exposed | 2 / 826 (0.24%) | 0 / 822 (0.00%) | 3 / 824 (0.36%) |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 0 | 1 / 3 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 1 / 2 |
| Intra-abdominal haematoma | | | |
| subjects affected / exposed | 1 / 826 (0.12%) | 0 / 822 (0.00%) | 0 / 824 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Leriche syndrome | | | |
| subjects affected / exposed | 0 / 826 (0.00%) | 1 / 822 (0.12%) | 0 / 824 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Orthostatic hypotension | | | |
| subjects affected / exposed | 2 / 826 (0.24%) | 1 / 822 (0.12%) | 0 / 824 (0.00%) |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Peripheral arterial occlusive disease | | | |

| | | | |
|---|-----------------|-----------------|-----------------|
| subjects affected / exposed | 3 / 826 (0.36%) | 2 / 822 (0.24%) | 1 / 824 (0.12%) |
| occurrences causally related to treatment / all | 0 / 3 | 0 / 2 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Peripheral artery aneurysm | | | |
| subjects affected / exposed | 0 / 826 (0.00%) | 1 / 822 (0.12%) | 0 / 824 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Peripheral artery stenosis | | | |
| subjects affected / exposed | 0 / 826 (0.00%) | 0 / 822 (0.00%) | 1 / 824 (0.12%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Peripheral artery thrombosis | | | |
| subjects affected / exposed | 0 / 826 (0.00%) | 1 / 822 (0.12%) | 2 / 824 (0.24%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 2 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Peripheral ischaemia | | | |
| subjects affected / exposed | 0 / 826 (0.00%) | 0 / 822 (0.00%) | 1 / 824 (0.12%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Peripheral vascular disorder | | | |
| subjects affected / exposed | 0 / 826 (0.00%) | 0 / 822 (0.00%) | 2 / 824 (0.24%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 2 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Shock haemorrhagic | | | |
| subjects affected / exposed | 0 / 826 (0.00%) | 0 / 822 (0.00%) | 1 / 824 (0.12%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| Temporal arteritis | | | |
| subjects affected / exposed | 1 / 826 (0.12%) | 0 / 822 (0.00%) | 0 / 824 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Varicose vein | | | |

| | | | |
|---|-----------------|-----------------|-----------------|
| subjects affected / exposed | 0 / 826 (0.00%) | 1 / 822 (0.12%) | 0 / 824 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Vasculitis | | | |
| subjects affected / exposed | 0 / 826 (0.00%) | 0 / 822 (0.00%) | 1 / 824 (0.12%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 1 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Surgical and medical procedures | | | |
| Abdominal hernia repair | | | |
| subjects affected / exposed | 0 / 826 (0.00%) | 1 / 822 (0.12%) | 0 / 824 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Angioplasty | | | |
| subjects affected / exposed | 1 / 826 (0.12%) | 0 / 822 (0.00%) | 1 / 824 (0.12%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Brachytherapy | | | |
| subjects affected / exposed | 0 / 826 (0.00%) | 0 / 822 (0.00%) | 0 / 824 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Carotid angioplasty | | | |
| subjects affected / exposed | 0 / 826 (0.00%) | 0 / 822 (0.00%) | 0 / 824 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Carotid artery stent insertion | | | |
| subjects affected / exposed | 0 / 826 (0.00%) | 1 / 822 (0.12%) | 0 / 824 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Carotid endarterectomy | | | |
| subjects affected / exposed | 0 / 826 (0.00%) | 0 / 822 (0.00%) | 2 / 824 (0.24%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 2 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Carotid revascularisation | | | |

| | | | |
|---|------------------|------------------|------------------|
| subjects affected / exposed | 1 / 826 (0.12%) | 1 / 822 (0.12%) | 0 / 824 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Cataract operation | | | |
| subjects affected / exposed | 1 / 826 (0.12%) | 1 / 822 (0.12%) | 0 / 824 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Coronary angioplasty | | | |
| subjects affected / exposed | 1 / 826 (0.12%) | 1 / 822 (0.12%) | 4 / 824 (0.49%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 1 | 0 / 4 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Coronary arterial stent insertion | | | |
| subjects affected / exposed | 15 / 826 (1.82%) | 8 / 822 (0.97%) | 17 / 824 (2.06%) |
| occurrences causally related to treatment / all | 1 / 19 | 1 / 9 | 0 / 18 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Coronary artery bypass | | | |
| subjects affected / exposed | 8 / 826 (0.97%) | 5 / 822 (0.61%) | 14 / 824 (1.70%) |
| occurrences causally related to treatment / all | 0 / 8 | 0 / 5 | 1 / 14 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Coronary revascularisation | | | |
| subjects affected / exposed | 11 / 826 (1.33%) | 10 / 822 (1.22%) | 15 / 824 (1.82%) |
| occurrences causally related to treatment / all | 0 / 12 | 0 / 10 | 1 / 17 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Hospitalisation | | | |
| subjects affected / exposed | 1 / 826 (0.12%) | 0 / 822 (0.00%) | 1 / 824 (0.12%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Laparotomy | | | |
| subjects affected / exposed | 1 / 826 (0.12%) | 0 / 822 (0.00%) | 0 / 824 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Mechanical ventilation | | | |

| | | | |
|---|-----------------|-----------------|-----------------|
| subjects affected / exposed | 1 / 826 (0.12%) | 0 / 822 (0.00%) | 0 / 824 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Nasal polypectomy | | | |
| subjects affected / exposed | 0 / 826 (0.00%) | 0 / 822 (0.00%) | 0 / 824 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Percutaneous coronary intervention | | | |
| subjects affected / exposed | 2 / 826 (0.24%) | 1 / 822 (0.12%) | 3 / 824 (0.36%) |
| occurrences causally related to treatment / all | 1 / 2 | 0 / 1 | 0 / 4 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Peripheral artery angioplasty | | | |
| subjects affected / exposed | 2 / 826 (0.24%) | 1 / 822 (0.12%) | 0 / 824 (0.00%) |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Peripheral artery bypass | | | |
| subjects affected / exposed | 1 / 826 (0.12%) | 1 / 822 (0.12%) | 1 / 824 (0.12%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 1 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Peripheral artery stent insertion | | | |
| subjects affected / exposed | 1 / 826 (0.12%) | 3 / 822 (0.36%) | 0 / 824 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 3 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Peripheral endarterectomy | | | |
| subjects affected / exposed | 0 / 826 (0.00%) | 1 / 822 (0.12%) | 0 / 824 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Peripheral revascularisation | | | |
| subjects affected / exposed | 2 / 826 (0.24%) | 4 / 822 (0.49%) | 5 / 824 (0.61%) |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 4 | 0 / 5 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Pterygium operation | | | |

| | | | |
|--|-----------------|-----------------|-----------------|
| subjects affected / exposed | 1 / 826 (0.12%) | 0 / 822 (0.00%) | 0 / 824 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Removal of internal fixation | | | |
| subjects affected / exposed | 0 / 826 (0.00%) | 0 / 822 (0.00%) | 1 / 824 (0.12%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Renal artery stent placement | | | |
| subjects affected / exposed | 0 / 826 (0.00%) | 1 / 822 (0.12%) | 0 / 824 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Stent placement | | | |
| subjects affected / exposed | 2 / 826 (0.24%) | 2 / 822 (0.24%) | 1 / 824 (0.12%) |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 2 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Tendon sheath incision | | | |
| subjects affected / exposed | 0 / 826 (0.00%) | 1 / 822 (0.12%) | 0 / 824 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Umbilical hernia repair | | | |
| subjects affected / exposed | 0 / 826 (0.00%) | 1 / 822 (0.12%) | 0 / 824 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| General disorders and administration site conditions | | | |
| Asthenia | | | |
| subjects affected / exposed | 0 / 826 (0.00%) | 0 / 822 (0.00%) | 1 / 824 (0.12%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Chest discomfort | | | |
| subjects affected / exposed | 1 / 826 (0.12%) | 1 / 822 (0.12%) | 1 / 824 (0.12%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 1 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Chest pain | | | |

| | | | |
|---|-----------------|-----------------|-----------------|
| subjects affected / exposed | 1 / 826 (0.12%) | 3 / 822 (0.36%) | 5 / 824 (0.61%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 3 | 0 / 6 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Death | | | |
| subjects affected / exposed | 2 / 826 (0.24%) | 3 / 822 (0.36%) | 3 / 824 (0.36%) |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 3 | 0 / 3 |
| deaths causally related to treatment / all | 0 / 2 | 0 / 3 | 0 / 3 |
| Device malfunction | | | |
| subjects affected / exposed | 1 / 826 (0.12%) | 1 / 822 (0.12%) | 0 / 824 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Drug intolerance | | | |
| subjects affected / exposed | 0 / 826 (0.00%) | 1 / 822 (0.12%) | 0 / 824 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Gait disturbance | | | |
| subjects affected / exposed | 0 / 826 (0.00%) | 0 / 822 (0.00%) | 0 / 824 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Generalised oedema | | | |
| subjects affected / exposed | 1 / 826 (0.12%) | 0 / 822 (0.00%) | 0 / 824 (0.00%) |
| occurrences causally related to treatment / all | 1 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Hyperthermia malignant | | | |
| subjects affected / exposed | 0 / 826 (0.00%) | 1 / 822 (0.12%) | 0 / 824 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Impaired healing | | | |
| subjects affected / exposed | 0 / 826 (0.00%) | 0 / 822 (0.00%) | 1 / 824 (0.12%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Metaplasia | | | |

| | | | |
|---|-----------------|-----------------|-----------------|
| subjects affected / exposed | 1 / 826 (0.12%) | 0 / 822 (0.00%) | 0 / 824 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Microolithiasis | | | |
| subjects affected / exposed | 0 / 826 (0.00%) | 0 / 822 (0.00%) | 1 / 824 (0.12%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 1 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Multi-organ failure | | | |
| subjects affected / exposed | 0 / 826 (0.00%) | 0 / 822 (0.00%) | 1 / 824 (0.12%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| Necrosis | | | |
| subjects affected / exposed | 1 / 826 (0.12%) | 0 / 822 (0.00%) | 0 / 824 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Non-cardiac chest pain | | | |
| subjects affected / exposed | 8 / 826 (0.97%) | 5 / 822 (0.61%) | 8 / 824 (0.97%) |
| occurrences causally related to treatment / all | 1 / 8 | 0 / 5 | 0 / 8 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Oedema | | | |
| subjects affected / exposed | 0 / 826 (0.00%) | 1 / 822 (0.12%) | 0 / 824 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Oedema peripheral | | | |
| subjects affected / exposed | 0 / 826 (0.00%) | 1 / 822 (0.12%) | 1 / 824 (0.12%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Pyrexia | | | |
| subjects affected / exposed | 1 / 826 (0.12%) | 1 / 822 (0.12%) | 2 / 824 (0.24%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 1 | 0 / 2 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Sudden cardiac death | | | |

| | | | |
|---|-----------------|-----------------|-----------------|
| subjects affected / exposed | 1 / 826 (0.12%) | 0 / 822 (0.00%) | 0 / 824 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| Sudden death | | | |
| subjects affected / exposed | 1 / 826 (0.12%) | 0 / 822 (0.00%) | 1 / 824 (0.12%) |
| occurrences causally related to treatment / all | 1 / 1 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 1 / 1 | 0 / 0 | 0 / 1 |
| Immune system disorders | | | |
| Anaphylactic shock | | | |
| subjects affected / exposed | 1 / 826 (0.12%) | 0 / 822 (0.00%) | 1 / 824 (0.12%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| Drug hypersensitivity | | | |
| subjects affected / exposed | 1 / 826 (0.12%) | 0 / 822 (0.00%) | 0 / 824 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Hypersensitivity | | | |
| subjects affected / exposed | 1 / 826 (0.12%) | 0 / 822 (0.00%) | 0 / 824 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Sarcoidosis | | | |
| subjects affected / exposed | 0 / 826 (0.00%) | 1 / 822 (0.12%) | 0 / 824 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Reproductive system and breast disorders | | | |
| Benign prostatic hyperplasia | | | |
| subjects affected / exposed | 3 / 826 (0.36%) | 2 / 822 (0.24%) | 0 / 824 (0.00%) |
| occurrences causally related to treatment / all | 0 / 3 | 0 / 2 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Breast cyst | | | |
| subjects affected / exposed | 0 / 826 (0.00%) | 1 / 822 (0.12%) | 0 / 824 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |

| | | | |
|---|-----------------|-----------------|-----------------|
| Cystocele | | | |
| subjects affected / exposed | 0 / 826 (0.00%) | 0 / 822 (0.00%) | 0 / 824 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Endometrial hyperplasia | | | |
| subjects affected / exposed | 0 / 826 (0.00%) | 0 / 822 (0.00%) | 1 / 824 (0.12%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Epididymal tenderness | | | |
| subjects affected / exposed | 0 / 826 (0.00%) | 0 / 822 (0.00%) | 1 / 824 (0.12%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Erectile dysfunction | | | |
| subjects affected / exposed | 0 / 826 (0.00%) | 1 / 822 (0.12%) | 0 / 824 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Genital haemorrhage | | | |
| subjects affected / exposed | 0 / 826 (0.00%) | 1 / 822 (0.12%) | 0 / 824 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Menorrhagia | | | |
| subjects affected / exposed | 0 / 826 (0.00%) | 1 / 822 (0.12%) | 0 / 824 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Ovarian cyst | | | |
| subjects affected / exposed | 0 / 826 (0.00%) | 0 / 822 (0.00%) | 0 / 824 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Prostatic obstruction | | | |
| subjects affected / exposed | 0 / 826 (0.00%) | 0 / 822 (0.00%) | 1 / 824 (0.12%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Prostatomegaly | | | |

| | | | |
|---|-----------------|-----------------|-----------------|
| subjects affected / exposed | 1 / 826 (0.12%) | 0 / 822 (0.00%) | 0 / 824 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Testicular cyst | | | |
| subjects affected / exposed | 1 / 826 (0.12%) | 0 / 822 (0.00%) | 0 / 824 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Uterine polyp | | | |
| subjects affected / exposed | 0 / 826 (0.00%) | 0 / 822 (0.00%) | 1 / 824 (0.12%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Vaginal prolapse | | | |
| subjects affected / exposed | 0 / 826 (0.00%) | 1 / 822 (0.12%) | 1 / 824 (0.12%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Respiratory, thoracic and mediastinal disorders | | | |
| Acquired diaphragmatic eventration | | | |
| subjects affected / exposed | 1 / 826 (0.12%) | 0 / 822 (0.00%) | 0 / 824 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Acute pulmonary oedema | | | |
| subjects affected / exposed | 3 / 826 (0.36%) | 2 / 822 (0.24%) | 0 / 824 (0.00%) |
| occurrences causally related to treatment / all | 0 / 3 | 0 / 2 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| Acute respiratory failure | | | |
| subjects affected / exposed | 3 / 826 (0.36%) | 1 / 822 (0.12%) | 3 / 824 (0.36%) |
| occurrences causally related to treatment / all | 0 / 3 | 0 / 1 | 0 / 3 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 2 |
| Asthma | | | |
| subjects affected / exposed | 0 / 826 (0.00%) | 0 / 822 (0.00%) | 0 / 824 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Atelectasis | | | |

| | | | |
|---|-----------------|-----------------|-----------------|
| subjects affected / exposed | 1 / 826 (0.12%) | 0 / 822 (0.00%) | 1 / 824 (0.12%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Bronchitis chronic | | | |
| subjects affected / exposed | 0 / 826 (0.00%) | 1 / 822 (0.12%) | 0 / 824 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Bronchospasm | | | |
| subjects affected / exposed | 1 / 826 (0.12%) | 0 / 822 (0.00%) | 0 / 824 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Chronic obstructive pulmonary disease | | | |
| subjects affected / exposed | 3 / 826 (0.36%) | 5 / 822 (0.61%) | 7 / 824 (0.85%) |
| occurrences causally related to treatment / all | 0 / 6 | 0 / 5 | 0 / 7 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 3 | 0 / 0 |
| Dyspnoea | | | |
| subjects affected / exposed | 6 / 826 (0.73%) | 5 / 822 (0.61%) | 3 / 824 (0.36%) |
| occurrences causally related to treatment / all | 0 / 6 | 0 / 5 | 0 / 3 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Dyspnoea at rest | | | |
| subjects affected / exposed | 0 / 826 (0.00%) | 0 / 822 (0.00%) | 1 / 824 (0.12%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Epistaxis | | | |
| subjects affected / exposed | 0 / 826 (0.00%) | 1 / 822 (0.12%) | 0 / 824 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 1 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Haemoptysis | | | |
| subjects affected / exposed | 0 / 826 (0.00%) | 1 / 822 (0.12%) | 0 / 824 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 3 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Hydrothorax | | | |

| | | | |
|---|-----------------|-----------------|-----------------|
| subjects affected / exposed | 1 / 826 (0.12%) | 0 / 822 (0.00%) | 0 / 824 (0.00%) |
| occurrences causally related to treatment / all | 1 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Hyperventilation | | | |
| subjects affected / exposed | 0 / 826 (0.00%) | 1 / 822 (0.12%) | 0 / 824 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Hypoxia | | | |
| subjects affected / exposed | 1 / 826 (0.12%) | 0 / 822 (0.00%) | 0 / 824 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Idiopathic pulmonary fibrosis | | | |
| subjects affected / exposed | 1 / 826 (0.12%) | 0 / 822 (0.00%) | 0 / 824 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Laryngeal stenosis | | | |
| subjects affected / exposed | 0 / 826 (0.00%) | 0 / 822 (0.00%) | 1 / 824 (0.12%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| Lung cyst | | | |
| subjects affected / exposed | 0 / 826 (0.00%) | 1 / 822 (0.12%) | 0 / 824 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Pleural effusion | | | |
| subjects affected / exposed | 1 / 826 (0.12%) | 1 / 822 (0.12%) | 2 / 824 (0.24%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 1 | 0 / 3 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Pleurisy | | | |
| subjects affected / exposed | 0 / 826 (0.00%) | 0 / 822 (0.00%) | 0 / 824 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Pneumonia aspiration | | | |

| | | | |
|---|-----------------|-----------------|-----------------|
| subjects affected / exposed | 0 / 826 (0.00%) | 2 / 822 (0.24%) | 0 / 824 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 3 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| Pneumothorax | | | |
| subjects affected / exposed | 1 / 826 (0.12%) | 0 / 822 (0.00%) | 1 / 824 (0.12%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Pulmonary congestion | | | |
| subjects affected / exposed | 0 / 826 (0.00%) | 0 / 822 (0.00%) | 0 / 824 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Pulmonary embolism | | | |
| subjects affected / exposed | 2 / 826 (0.24%) | 4 / 822 (0.49%) | 3 / 824 (0.36%) |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 4 | 0 / 3 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Pulmonary hypertension | | | |
| subjects affected / exposed | 1 / 826 (0.12%) | 1 / 822 (0.12%) | 0 / 824 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Pulmonary mass | | | |
| subjects affected / exposed | 0 / 826 (0.00%) | 1 / 822 (0.12%) | 0 / 824 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Pulmonary oedema | | | |
| subjects affected / exposed | 2 / 826 (0.24%) | 1 / 822 (0.12%) | 2 / 824 (0.24%) |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 1 | 0 / 2 |
| deaths causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| Respiratory arrest | | | |
| subjects affected / exposed | 0 / 826 (0.00%) | 0 / 822 (0.00%) | 1 / 824 (0.12%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Respiratory distress | | | |

| | | | |
|---|-----------------|-----------------|-----------------|
| subjects affected / exposed | 1 / 826 (0.12%) | 0 / 822 (0.00%) | 1 / 824 (0.12%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Respiratory failure | | | |
| subjects affected / exposed | 2 / 826 (0.24%) | 3 / 822 (0.36%) | 3 / 824 (0.36%) |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 3 | 0 / 3 |
| deaths causally related to treatment / all | 0 / 2 | 0 / 1 | 0 / 1 |
| Psychiatric disorders | | | |
| Anxiety | | | |
| subjects affected / exposed | 0 / 826 (0.00%) | 1 / 822 (0.12%) | 0 / 824 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Confusional state | | | |
| subjects affected / exposed | 0 / 826 (0.00%) | 1 / 822 (0.12%) | 0 / 824 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Delirium | | | |
| subjects affected / exposed | 0 / 826 (0.00%) | 2 / 822 (0.24%) | 1 / 824 (0.12%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 2 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Depression | | | |
| subjects affected / exposed | 1 / 826 (0.12%) | 2 / 822 (0.24%) | 3 / 824 (0.36%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 2 | 0 / 3 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Homicidal ideation | | | |
| subjects affected / exposed | 0 / 826 (0.00%) | 0 / 822 (0.00%) | 1 / 824 (0.12%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Mental status changes | | | |
| subjects affected / exposed | 1 / 826 (0.12%) | 0 / 822 (0.00%) | 2 / 824 (0.24%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 2 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Post-traumatic stress disorder | | | |

| | | | |
|---|-----------------|-----------------|-----------------|
| subjects affected / exposed | 0 / 826 (0.00%) | 0 / 822 (0.00%) | 1 / 824 (0.12%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Schizoaffective disorder | | | |
| subjects affected / exposed | 0 / 826 (0.00%) | 1 / 822 (0.12%) | 0 / 824 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Sleep terror | | | |
| subjects affected / exposed | 1 / 826 (0.12%) | 0 / 822 (0.00%) | 0 / 824 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Investigations | | | |
| Amylase increased | | | |
| subjects affected / exposed | 0 / 826 (0.00%) | 1 / 822 (0.12%) | 0 / 824 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 1 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Arteriogram coronary | | | |
| subjects affected / exposed | 1 / 826 (0.12%) | 0 / 822 (0.00%) | 0 / 824 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Bacterial test positive | | | |
| subjects affected / exposed | 0 / 826 (0.00%) | 0 / 822 (0.00%) | 0 / 824 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Blood alkaline phosphatase increased | | | |
| subjects affected / exposed | 0 / 826 (0.00%) | 0 / 822 (0.00%) | 1 / 824 (0.12%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 1 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Blood bilirubin increased | | | |
| subjects affected / exposed | 0 / 826 (0.00%) | 0 / 822 (0.00%) | 1 / 824 (0.12%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 1 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Blood creatinine increased | | | |

| | | | |
|---|-----------------|-----------------|-----------------|
| subjects affected / exposed | 0 / 826 (0.00%) | 0 / 822 (0.00%) | 1 / 824 (0.12%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 1 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Blood glucose fluctuation | | | |
| subjects affected / exposed | 0 / 826 (0.00%) | 0 / 822 (0.00%) | 0 / 824 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Blood glucose increased | | | |
| subjects affected / exposed | 1 / 826 (0.12%) | 0 / 822 (0.00%) | 0 / 824 (0.00%) |
| occurrences causally related to treatment / all | 2 / 6 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Blood urea increased | | | |
| subjects affected / exposed | 0 / 826 (0.00%) | 0 / 822 (0.00%) | 1 / 824 (0.12%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 1 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Catheterisation cardiac | | | |
| subjects affected / exposed | 0 / 826 (0.00%) | 0 / 822 (0.00%) | 1 / 824 (0.12%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Coagulation time prolonged | | | |
| subjects affected / exposed | 1 / 826 (0.12%) | 0 / 822 (0.00%) | 0 / 824 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Ejection fraction decreased | | | |
| subjects affected / exposed | 1 / 826 (0.12%) | 0 / 822 (0.00%) | 0 / 824 (0.00%) |
| occurrences causally related to treatment / all | 1 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Electrocardiogram QT prolonged | | | |
| subjects affected / exposed | 0 / 826 (0.00%) | 1 / 822 (0.12%) | 0 / 824 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Electrocardiogram ST segment abnormal | | | |

| | | | |
|---|-----------------|-----------------|-----------------|
| subjects affected / exposed | 0 / 826 (0.00%) | 0 / 822 (0.00%) | 1 / 824 (0.12%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Electrocardiogram T wave inversion | | | |
| subjects affected / exposed | 0 / 826 (0.00%) | 0 / 822 (0.00%) | 1 / 824 (0.12%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Electrocardiogram change | | | |
| subjects affected / exposed | 0 / 826 (0.00%) | 0 / 822 (0.00%) | 0 / 824 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Lipase increased | | | |
| subjects affected / exposed | 0 / 826 (0.00%) | 1 / 822 (0.12%) | 0 / 824 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 1 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Liver function test abnormal | | | |
| subjects affected / exposed | 0 / 826 (0.00%) | 1 / 822 (0.12%) | 0 / 824 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 1 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Pancreatic enzymes increased | | | |
| subjects affected / exposed | 1 / 826 (0.12%) | 0 / 822 (0.00%) | 0 / 824 (0.00%) |
| occurrences causally related to treatment / all | 1 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Transaminases increased | | | |
| subjects affected / exposed | 0 / 826 (0.00%) | 0 / 822 (0.00%) | 1 / 824 (0.12%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 1 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Troponin increased | | | |
| subjects affected / exposed | 0 / 826 (0.00%) | 1 / 822 (0.12%) | 1 / 824 (0.12%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Weight decreased | | | |

| | | | |
|---|-----------------|-----------------|-----------------|
| subjects affected / exposed | 0 / 826 (0.00%) | 1 / 822 (0.12%) | 0 / 824 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 1 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Injury, poisoning and procedural complications | | | |
| Accident at work | | | |
| subjects affected / exposed | 1 / 826 (0.12%) | 0 / 822 (0.00%) | 1 / 824 (0.12%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Alcohol poisoning | | | |
| subjects affected / exposed | 0 / 826 (0.00%) | 1 / 822 (0.12%) | 0 / 824 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Anaemia postoperative | | | |
| subjects affected / exposed | 1 / 826 (0.12%) | 0 / 822 (0.00%) | 0 / 824 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Animal bite | | | |
| subjects affected / exposed | 1 / 826 (0.12%) | 0 / 822 (0.00%) | 0 / 824 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Ankle fracture | | | |
| subjects affected / exposed | 2 / 826 (0.24%) | 0 / 822 (0.00%) | 2 / 824 (0.24%) |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 0 | 0 / 2 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Burns third degree | | | |
| subjects affected / exposed | 0 / 826 (0.00%) | 1 / 822 (0.12%) | 0 / 824 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Cervical vertebral fracture | | | |
| subjects affected / exposed | 0 / 826 (0.00%) | 0 / 822 (0.00%) | 1 / 824 (0.12%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Contusion | | | |

| | | | |
|---|------------------|-----------------|------------------|
| subjects affected / exposed | 0 / 826 (0.00%) | 0 / 822 (0.00%) | 1 / 824 (0.12%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Dural tear | | | |
| subjects affected / exposed | 0 / 826 (0.00%) | 0 / 822 (0.00%) | 1 / 824 (0.12%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Failure to anastomose | | | |
| subjects affected / exposed | 0 / 826 (0.00%) | 0 / 822 (0.00%) | 0 / 824 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Fall | | | |
| subjects affected / exposed | 11 / 826 (1.33%) | 5 / 822 (0.61%) | 11 / 824 (1.33%) |
| occurrences causally related to treatment / all | 0 / 11 | 0 / 5 | 0 / 11 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Femur fracture | | | |
| subjects affected / exposed | 1 / 826 (0.12%) | 1 / 822 (0.12%) | 0 / 824 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Foot fracture | | | |
| subjects affected / exposed | 0 / 826 (0.00%) | 0 / 822 (0.00%) | 0 / 824 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Hand fracture | | | |
| subjects affected / exposed | 0 / 826 (0.00%) | 0 / 822 (0.00%) | 0 / 824 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Head injury | | | |
| subjects affected / exposed | 1 / 826 (0.12%) | 0 / 822 (0.00%) | 1 / 824 (0.12%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Hip fracture | | | |

| | | | |
|---|-----------------|-----------------|-----------------|
| subjects affected / exposed | 0 / 826 (0.00%) | 1 / 822 (0.12%) | 0 / 824 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Humerus fracture | | | |
| subjects affected / exposed | 0 / 826 (0.00%) | 2 / 822 (0.24%) | 0 / 824 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 3 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Incisional hernia | | | |
| subjects affected / exposed | 0 / 826 (0.00%) | 0 / 822 (0.00%) | 1 / 824 (0.12%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Incorrect dose administered | | | |
| subjects affected / exposed | 1 / 826 (0.12%) | 0 / 822 (0.00%) | 0 / 824 (0.00%) |
| occurrences causally related to treatment / all | 2 / 2 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Injury | | | |
| subjects affected / exposed | 0 / 826 (0.00%) | 1 / 822 (0.12%) | 0 / 824 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Intentional overdose | | | |
| subjects affected / exposed | 0 / 826 (0.00%) | 0 / 822 (0.00%) | 0 / 824 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Laceration | | | |
| subjects affected / exposed | 1 / 826 (0.12%) | 0 / 822 (0.00%) | 0 / 824 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Limb injury | | | |
| subjects affected / exposed | 1 / 826 (0.12%) | 0 / 822 (0.00%) | 0 / 824 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Lumbar vertebral fracture | | | |

| | | | |
|---|-----------------|-----------------|-----------------|
| subjects affected / exposed | 0 / 826 (0.00%) | 0 / 822 (0.00%) | 1 / 824 (0.12%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Meniscus injury | | | |
| subjects affected / exposed | 0 / 826 (0.00%) | 1 / 822 (0.12%) | 0 / 824 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Muscle strain | | | |
| subjects affected / exposed | 0 / 826 (0.00%) | 0 / 822 (0.00%) | 0 / 824 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Near drowning | | | |
| subjects affected / exposed | 0 / 826 (0.00%) | 1 / 822 (0.12%) | 0 / 824 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Overdose | | | |
| subjects affected / exposed | 0 / 826 (0.00%) | 0 / 822 (0.00%) | 0 / 824 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Post procedural haematoma | | | |
| subjects affected / exposed | 0 / 826 (0.00%) | 0 / 822 (0.00%) | 0 / 824 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Postoperative ileus | | | |
| subjects affected / exposed | 0 / 826 (0.00%) | 1 / 822 (0.12%) | 1 / 824 (0.12%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Postoperative respiratory failure | | | |
| subjects affected / exposed | 1 / 826 (0.12%) | 0 / 822 (0.00%) | 1 / 824 (0.12%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Radius fracture | | | |

| | | | |
|---|-----------------|-----------------|-----------------|
| subjects affected / exposed | 0 / 826 (0.00%) | 1 / 822 (0.12%) | 0 / 824 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Rib fracture | | | |
| subjects affected / exposed | 0 / 826 (0.00%) | 0 / 822 (0.00%) | 1 / 824 (0.12%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Road traffic accident | | | |
| subjects affected / exposed | 2 / 826 (0.24%) | 4 / 822 (0.49%) | 3 / 824 (0.36%) |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 4 | 0 / 3 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Scapula fracture | | | |
| subjects affected / exposed | 0 / 826 (0.00%) | 0 / 822 (0.00%) | 0 / 824 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Seroma | | | |
| subjects affected / exposed | 0 / 826 (0.00%) | 0 / 822 (0.00%) | 1 / 824 (0.12%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Skin abrasion | | | |
| subjects affected / exposed | 0 / 826 (0.00%) | 0 / 822 (0.00%) | 0 / 824 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Skull fracture | | | |
| subjects affected / exposed | 0 / 826 (0.00%) | 0 / 822 (0.00%) | 0 / 824 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Spinal compression fracture | | | |
| subjects affected / exposed | 0 / 826 (0.00%) | 0 / 822 (0.00%) | 1 / 824 (0.12%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Subdural haematoma | | | |

| | | | |
|---|-----------------|-----------------|-----------------|
| subjects affected / exposed | 1 / 826 (0.12%) | 2 / 822 (0.24%) | 1 / 824 (0.12%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 2 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| Tendon rupture | | | |
| subjects affected / exposed | 0 / 826 (0.00%) | 0 / 822 (0.00%) | 0 / 824 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Thermal burn | | | |
| subjects affected / exposed | 0 / 826 (0.00%) | 1 / 822 (0.12%) | 0 / 824 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Toxicity to various agents | | | |
| subjects affected / exposed | 0 / 826 (0.00%) | 0 / 822 (0.00%) | 1 / 824 (0.12%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 1 / 2 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 1 / 1 |
| Traumatic fracture | | | |
| subjects affected / exposed | 1 / 826 (0.12%) | 0 / 822 (0.00%) | 0 / 824 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Traumatic haemothorax | | | |
| subjects affected / exposed | 0 / 826 (0.00%) | 0 / 822 (0.00%) | 1 / 824 (0.12%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Traumatic ulcer | | | |
| subjects affected / exposed | 0 / 826 (0.00%) | 1 / 822 (0.12%) | 0 / 824 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Vascular graft complication | | | |
| subjects affected / exposed | 0 / 826 (0.00%) | 0 / 822 (0.00%) | 1 / 824 (0.12%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Vascular graft occlusion | | | |

| | | | |
|---|-----------------|-----------------|-----------------|
| subjects affected / exposed | 0 / 826 (0.00%) | 0 / 822 (0.00%) | 1 / 824 (0.12%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Vascular pseudoaneurysm | | | |
| subjects affected / exposed | 1 / 826 (0.12%) | 1 / 822 (0.12%) | 0 / 824 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Wound | | | |
| subjects affected / exposed | 1 / 826 (0.12%) | 0 / 822 (0.00%) | 0 / 824 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Wound necrosis | | | |
| subjects affected / exposed | 0 / 826 (0.00%) | 0 / 822 (0.00%) | 1 / 824 (0.12%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Wrong drug administered | | | |
| subjects affected / exposed | 1 / 826 (0.12%) | 0 / 822 (0.00%) | 0 / 824 (0.00%) |
| occurrences causally related to treatment / all | 1 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Congenital, familial and genetic disorders | | | |
| Phimosis | | | |
| subjects affected / exposed | 0 / 826 (0.00%) | 1 / 822 (0.12%) | 0 / 824 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Cardiac disorders | | | |
| Acute coronary syndrome | | | |
| subjects affected / exposed | 4 / 826 (0.48%) | 3 / 822 (0.36%) | 1 / 824 (0.12%) |
| occurrences causally related to treatment / all | 1 / 4 | 0 / 3 | 0 / 1 |
| deaths causally related to treatment / all | 1 / 1 | 0 / 0 | 0 / 0 |
| Acute left ventricular failure | | | |
| subjects affected / exposed | 0 / 826 (0.00%) | 0 / 822 (0.00%) | 0 / 824 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |

| | | | |
|---|------------------|------------------|------------------|
| Acute myocardial infarction | | | |
| subjects affected / exposed | 16 / 826 (1.94%) | 13 / 822 (1.58%) | 15 / 824 (1.82%) |
| occurrences causally related to treatment / all | 1 / 21 | 2 / 14 | 1 / 15 |
| deaths causally related to treatment / all | 1 / 5 | 0 / 0 | 0 / 0 |
| Angina pectoris | | | |
| subjects affected / exposed | 9 / 826 (1.09%) | 9 / 822 (1.09%) | 16 / 824 (1.94%) |
| occurrences causally related to treatment / all | 1 / 9 | 1 / 10 | 2 / 17 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Angina unstable | | | |
| subjects affected / exposed | 13 / 826 (1.57%) | 15 / 822 (1.82%) | 19 / 824 (2.31%) |
| occurrences causally related to treatment / all | 0 / 16 | 0 / 18 | 0 / 21 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Aortic valve disease | | | |
| subjects affected / exposed | 1 / 826 (0.12%) | 0 / 822 (0.00%) | 0 / 824 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| Aortic valve stenosis | | | |
| subjects affected / exposed | 0 / 826 (0.00%) | 1 / 822 (0.12%) | 0 / 824 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Arrhythmia | | | |
| subjects affected / exposed | 1 / 826 (0.12%) | 1 / 822 (0.12%) | 1 / 824 (0.12%) |
| occurrences causally related to treatment / all | 2 / 2 | 0 / 1 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| Arteriosclerosis coronary artery | | | |
| subjects affected / exposed | 0 / 826 (0.00%) | 0 / 822 (0.00%) | 0 / 824 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Atrial fibrillation | | | |
| subjects affected / exposed | 14 / 826 (1.69%) | 12 / 822 (1.46%) | 20 / 824 (2.43%) |
| occurrences causally related to treatment / all | 1 / 16 | 2 / 15 | 4 / 22 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Atrial flutter | | | |

| | | | |
|---|-----------------|-----------------|-----------------|
| subjects affected / exposed | 1 / 826 (0.12%) | 1 / 822 (0.12%) | 4 / 824 (0.49%) |
| occurrences causally related to treatment / all | 0 / 1 | 1 / 1 | 0 / 4 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Atrial thrombosis | | | |
| subjects affected / exposed | 0 / 826 (0.00%) | 0 / 822 (0.00%) | 1 / 824 (0.12%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Atrioventricular block | | | |
| subjects affected / exposed | 0 / 826 (0.00%) | 0 / 822 (0.00%) | 1 / 824 (0.12%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Atrioventricular block complete | | | |
| subjects affected / exposed | 1 / 826 (0.12%) | 0 / 822 (0.00%) | 2 / 824 (0.24%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 2 |
| deaths causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| Atrioventricular block first degree | | | |
| subjects affected / exposed | 0 / 826 (0.00%) | 1 / 822 (0.12%) | 1 / 824 (0.12%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 1 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 1 / 1 |
| Atrioventricular block second degree | | | |
| subjects affected / exposed | 0 / 826 (0.00%) | 2 / 822 (0.24%) | 1 / 824 (0.12%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 2 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Bradyarrhythmia | | | |
| subjects affected / exposed | 0 / 826 (0.00%) | 0 / 822 (0.00%) | 2 / 824 (0.24%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 2 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Bradycardia | | | |
| subjects affected / exposed | 1 / 826 (0.12%) | 1 / 822 (0.12%) | 2 / 824 (0.24%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 1 | 1 / 2 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 1 / 1 |
| Bundle branch block left | | | |

| | | | |
|---|------------------|------------------|------------------|
| subjects affected / exposed | 2 / 826 (0.24%) | 1 / 822 (0.12%) | 0 / 824 (0.00%) |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Bundle branch block right | | | |
| subjects affected / exposed | 0 / 826 (0.00%) | 1 / 822 (0.12%) | 0 / 824 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Cardiac arrest | | | |
| subjects affected / exposed | 5 / 826 (0.61%) | 2 / 822 (0.24%) | 3 / 824 (0.36%) |
| occurrences causally related to treatment / all | 0 / 6 | 0 / 2 | 0 / 3 |
| deaths causally related to treatment / all | 0 / 4 | 0 / 2 | 0 / 3 |
| Cardiac asthma | | | |
| subjects affected / exposed | 1 / 826 (0.12%) | 0 / 822 (0.00%) | 0 / 824 (0.00%) |
| occurrences causally related to treatment / all | 1 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Cardiac failure | | | |
| subjects affected / exposed | 10 / 826 (1.21%) | 10 / 822 (1.22%) | 7 / 824 (0.85%) |
| occurrences causally related to treatment / all | 0 / 11 | 2 / 10 | 0 / 9 |
| deaths causally related to treatment / all | 0 / 2 | 1 / 1 | 0 / 0 |
| Cardiac failure acute | | | |
| subjects affected / exposed | 2 / 826 (0.24%) | 0 / 822 (0.00%) | 4 / 824 (0.49%) |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 0 | 0 / 4 |
| deaths causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 3 |
| Cardiac failure chronic | | | |
| subjects affected / exposed | 8 / 826 (0.97%) | 4 / 822 (0.49%) | 6 / 824 (0.73%) |
| occurrences causally related to treatment / all | 2 / 8 | 0 / 4 | 2 / 6 |
| deaths causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| Cardiac failure congestive | | | |
| subjects affected / exposed | 21 / 826 (2.54%) | 14 / 822 (1.70%) | 15 / 824 (1.82%) |
| occurrences causally related to treatment / all | 2 / 31 | 0 / 17 | 0 / 19 |
| deaths causally related to treatment / all | 0 / 1 | 0 / 2 | 0 / 2 |
| Cardiac tamponade | | | |

| | | | |
|---|-----------------|-----------------|-----------------|
| subjects affected / exposed | 1 / 826 (0.12%) | 0 / 822 (0.00%) | 0 / 824 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Cardiac ventricular thrombosis | | | |
| subjects affected / exposed | 0 / 826 (0.00%) | 0 / 822 (0.00%) | 0 / 824 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Cardio-respiratory arrest | | | |
| subjects affected / exposed | 1 / 826 (0.12%) | 1 / 822 (0.12%) | 0 / 824 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 1 | 0 / 1 | 0 / 0 |
| Cardiogenic shock | | | |
| subjects affected / exposed | 0 / 826 (0.00%) | 1 / 822 (0.12%) | 3 / 824 (0.36%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 1 / 3 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 1 | 1 / 3 |
| Cardiomyopathy | | | |
| subjects affected / exposed | 0 / 826 (0.00%) | 1 / 822 (0.12%) | 0 / 824 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Cardiopulmonary failure | | | |
| subjects affected / exposed | 0 / 826 (0.00%) | 1 / 822 (0.12%) | 1 / 824 (0.12%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| Cardiovascular insufficiency | | | |
| subjects affected / exposed | 0 / 826 (0.00%) | 1 / 822 (0.12%) | 0 / 824 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| Congestive cardiomyopathy | | | |
| subjects affected / exposed | 1 / 826 (0.12%) | 0 / 822 (0.00%) | 0 / 824 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Cor pulmonale acute | | | |

| | | | |
|---|------------------|-----------------|-----------------|
| subjects affected / exposed | 1 / 826 (0.12%) | 0 / 822 (0.00%) | 0 / 824 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Coronary artery disease | | | |
| subjects affected / exposed | 11 / 826 (1.33%) | 9 / 822 (1.09%) | 5 / 824 (0.61%) |
| occurrences causally related to treatment / all | 1 / 11 | 1 / 9 | 1 / 6 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| Coronary artery insufficiency | | | |
| subjects affected / exposed | 1 / 826 (0.12%) | 0 / 822 (0.00%) | 0 / 824 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Coronary artery occlusion | | | |
| subjects affected / exposed | 0 / 826 (0.00%) | 1 / 822 (0.12%) | 0 / 824 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Coronary artery stenosis | | | |
| subjects affected / exposed | 7 / 826 (0.85%) | 2 / 822 (0.24%) | 4 / 824 (0.49%) |
| occurrences causally related to treatment / all | 0 / 7 | 0 / 2 | 0 / 4 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Diabetic cardiomyopathy | | | |
| subjects affected / exposed | 0 / 826 (0.00%) | 0 / 822 (0.00%) | 0 / 824 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Hypertensive cardiomyopathy | | | |
| subjects affected / exposed | 0 / 826 (0.00%) | 1 / 822 (0.12%) | 0 / 824 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Ischaemic cardiomyopathy | | | |
| subjects affected / exposed | 0 / 826 (0.00%) | 0 / 822 (0.00%) | 0 / 824 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Left ventricular failure | | | |

| | | | |
|---|-----------------|------------------|-----------------|
| subjects affected / exposed | 1 / 826 (0.12%) | 1 / 822 (0.12%) | 0 / 824 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Mitral valve incompetence | | | |
| subjects affected / exposed | 1 / 826 (0.12%) | 0 / 822 (0.00%) | 0 / 824 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Myocardial infarction | | | |
| subjects affected / exposed | 4 / 826 (0.48%) | 10 / 822 (1.22%) | 9 / 824 (1.09%) |
| occurrences causally related to treatment / all | 2 / 4 | 1 / 10 | 0 / 10 |
| deaths causally related to treatment / all | 0 / 1 | 1 / 3 | 0 / 1 |
| Myocardial ischaemia | | | |
| subjects affected / exposed | 6 / 826 (0.73%) | 2 / 822 (0.24%) | 3 / 824 (0.36%) |
| occurrences causally related to treatment / all | 1 / 6 | 0 / 2 | 0 / 3 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| Myocarditis | | | |
| subjects affected / exposed | 1 / 826 (0.12%) | 0 / 822 (0.00%) | 0 / 824 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Nodal arrhythmia | | | |
| subjects affected / exposed | 1 / 826 (0.12%) | 0 / 822 (0.00%) | 0 / 824 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Pericardial effusion | | | |
| subjects affected / exposed | 2 / 826 (0.24%) | 0 / 822 (0.00%) | 0 / 824 (0.00%) |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Pulmonary valve stenosis | | | |
| subjects affected / exposed | 0 / 826 (0.00%) | 1 / 822 (0.12%) | 0 / 824 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| Right ventricular failure | | | |

| | | | |
|---|-----------------|-----------------|-----------------|
| subjects affected / exposed | 0 / 826 (0.00%) | 0 / 822 (0.00%) | 0 / 824 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Silent myocardial infarction | | | |
| subjects affected / exposed | 0 / 826 (0.00%) | 2 / 822 (0.24%) | 1 / 824 (0.12%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 2 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Sinus bradycardia | | | |
| subjects affected / exposed | 1 / 826 (0.12%) | 0 / 822 (0.00%) | 0 / 824 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| Sinus node dysfunction | | | |
| subjects affected / exposed | 0 / 826 (0.00%) | 2 / 822 (0.24%) | 2 / 824 (0.24%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 2 | 0 / 2 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Stress cardiomyopathy | | | |
| subjects affected / exposed | 0 / 826 (0.00%) | 1 / 822 (0.12%) | 0 / 824 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Supraventricular extrasystoles | | | |
| subjects affected / exposed | 0 / 826 (0.00%) | 1 / 822 (0.12%) | 0 / 824 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Supraventricular tachycardia | | | |
| subjects affected / exposed | 2 / 826 (0.24%) | 2 / 822 (0.24%) | 2 / 824 (0.24%) |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 2 | 0 / 2 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Tachycardia | | | |
| subjects affected / exposed | 0 / 826 (0.00%) | 1 / 822 (0.12%) | 0 / 824 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Tricuspid valve incompetence | | | |

| | | | |
|---|-----------------|-----------------|-----------------|
| subjects affected / exposed | 1 / 826 (0.12%) | 0 / 822 (0.00%) | 0 / 824 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Ventricular arrhythmia | | | |
| subjects affected / exposed | 1 / 826 (0.12%) | 0 / 822 (0.00%) | 0 / 824 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Ventricular asystole | | | |
| subjects affected / exposed | 0 / 826 (0.00%) | 0 / 822 (0.00%) | 0 / 824 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Ventricular extrasystoles | | | |
| subjects affected / exposed | 1 / 826 (0.12%) | 0 / 822 (0.00%) | 1 / 824 (0.12%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Ventricular fibrillation | | | |
| subjects affected / exposed | 0 / 826 (0.00%) | 2 / 822 (0.24%) | 1 / 824 (0.12%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 2 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Ventricular hypokinesia | | | |
| subjects affected / exposed | 0 / 826 (0.00%) | 0 / 822 (0.00%) | 1 / 824 (0.12%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Ventricular tachyarrhythmia | | | |
| subjects affected / exposed | 1 / 826 (0.12%) | 0 / 822 (0.00%) | 0 / 824 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Ventricular tachycardia | | | |
| subjects affected / exposed | 1 / 826 (0.12%) | 8 / 822 (0.97%) | 1 / 824 (0.12%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 8 | 0 / 2 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| Nervous system disorders | | | |
| Brain oedema | | | |

| | | | |
|---|-----------------|-----------------|-----------------|
| subjects affected / exposed | 0 / 826 (0.00%) | 0 / 822 (0.00%) | 0 / 824 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Brain stem infarction | | | |
| subjects affected / exposed | 1 / 826 (0.12%) | 0 / 822 (0.00%) | 0 / 824 (0.00%) |
| occurrences causally related to treatment / all | 1 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Carotid artery occlusion | | | |
| subjects affected / exposed | 0 / 826 (0.00%) | 0 / 822 (0.00%) | 0 / 824 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Carotid artery stenosis | | | |
| subjects affected / exposed | 0 / 826 (0.00%) | 0 / 822 (0.00%) | 3 / 824 (0.36%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 3 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Cerebellar haemorrhage | | | |
| subjects affected / exposed | 0 / 826 (0.00%) | 0 / 822 (0.00%) | 1 / 824 (0.12%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Cerebellar syndrome | | | |
| subjects affected / exposed | 0 / 826 (0.00%) | 0 / 822 (0.00%) | 1 / 824 (0.12%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Cerebral haemorrhage | | | |
| subjects affected / exposed | 1 / 826 (0.12%) | 0 / 822 (0.00%) | 0 / 824 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Cerebral infarction | | | |
| subjects affected / exposed | 2 / 826 (0.24%) | 2 / 822 (0.24%) | 3 / 824 (0.36%) |
| occurrences causally related to treatment / all | 1 / 2 | 1 / 3 | 1 / 3 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 1 |
| Cerebral ischaemia | | | |

| | | | |
|---|-----------------|-----------------|-----------------|
| subjects affected / exposed | 0 / 826 (0.00%) | 0 / 822 (0.00%) | 0 / 824 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Cerebrospinal fluid leakage | | | |
| subjects affected / exposed | 0 / 826 (0.00%) | 0 / 822 (0.00%) | 1 / 824 (0.12%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Cerebrovascular accident | | | |
| subjects affected / exposed | 3 / 826 (0.36%) | 3 / 822 (0.36%) | 6 / 824 (0.73%) |
| occurrences causally related to treatment / all | 0 / 3 | 1 / 3 | 0 / 6 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| Cerebrovascular disorder | | | |
| subjects affected / exposed | 1 / 826 (0.12%) | 0 / 822 (0.00%) | 0 / 824 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Cervical myelopathy | | | |
| subjects affected / exposed | 0 / 826 (0.00%) | 0 / 822 (0.00%) | 0 / 824 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Cervical radiculopathy | | | |
| subjects affected / exposed | 0 / 826 (0.00%) | 1 / 822 (0.12%) | 0 / 824 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Chronic inflammatory demyelinating polyradiculoneuropathy | | | |
| subjects affected / exposed | 1 / 826 (0.12%) | 0 / 822 (0.00%) | 0 / 824 (0.00%) |
| occurrences causally related to treatment / all | 1 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Coma | | | |
| subjects affected / exposed | 0 / 826 (0.00%) | 2 / 822 (0.24%) | 0 / 824 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 3 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Coordination abnormal | | | |

| | | | |
|---|-----------------|-----------------|-----------------|
| subjects affected / exposed | 0 / 826 (0.00%) | 0 / 822 (0.00%) | 0 / 824 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Cranial nerve disorder | | | |
| subjects affected / exposed | 1 / 826 (0.12%) | 0 / 822 (0.00%) | 0 / 824 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Diabetic mononeuropathy | | | |
| subjects affected / exposed | 1 / 826 (0.12%) | 0 / 822 (0.00%) | 0 / 824 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Dizziness | | | |
| subjects affected / exposed | 0 / 826 (0.00%) | 0 / 822 (0.00%) | 1 / 824 (0.12%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 2 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Embololic stroke | | | |
| subjects affected / exposed | 0 / 826 (0.00%) | 0 / 822 (0.00%) | 0 / 824 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Epilepsy | | | |
| subjects affected / exposed | 1 / 826 (0.12%) | 1 / 822 (0.12%) | 1 / 824 (0.12%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 1 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Haemorrhage intracranial | | | |
| subjects affected / exposed | 0 / 826 (0.00%) | 0 / 822 (0.00%) | 1 / 824 (0.12%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Haemorrhagic stroke | | | |
| subjects affected / exposed | 1 / 826 (0.12%) | 1 / 822 (0.12%) | 4 / 824 (0.49%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 1 | 0 / 4 |
| deaths causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 1 |
| Headache | | | |

| | | | |
|---|-----------------|-----------------|-----------------|
| subjects affected / exposed | 1 / 826 (0.12%) | 1 / 822 (0.12%) | 0 / 824 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 1 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Hepatic encephalopathy | | | |
| subjects affected / exposed | 1 / 826 (0.12%) | 0 / 822 (0.00%) | 0 / 824 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Hydrocephalus | | | |
| subjects affected / exposed | 0 / 826 (0.00%) | 0 / 822 (0.00%) | 0 / 824 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Hypertensive encephalopathy | | | |
| subjects affected / exposed | 0 / 826 (0.00%) | 0 / 822 (0.00%) | 0 / 824 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Hypoaesthesia | | | |
| subjects affected / exposed | 0 / 826 (0.00%) | 1 / 822 (0.12%) | 0 / 824 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Hypoglycaemic coma | | | |
| subjects affected / exposed | 0 / 826 (0.00%) | 0 / 822 (0.00%) | 1 / 824 (0.12%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Hypoglycaemic unconsciousness | | | |
| subjects affected / exposed | 5 / 826 (0.61%) | 3 / 822 (0.36%) | 1 / 824 (0.12%) |
| occurrences causally related to treatment / all | 2 / 5 | 0 / 3 | 1 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Hypoxic-ischaemic encephalopathy | | | |
| subjects affected / exposed | 1 / 826 (0.12%) | 0 / 822 (0.00%) | 1 / 824 (0.12%) |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| Intracranial aneurysm | | | |

| | | | |
|---|-----------------|-----------------|------------------|
| subjects affected / exposed | 1 / 826 (0.12%) | 1 / 822 (0.12%) | 0 / 824 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Intracranial hypotension | | | |
| subjects affected / exposed | 0 / 826 (0.00%) | 0 / 822 (0.00%) | 1 / 824 (0.12%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Intraventricular haemorrhage | | | |
| subjects affected / exposed | 0 / 826 (0.00%) | 0 / 822 (0.00%) | 0 / 824 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Ischaemic cerebral infarction | | | |
| subjects affected / exposed | 0 / 826 (0.00%) | 0 / 822 (0.00%) | 0 / 824 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Ischaemic stroke | | | |
| subjects affected / exposed | 8 / 826 (0.97%) | 7 / 822 (0.85%) | 16 / 824 (1.94%) |
| occurrences causally related to treatment / all | 2 / 8 | 3 / 8 | 0 / 16 |
| deaths causally related to treatment / all | 0 / 0 | 1 / 2 | 0 / 1 |
| Lacunar infarction | | | |
| subjects affected / exposed | 1 / 826 (0.12%) | 0 / 822 (0.00%) | 0 / 824 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Loss of consciousness | | | |
| subjects affected / exposed | 0 / 826 (0.00%) | 1 / 822 (0.12%) | 0 / 824 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Metabolic encephalopathy | | | |
| subjects affected / exposed | 2 / 826 (0.24%) | 0 / 822 (0.00%) | 2 / 824 (0.24%) |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 0 | 0 / 2 |
| deaths causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| Migraine | | | |

| | | | |
|---|-----------------|-----------------|-----------------|
| subjects affected / exposed | 0 / 826 (0.00%) | 0 / 822 (0.00%) | 1 / 824 (0.12%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Movement disorder | | | |
| subjects affected / exposed | 0 / 826 (0.00%) | 0 / 822 (0.00%) | 1 / 824 (0.12%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Multiple sclerosis | | | |
| subjects affected / exposed | 0 / 826 (0.00%) | 0 / 822 (0.00%) | 1 / 824 (0.12%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Myelitis transverse | | | |
| subjects affected / exposed | 0 / 826 (0.00%) | 1 / 822 (0.12%) | 0 / 824 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Neuralgia | | | |
| subjects affected / exposed | 0 / 826 (0.00%) | 1 / 822 (0.12%) | 0 / 824 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Parkinsonism | | | |
| subjects affected / exposed | 1 / 826 (0.12%) | 1 / 822 (0.12%) | 0 / 824 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 1 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Presyncope | | | |
| subjects affected / exposed | 0 / 826 (0.00%) | 2 / 822 (0.24%) | 2 / 824 (0.24%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 2 | 0 / 2 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Radiculitis lumbosacral | | | |
| subjects affected / exposed | 1 / 826 (0.12%) | 0 / 822 (0.00%) | 0 / 824 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Radiculopathy | | | |

| | | | |
|---|-----------------|-----------------|------------------|
| subjects affected / exposed | 0 / 826 (0.00%) | 1 / 822 (0.12%) | 1 / 824 (0.12%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Seizure | | | |
| subjects affected / exposed | 1 / 826 (0.12%) | 0 / 822 (0.00%) | 0 / 824 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Speech disorder | | | |
| subjects affected / exposed | 1 / 826 (0.12%) | 0 / 822 (0.00%) | 0 / 824 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Syncope | | | |
| subjects affected / exposed | 2 / 826 (0.24%) | 4 / 822 (0.49%) | 3 / 824 (0.36%) |
| occurrences causally related to treatment / all | 0 / 2 | 1 / 4 | 0 / 4 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Thalamic infarction | | | |
| subjects affected / exposed | 0 / 826 (0.00%) | 1 / 822 (0.12%) | 0 / 824 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Transient ischaemic attack | | | |
| subjects affected / exposed | 7 / 826 (0.85%) | 6 / 822 (0.73%) | 10 / 824 (1.21%) |
| occurrences causally related to treatment / all | 0 / 8 | 0 / 7 | 0 / 10 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| VIIth nerve paralysis | | | |
| subjects affected / exposed | 1 / 826 (0.12%) | 0 / 822 (0.00%) | 2 / 824 (0.24%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 2 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| VIth nerve disorder | | | |
| subjects affected / exposed | 1 / 826 (0.12%) | 0 / 822 (0.00%) | 0 / 824 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Vascular parkinsonism | | | |

| | | | |
|---|-----------------|-----------------|-----------------|
| subjects affected / exposed | 1 / 826 (0.12%) | 0 / 822 (0.00%) | 0 / 824 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| Visual field defect | | | |
| subjects affected / exposed | 0 / 826 (0.00%) | 1 / 822 (0.12%) | 0 / 824 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Blood and lymphatic system disorders | | | |
| Anaemia | | | |
| subjects affected / exposed | 5 / 826 (0.61%) | 4 / 822 (0.49%) | 2 / 824 (0.24%) |
| occurrences causally related to treatment / all | 0 / 5 | 0 / 4 | 1 / 2 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Haemorrhagic anaemia | | | |
| subjects affected / exposed | 1 / 826 (0.12%) | 2 / 822 (0.24%) | 0 / 824 (0.00%) |
| occurrences causally related to treatment / all | 1 / 1 | 0 / 2 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Iron deficiency anaemia | | | |
| subjects affected / exposed | 1 / 826 (0.12%) | 0 / 822 (0.00%) | 0 / 824 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Leukocytosis | | | |
| subjects affected / exposed | 1 / 826 (0.12%) | 0 / 822 (0.00%) | 0 / 824 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Lymphadenopathy | | | |
| subjects affected / exposed | 1 / 826 (0.12%) | 1 / 822 (0.12%) | 0 / 824 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Lymphadenopathy mediastinal | | | |
| subjects affected / exposed | 0 / 826 (0.00%) | 2 / 822 (0.24%) | 1 / 824 (0.12%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 2 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| Microcytic anaemia | | | |

| | | | |
|---|-----------------|-----------------|-----------------|
| subjects affected / exposed | 0 / 826 (0.00%) | 0 / 822 (0.00%) | 0 / 824 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Splenic vein thrombosis | | | |
| subjects affected / exposed | 0 / 826 (0.00%) | 0 / 822 (0.00%) | 0 / 824 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Splenomegaly | | | |
| subjects affected / exposed | 0 / 826 (0.00%) | 0 / 822 (0.00%) | 0 / 824 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Thrombocytopenia | | | |
| subjects affected / exposed | 0 / 826 (0.00%) | 0 / 822 (0.00%) | 0 / 824 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Ear and labyrinth disorders | | | |
| Deafness neurosensory | | | |
| subjects affected / exposed | 0 / 826 (0.00%) | 0 / 822 (0.00%) | 1 / 824 (0.12%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Otosclerosis | | | |
| subjects affected / exposed | 0 / 826 (0.00%) | 0 / 822 (0.00%) | 1 / 824 (0.12%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Tympanic membrane perforation | | | |
| subjects affected / exposed | 1 / 826 (0.12%) | 0 / 822 (0.00%) | 0 / 824 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Vertigo | | | |
| subjects affected / exposed | 0 / 826 (0.00%) | 0 / 822 (0.00%) | 1 / 824 (0.12%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Eye disorders | | | |

| | | | |
|---|-----------------|-----------------|-----------------|
| Amaurosis fugax | | | |
| subjects affected / exposed | 0 / 826 (0.00%) | 1 / 822 (0.12%) | 0 / 824 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Blindness | | | |
| subjects affected / exposed | 1 / 826 (0.12%) | 0 / 822 (0.00%) | 1 / 824 (0.12%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Cataract | | | |
| subjects affected / exposed | 1 / 826 (0.12%) | 1 / 822 (0.12%) | 1 / 824 (0.12%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 1 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Cataract cortical | | | |
| subjects affected / exposed | 0 / 826 (0.00%) | 0 / 822 (0.00%) | 0 / 824 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Cataract nuclear | | | |
| subjects affected / exposed | 1 / 826 (0.12%) | 0 / 822 (0.00%) | 0 / 824 (0.00%) |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Cystoid macular oedema | | | |
| subjects affected / exposed | 1 / 826 (0.12%) | 0 / 822 (0.00%) | 0 / 824 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Diabetic retinopathy | | | |
| subjects affected / exposed | 4 / 826 (0.48%) | 2 / 822 (0.24%) | 2 / 824 (0.24%) |
| occurrences causally related to treatment / all | 1 / 4 | 0 / 3 | 2 / 2 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Diplopia | | | |
| subjects affected / exposed | 1 / 826 (0.12%) | 0 / 822 (0.00%) | 0 / 824 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Eyelid dermatochalasis | | | |

| | | | |
|---|-----------------|-----------------|-----------------|
| subjects affected / exposed | 1 / 826 (0.12%) | 0 / 822 (0.00%) | 0 / 824 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Eyelid ptosis | | | |
| subjects affected / exposed | 0 / 826 (0.00%) | 0 / 822 (0.00%) | 1 / 824 (0.12%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Glaucoma | | | |
| subjects affected / exposed | 0 / 826 (0.00%) | 0 / 822 (0.00%) | 1 / 824 (0.12%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Iridocyclitis | | | |
| subjects affected / exposed | 0 / 826 (0.00%) | 0 / 822 (0.00%) | 0 / 824 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Macular fibrosis | | | |
| subjects affected / exposed | 0 / 826 (0.00%) | 1 / 822 (0.12%) | 1 / 824 (0.12%) |
| occurrences causally related to treatment / all | 0 / 0 | 1 / 1 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Macular oedema | | | |
| subjects affected / exposed | 0 / 826 (0.00%) | 1 / 822 (0.12%) | 0 / 824 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Open angle glaucoma | | | |
| subjects affected / exposed | 0 / 826 (0.00%) | 0 / 822 (0.00%) | 0 / 824 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Optic ischaemic neuropathy | | | |
| subjects affected / exposed | 0 / 826 (0.00%) | 2 / 822 (0.24%) | 0 / 824 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 2 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Retinal artery occlusion | | | |

| | | | |
|---|-----------------|-----------------|-----------------|
| subjects affected / exposed | 0 / 826 (0.00%) | 1 / 822 (0.12%) | 0 / 824 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Retinal degeneration | | | |
| subjects affected / exposed | 1 / 826 (0.12%) | 0 / 822 (0.00%) | 0 / 824 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Retinal detachment | | | |
| subjects affected / exposed | 0 / 826 (0.00%) | 0 / 822 (0.00%) | 0 / 824 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Retinopathy haemorrhagic | | | |
| subjects affected / exposed | 1 / 826 (0.12%) | 0 / 822 (0.00%) | 0 / 824 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Vitreous haemorrhage | | | |
| subjects affected / exposed | 2 / 826 (0.24%) | 2 / 822 (0.24%) | 0 / 824 (0.00%) |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 2 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Gastrointestinal disorders | | | |
| Abdominal mass | | | |
| subjects affected / exposed | 0 / 826 (0.00%) | 1 / 822 (0.12%) | 0 / 824 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Abdominal pain | | | |
| subjects affected / exposed | 2 / 826 (0.24%) | 6 / 822 (0.73%) | 2 / 824 (0.24%) |
| occurrences causally related to treatment / all | 1 / 2 | 2 / 6 | 0 / 3 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Abdominal pain lower | | | |
| subjects affected / exposed | 1 / 826 (0.12%) | 0 / 822 (0.00%) | 0 / 824 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Abdominal pain upper | | | |

| | | | |
|---|-----------------|-----------------|-----------------|
| subjects affected / exposed | 0 / 826 (0.00%) | 0 / 822 (0.00%) | 1 / 824 (0.12%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Ascites | | | |
| subjects affected / exposed | 1 / 826 (0.12%) | 1 / 822 (0.12%) | 0 / 824 (0.00%) |
| occurrences causally related to treatment / all | 1 / 1 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Change of bowel habit | | | |
| subjects affected / exposed | 0 / 826 (0.00%) | 1 / 822 (0.12%) | 0 / 824 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Chronic gastritis | | | |
| subjects affected / exposed | 1 / 826 (0.12%) | 1 / 822 (0.12%) | 0 / 824 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Colitis | | | |
| subjects affected / exposed | 1 / 826 (0.12%) | 0 / 822 (0.00%) | 0 / 824 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Colitis ischaemic | | | |
| subjects affected / exposed | 0 / 826 (0.00%) | 0 / 822 (0.00%) | 0 / 824 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Colitis ulcerative | | | |
| subjects affected / exposed | 0 / 826 (0.00%) | 1 / 822 (0.12%) | 0 / 824 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Constipation | | | |
| subjects affected / exposed | 1 / 826 (0.12%) | 1 / 822 (0.12%) | 1 / 824 (0.12%) |
| occurrences causally related to treatment / all | 0 / 1 | 1 / 1 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Diaphragmatic hernia | | | |

| | | | |
|---|-----------------|-----------------|-----------------|
| subjects affected / exposed | 0 / 826 (0.00%) | 0 / 822 (0.00%) | 0 / 824 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Diarrhoea | | | |
| subjects affected / exposed | 2 / 826 (0.24%) | 6 / 822 (0.73%) | 2 / 824 (0.24%) |
| occurrences causally related to treatment / all | 0 / 2 | 4 / 6 | 0 / 2 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Diverticulum | | | |
| subjects affected / exposed | 0 / 826 (0.00%) | 1 / 822 (0.12%) | 0 / 824 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Diverticulum intestinal | | | |
| subjects affected / exposed | 1 / 826 (0.12%) | 0 / 822 (0.00%) | 0 / 824 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Duodenal ulcer | | | |
| subjects affected / exposed | 0 / 826 (0.00%) | 1 / 822 (0.12%) | 1 / 824 (0.12%) |
| occurrences causally related to treatment / all | 0 / 0 | 1 / 1 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Duodenal ulcer haemorrhage | | | |
| subjects affected / exposed | 0 / 826 (0.00%) | 1 / 822 (0.12%) | 0 / 824 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Duodenitis | | | |
| subjects affected / exposed | 0 / 826 (0.00%) | 0 / 822 (0.00%) | 1 / 824 (0.12%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Enterocolitis haemorrhagic | | | |
| subjects affected / exposed | 0 / 826 (0.00%) | 0 / 822 (0.00%) | 0 / 824 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Epigastric discomfort | | | |

| | | | |
|---|-----------------|-----------------|-----------------|
| subjects affected / exposed | 0 / 826 (0.00%) | 1 / 822 (0.12%) | 0 / 824 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Faeces discoloured | | | |
| subjects affected / exposed | 0 / 826 (0.00%) | 0 / 822 (0.00%) | 0 / 824 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Gastric disorder | | | |
| subjects affected / exposed | 0 / 826 (0.00%) | 1 / 822 (0.12%) | 0 / 824 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 1 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Gastric ileus | | | |
| subjects affected / exposed | 0 / 826 (0.00%) | 0 / 822 (0.00%) | 0 / 824 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Gastric polyps | | | |
| subjects affected / exposed | 0 / 826 (0.00%) | 0 / 822 (0.00%) | 0 / 824 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Gastric ulcer | | | |
| subjects affected / exposed | 1 / 826 (0.12%) | 0 / 822 (0.00%) | 0 / 824 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Gastric ulcer haemorrhage | | | |
| subjects affected / exposed | 2 / 826 (0.24%) | 0 / 822 (0.00%) | 0 / 824 (0.00%) |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Gastritis | | | |
| subjects affected / exposed | 1 / 826 (0.12%) | 0 / 822 (0.00%) | 2 / 824 (0.24%) |
| occurrences causally related to treatment / all | 1 / 1 | 0 / 0 | 0 / 2 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Gastritis haemorrhagic | | | |

| | | | |
|---|-----------------|-----------------|-----------------|
| subjects affected / exposed | 1 / 826 (0.12%) | 1 / 822 (0.12%) | 0 / 824 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Gastroduodenitis | | | |
| subjects affected / exposed | 0 / 826 (0.00%) | 0 / 822 (0.00%) | 0 / 824 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Gastrointestinal haemorrhage | | | |
| subjects affected / exposed | 5 / 826 (0.61%) | 1 / 822 (0.12%) | 1 / 824 (0.12%) |
| occurrences causally related to treatment / all | 0 / 5 | 0 / 1 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| Gastrointestinal ischaemia | | | |
| subjects affected / exposed | 0 / 826 (0.00%) | 0 / 822 (0.00%) | 0 / 824 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Gastrooesophageal reflux disease | | | |
| subjects affected / exposed | 3 / 826 (0.36%) | 3 / 822 (0.36%) | 0 / 824 (0.00%) |
| occurrences causally related to treatment / all | 0 / 3 | 1 / 3 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Haematemesis | | | |
| subjects affected / exposed | 0 / 826 (0.00%) | 0 / 822 (0.00%) | 1 / 824 (0.12%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Hiatus hernia | | | |
| subjects affected / exposed | 0 / 826 (0.00%) | 1 / 822 (0.12%) | 2 / 824 (0.24%) |
| occurrences causally related to treatment / all | 0 / 0 | 1 / 1 | 0 / 2 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Impaired gastric emptying | | | |
| subjects affected / exposed | 1 / 826 (0.12%) | 0 / 822 (0.00%) | 0 / 824 (0.00%) |
| occurrences causally related to treatment / all | 1 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Inguinal hernia | | | |

| | | | |
|---|-----------------|-----------------|-----------------|
| subjects affected / exposed | 4 / 826 (0.48%) | 0 / 822 (0.00%) | 0 / 824 (0.00%) |
| occurrences causally related to treatment / all | 0 / 4 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Intestinal haemorrhage | | | |
| subjects affected / exposed | 0 / 826 (0.00%) | 0 / 822 (0.00%) | 0 / 824 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Intestinal ischaemia | | | |
| subjects affected / exposed | 1 / 826 (0.12%) | 1 / 822 (0.12%) | 0 / 824 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 1 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Intestinal obstruction | | | |
| subjects affected / exposed | 1 / 826 (0.12%) | 1 / 822 (0.12%) | 0 / 824 (0.00%) |
| occurrences causally related to treatment / all | 1 / 1 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Intestinal perforation | | | |
| subjects affected / exposed | 1 / 826 (0.12%) | 0 / 822 (0.00%) | 0 / 824 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Large intestinal haemorrhage | | | |
| subjects affected / exposed | 0 / 826 (0.00%) | 1 / 822 (0.12%) | 0 / 824 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Large intestine polyp | | | |
| subjects affected / exposed | 0 / 826 (0.00%) | 2 / 822 (0.24%) | 1 / 824 (0.12%) |
| occurrences causally related to treatment / all | 0 / 0 | 1 / 2 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Lower gastrointestinal haemorrhage | | | |
| subjects affected / exposed | 1 / 826 (0.12%) | 0 / 822 (0.00%) | 0 / 824 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Melaena | | | |

| | | | |
|---|-----------------|-----------------|-----------------|
| subjects affected / exposed | 0 / 826 (0.00%) | 1 / 822 (0.12%) | 1 / 824 (0.12%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Mouth ulceration | | | |
| subjects affected / exposed | 1 / 826 (0.12%) | 0 / 822 (0.00%) | 0 / 824 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Nausea | | | |
| subjects affected / exposed | 0 / 826 (0.00%) | 3 / 822 (0.36%) | 1 / 824 (0.12%) |
| occurrences causally related to treatment / all | 0 / 0 | 2 / 3 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Oesophageal spasm | | | |
| subjects affected / exposed | 0 / 826 (0.00%) | 0 / 822 (0.00%) | 0 / 824 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Pancreatic cyst | | | |
| subjects affected / exposed | 1 / 826 (0.12%) | 0 / 822 (0.00%) | 0 / 824 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Pancreatitis | | | |
| subjects affected / exposed | 2 / 826 (0.24%) | 0 / 822 (0.00%) | 1 / 824 (0.12%) |
| occurrences causally related to treatment / all | 1 / 2 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Pancreatitis acute | | | |
| subjects affected / exposed | 1 / 826 (0.12%) | 1 / 822 (0.12%) | 1 / 824 (0.12%) |
| occurrences causally related to treatment / all | 0 / 1 | 1 / 1 | 1 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Peptic ulcer | | | |
| subjects affected / exposed | 1 / 826 (0.12%) | 1 / 822 (0.12%) | 1 / 824 (0.12%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 1 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Peritoneal haemorrhage | | | |

| | | | |
|---|-----------------|-----------------|-----------------|
| subjects affected / exposed | 1 / 826 (0.12%) | 0 / 822 (0.00%) | 0 / 824 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Pneumoperitoneum | | | |
| subjects affected / exposed | 1 / 826 (0.12%) | 0 / 822 (0.00%) | 0 / 824 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Proctitis haemorrhagic | | | |
| subjects affected / exposed | 0 / 826 (0.00%) | 0 / 822 (0.00%) | 1 / 824 (0.12%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Rectal prolapse | | | |
| subjects affected / exposed | 1 / 826 (0.12%) | 0 / 822 (0.00%) | 0 / 824 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Small intestinal obstruction | | | |
| subjects affected / exposed | 0 / 826 (0.00%) | 0 / 822 (0.00%) | 0 / 824 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Umbilical hernia | | | |
| subjects affected / exposed | 2 / 826 (0.24%) | 0 / 822 (0.00%) | 0 / 824 (0.00%) |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Upper gastrointestinal haemorrhage | | | |
| subjects affected / exposed | 2 / 826 (0.24%) | 1 / 822 (0.12%) | 2 / 824 (0.24%) |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 1 | 0 / 2 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| Volvulus of small bowel | | | |
| subjects affected / exposed | 0 / 826 (0.00%) | 1 / 822 (0.12%) | 0 / 824 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Vomiting | | | |

| | | | |
|---|-----------------|-----------------|-----------------|
| subjects affected / exposed | 0 / 826 (0.00%) | 3 / 822 (0.36%) | 2 / 824 (0.24%) |
| occurrences causally related to treatment / all | 0 / 0 | 2 / 3 | 1 / 2 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Hepatobiliary disorders | | | |
| Bile duct stone | | | |
| subjects affected / exposed | 0 / 826 (0.00%) | 2 / 822 (0.24%) | 2 / 824 (0.24%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 2 | 0 / 2 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Biliary colic | | | |
| subjects affected / exposed | 1 / 826 (0.12%) | 0 / 822 (0.00%) | 1 / 824 (0.12%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Cholangitis | | | |
| subjects affected / exposed | 1 / 826 (0.12%) | 0 / 822 (0.00%) | 0 / 824 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Cholecystitis | | | |
| subjects affected / exposed | 0 / 826 (0.00%) | 1 / 822 (0.12%) | 4 / 824 (0.49%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 1 / 4 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Cholecystitis acute | | | |
| subjects affected / exposed | 3 / 826 (0.36%) | 0 / 822 (0.00%) | 6 / 824 (0.73%) |
| occurrences causally related to treatment / all | 2 / 3 | 0 / 0 | 1 / 6 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Cholecystitis chronic | | | |
| subjects affected / exposed | 0 / 826 (0.00%) | 0 / 822 (0.00%) | 0 / 824 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Cholelithiasis | | | |
| subjects affected / exposed | 4 / 826 (0.48%) | 2 / 822 (0.24%) | 4 / 824 (0.49%) |
| occurrences causally related to treatment / all | 1 / 4 | 0 / 2 | 0 / 4 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Cholelithiasis obstructive | | | |

| | | | |
|---|-----------------|-----------------|-----------------|
| subjects affected / exposed | 1 / 826 (0.12%) | 0 / 822 (0.00%) | 0 / 824 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Cholestasis | | | |
| subjects affected / exposed | 0 / 826 (0.00%) | 0 / 822 (0.00%) | 1 / 824 (0.12%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 1 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Gallbladder necrosis | | | |
| subjects affected / exposed | 0 / 826 (0.00%) | 0 / 822 (0.00%) | 1 / 824 (0.12%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Gallbladder polyp | | | |
| subjects affected / exposed | 0 / 826 (0.00%) | 0 / 822 (0.00%) | 1 / 824 (0.12%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Hepatic cirrhosis | | | |
| subjects affected / exposed | 0 / 826 (0.00%) | 1 / 822 (0.12%) | 0 / 824 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Hepatic congestion | | | |
| subjects affected / exposed | 0 / 826 (0.00%) | 0 / 822 (0.00%) | 0 / 824 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Hepatic failure | | | |
| subjects affected / exposed | 1 / 826 (0.12%) | 0 / 822 (0.00%) | 0 / 824 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Hydrocholecystitis | | | |
| subjects affected / exposed | 1 / 826 (0.12%) | 0 / 822 (0.00%) | 0 / 824 (0.00%) |
| occurrences causally related to treatment / all | 1 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Ischaemic hepatitis | | | |

| | | | |
|---|-----------------|-----------------|-----------------|
| subjects affected / exposed | 1 / 826 (0.12%) | 1 / 822 (0.12%) | 1 / 824 (0.12%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 1 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| Jaundice | | | |
| subjects affected / exposed | 1 / 826 (0.12%) | 0 / 822 (0.00%) | 0 / 824 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Pneumobilia | | | |
| subjects affected / exposed | 0 / 826 (0.00%) | 0 / 822 (0.00%) | 0 / 824 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Skin and subcutaneous tissue disorders | | | |
| Actinic keratosis | | | |
| subjects affected / exposed | 1 / 826 (0.12%) | 0 / 822 (0.00%) | 0 / 824 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Angioedema | | | |
| subjects affected / exposed | 0 / 826 (0.00%) | 1 / 822 (0.12%) | 0 / 824 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Decubitus ulcer | | | |
| subjects affected / exposed | 1 / 826 (0.12%) | 0 / 822 (0.00%) | 0 / 824 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| Diabetic foot | | | |
| subjects affected / exposed | 6 / 826 (0.73%) | 2 / 822 (0.24%) | 3 / 824 (0.36%) |
| occurrences causally related to treatment / all | 0 / 8 | 0 / 2 | 1 / 3 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Hyperkeratosis | | | |
| subjects affected / exposed | 0 / 826 (0.00%) | 0 / 822 (0.00%) | 1 / 824 (0.12%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 1 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Pruritus | | | |

| | | | |
|---|------------------|-----------------|------------------|
| subjects affected / exposed | 0 / 826 (0.00%) | 1 / 822 (0.12%) | 0 / 824 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Psoriasis | | | |
| subjects affected / exposed | 1 / 826 (0.12%) | 0 / 822 (0.00%) | 1 / 824 (0.12%) |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Rash papular | | | |
| subjects affected / exposed | 0 / 826 (0.00%) | 0 / 822 (0.00%) | 1 / 824 (0.12%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Skin necrosis | | | |
| subjects affected / exposed | 1 / 826 (0.12%) | 1 / 822 (0.12%) | 0 / 824 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Skin ulcer | | | |
| subjects affected / exposed | 3 / 826 (0.36%) | 0 / 822 (0.00%) | 1 / 824 (0.12%) |
| occurrences causally related to treatment / all | 0 / 3 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Stevens-Johnson syndrome | | | |
| subjects affected / exposed | 1 / 826 (0.12%) | 0 / 822 (0.00%) | 0 / 824 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Renal and urinary disorders | | | |
| Acute kidney injury | | | |
| subjects affected / exposed | 18 / 826 (2.18%) | 6 / 822 (0.73%) | 14 / 824 (1.70%) |
| occurrences causally related to treatment / all | 1 / 22 | 3 / 8 | 2 / 14 |
| deaths causally related to treatment / all | 0 / 2 | 0 / 0 | 1 / 2 |
| Acute prerenal failure | | | |
| subjects affected / exposed | 1 / 826 (0.12%) | 0 / 822 (0.00%) | 0 / 824 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Anuria | | | |

| | | | |
|---|------------------|-----------------|------------------|
| subjects affected / exposed | 1 / 826 (0.12%) | 0 / 822 (0.00%) | 0 / 824 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| Azotaemia | | | |
| subjects affected / exposed | 1 / 826 (0.12%) | 0 / 822 (0.00%) | 0 / 824 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Bladder trabeculation | | | |
| subjects affected / exposed | 0 / 826 (0.00%) | 0 / 822 (0.00%) | 1 / 824 (0.12%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Calculus ureteric | | | |
| subjects affected / exposed | 3 / 826 (0.36%) | 3 / 822 (0.36%) | 2 / 824 (0.24%) |
| occurrences causally related to treatment / all | 0 / 3 | 0 / 3 | 0 / 2 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Calculus urinary | | | |
| subjects affected / exposed | 1 / 826 (0.12%) | 0 / 822 (0.00%) | 1 / 824 (0.12%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Chronic kidney disease | | | |
| subjects affected / exposed | 10 / 826 (1.21%) | 5 / 822 (0.61%) | 14 / 824 (1.70%) |
| occurrences causally related to treatment / all | 1 / 10 | 0 / 5 | 1 / 17 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| Diabetic end stage renal disease | | | |
| subjects affected / exposed | 1 / 826 (0.12%) | 0 / 822 (0.00%) | 0 / 824 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Dysuria | | | |
| subjects affected / exposed | 1 / 826 (0.12%) | 0 / 822 (0.00%) | 1 / 824 (0.12%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Glomerulonephritis chronic | | | |

| | | | |
|---|-----------------|-----------------|-----------------|
| subjects affected / exposed | 1 / 826 (0.12%) | 0 / 822 (0.00%) | 0 / 824 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Haematuria | | | |
| subjects affected / exposed | 1 / 826 (0.12%) | 1 / 822 (0.12%) | 0 / 824 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Hydronephrosis | | | |
| subjects affected / exposed | 0 / 826 (0.00%) | 1 / 822 (0.12%) | 0 / 824 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Nephrolithiasis | | | |
| subjects affected / exposed | 2 / 826 (0.24%) | 3 / 822 (0.36%) | 1 / 824 (0.12%) |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 3 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Nephropathy | | | |
| subjects affected / exposed | 0 / 826 (0.00%) | 1 / 822 (0.12%) | 0 / 824 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 1 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Nephrotic syndrome | | | |
| subjects affected / exposed | 1 / 826 (0.12%) | 0 / 822 (0.00%) | 1 / 824 (0.12%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 2 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Proteinuria | | | |
| subjects affected / exposed | 0 / 826 (0.00%) | 1 / 822 (0.12%) | 0 / 824 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 1 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Renal artery arteriosclerosis | | | |
| subjects affected / exposed | 0 / 826 (0.00%) | 1 / 822 (0.12%) | 0 / 824 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Renal artery stenosis | | | |

| | | | |
|---|-----------------|-----------------|-----------------|
| subjects affected / exposed | 0 / 826 (0.00%) | 1 / 822 (0.12%) | 0 / 824 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 2 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Renal colic | | | |
| subjects affected / exposed | 0 / 826 (0.00%) | 0 / 822 (0.00%) | 0 / 824 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Renal cyst | | | |
| subjects affected / exposed | 1 / 826 (0.12%) | 1 / 822 (0.12%) | 0 / 824 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Renal failure | | | |
| subjects affected / exposed | 2 / 826 (0.24%) | 3 / 822 (0.36%) | 1 / 824 (0.12%) |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 3 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Renal impairment | | | |
| subjects affected / exposed | 3 / 826 (0.36%) | 1 / 822 (0.12%) | 3 / 824 (0.36%) |
| occurrences causally related to treatment / all | 0 / 3 | 0 / 1 | 0 / 3 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Stag horn calculus | | | |
| subjects affected / exposed | 0 / 826 (0.00%) | 1 / 822 (0.12%) | 0 / 824 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Urethral stenosis | | | |
| subjects affected / exposed | 0 / 826 (0.00%) | 0 / 822 (0.00%) | 0 / 824 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Urinary bladder polyp | | | |
| subjects affected / exposed | 0 / 826 (0.00%) | 0 / 822 (0.00%) | 0 / 824 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Urinary incontinence | | | |

| | | | |
|---|-----------------|-----------------|-----------------|
| subjects affected / exposed | 0 / 826 (0.00%) | 0 / 822 (0.00%) | 1 / 824 (0.12%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Urinary retention | | | |
| subjects affected / exposed | 2 / 826 (0.24%) | 1 / 822 (0.12%) | 0 / 824 (0.00%) |
| occurrences causally related to treatment / all | 0 / 3 | 1 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Endocrine disorders | | | |
| Goitre | | | |
| subjects affected / exposed | 0 / 826 (0.00%) | 1 / 822 (0.12%) | 1 / 824 (0.12%) |
| occurrences causally related to treatment / all | 0 / 0 | 1 / 1 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Hyperthyroidism | | | |
| subjects affected / exposed | 1 / 826 (0.12%) | 0 / 822 (0.00%) | 0 / 824 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Inappropriate antidiuretic hormone secretion | | | |
| subjects affected / exposed | 0 / 826 (0.00%) | 0 / 822 (0.00%) | 1 / 824 (0.12%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Thyroid mass | | | |
| subjects affected / exposed | 0 / 826 (0.00%) | 1 / 822 (0.12%) | 0 / 824 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Musculoskeletal and connective tissue disorders | | | |
| Arthralgia | | | |
| subjects affected / exposed | 0 / 826 (0.00%) | 0 / 822 (0.00%) | 2 / 824 (0.24%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 2 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Arthritis | | | |
| subjects affected / exposed | 0 / 826 (0.00%) | 1 / 822 (0.12%) | 1 / 824 (0.12%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |

| | | | |
|---|-----------------|-----------------|-----------------|
| Back pain | | | |
| subjects affected / exposed | 1 / 826 (0.12%) | 4 / 822 (0.49%) | 1 / 824 (0.12%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 4 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Chondrolysis | | | |
| subjects affected / exposed | 1 / 826 (0.12%) | 0 / 822 (0.00%) | 0 / 824 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Costochondritis | | | |
| subjects affected / exposed | 0 / 826 (0.00%) | 1 / 822 (0.12%) | 0 / 824 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Diabetic arthropathy | | | |
| subjects affected / exposed | 0 / 826 (0.00%) | 0 / 822 (0.00%) | 1 / 824 (0.12%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Fibromyalgia | | | |
| subjects affected / exposed | 0 / 826 (0.00%) | 0 / 822 (0.00%) | 1 / 824 (0.12%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Flank pain | | | |
| subjects affected / exposed | 1 / 826 (0.12%) | 0 / 822 (0.00%) | 0 / 824 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Foot deformity | | | |
| subjects affected / exposed | 1 / 826 (0.12%) | 0 / 822 (0.00%) | 0 / 824 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Intervertebral disc disorder | | | |
| subjects affected / exposed | 1 / 826 (0.12%) | 0 / 822 (0.00%) | 0 / 824 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Intervertebral disc protrusion | | | |

| | | | |
|---|-----------------|-----------------|-----------------|
| subjects affected / exposed | 3 / 826 (0.36%) | 0 / 822 (0.00%) | 1 / 824 (0.12%) |
| occurrences causally related to treatment / all | 0 / 3 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Lumbar spinal stenosis | | | |
| subjects affected / exposed | 0 / 826 (0.00%) | 0 / 822 (0.00%) | 2 / 824 (0.24%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 2 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Mobility decreased | | | |
| subjects affected / exposed | 0 / 826 (0.00%) | 0 / 822 (0.00%) | 0 / 824 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Muscle spasms | | | |
| subjects affected / exposed | 0 / 826 (0.00%) | 0 / 822 (0.00%) | 1 / 824 (0.12%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Muscular weakness | | | |
| subjects affected / exposed | 0 / 826 (0.00%) | 0 / 822 (0.00%) | 0 / 824 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Musculoskeletal chest pain | | | |
| subjects affected / exposed | 0 / 826 (0.00%) | 2 / 822 (0.24%) | 4 / 824 (0.49%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 2 | 0 / 5 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Musculoskeletal pain | | | |
| subjects affected / exposed | 0 / 826 (0.00%) | 1 / 822 (0.12%) | 0 / 824 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Neck pain | | | |
| subjects affected / exposed | 0 / 826 (0.00%) | 1 / 822 (0.12%) | 0 / 824 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Osteoarthritis | | | |

| | | | |
|---|-----------------|-----------------|-----------------|
| subjects affected / exposed | 6 / 826 (0.73%) | 8 / 822 (0.97%) | 9 / 824 (1.09%) |
| occurrences causally related to treatment / all | 0 / 7 | 0 / 8 | 0 / 9 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Osteonecrosis | | | |
| subjects affected / exposed | 0 / 826 (0.00%) | 0 / 822 (0.00%) | 1 / 824 (0.12%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Pain in extremity | | | |
| subjects affected / exposed | 1 / 826 (0.12%) | 0 / 822 (0.00%) | 0 / 824 (0.00%) |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Rheumatoid arthritis | | | |
| subjects affected / exposed | 0 / 826 (0.00%) | 1 / 822 (0.12%) | 0 / 824 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Soft tissue disorder | | | |
| subjects affected / exposed | 0 / 826 (0.00%) | 1 / 822 (0.12%) | 0 / 824 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Spinal column stenosis | | | |
| subjects affected / exposed | 0 / 826 (0.00%) | 1 / 822 (0.12%) | 1 / 824 (0.12%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 4 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Spinal osteoarthritis | | | |
| subjects affected / exposed | 0 / 826 (0.00%) | 1 / 822 (0.12%) | 1 / 824 (0.12%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Synovial cyst | | | |
| subjects affected / exposed | 0 / 826 (0.00%) | 0 / 822 (0.00%) | 1 / 824 (0.12%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Infections and infestations | | | |
| Abdominal sepsis | | | |

| | | | |
|---|-----------------|-----------------|-----------------|
| subjects affected / exposed | 1 / 826 (0.12%) | 0 / 822 (0.00%) | 0 / 824 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| Abscess | | | |
| subjects affected / exposed | 0 / 826 (0.00%) | 0 / 822 (0.00%) | 1 / 824 (0.12%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Abscess limb | | | |
| subjects affected / exposed | 1 / 826 (0.12%) | 1 / 822 (0.12%) | 0 / 824 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Acute hepatitis B | | | |
| subjects affected / exposed | 1 / 826 (0.12%) | 0 / 822 (0.00%) | 0 / 824 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Appendicitis | | | |
| subjects affected / exposed | 1 / 826 (0.12%) | 1 / 822 (0.12%) | 1 / 824 (0.12%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 1 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Aspergilloma | | | |
| subjects affected / exposed | 0 / 826 (0.00%) | 1 / 822 (0.12%) | 0 / 824 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Bacteraemia | | | |
| subjects affected / exposed | 0 / 826 (0.00%) | 0 / 822 (0.00%) | 0 / 824 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Boutonneuse fever | | | |
| subjects affected / exposed | 0 / 826 (0.00%) | 0 / 822 (0.00%) | 1 / 824 (0.12%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Bronchitis | | | |

| | | | |
|---|-----------------|-----------------|-----------------|
| subjects affected / exposed | 2 / 826 (0.24%) | 2 / 822 (0.24%) | 4 / 824 (0.49%) |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 2 | 0 / 4 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Bronchitis bacterial | | | |
| subjects affected / exposed | 0 / 826 (0.00%) | 1 / 822 (0.12%) | 0 / 824 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Bronchopneumonia | | | |
| subjects affected / exposed | 0 / 826 (0.00%) | 1 / 822 (0.12%) | 0 / 824 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Campylobacter gastroenteritis | | | |
| subjects affected / exposed | 0 / 826 (0.00%) | 1 / 822 (0.12%) | 0 / 824 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Campylobacter infection | | | |
| subjects affected / exposed | 1 / 826 (0.12%) | 0 / 822 (0.00%) | 0 / 824 (0.00%) |
| occurrences causally related to treatment / all | 1 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Cellulitis | | | |
| subjects affected / exposed | 6 / 826 (0.73%) | 3 / 822 (0.36%) | 7 / 824 (0.85%) |
| occurrences causally related to treatment / all | 0 / 6 | 1 / 3 | 0 / 7 |
| deaths causally related to treatment / all | 0 / 1 | 0 / 1 | 0 / 0 |
| Clostridium difficile colitis | | | |
| subjects affected / exposed | 1 / 826 (0.12%) | 0 / 822 (0.00%) | 1 / 824 (0.12%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Cystitis | | | |
| subjects affected / exposed | 0 / 826 (0.00%) | 0 / 822 (0.00%) | 1 / 824 (0.12%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Dengue fever | | | |

| | | | |
|---|-----------------|-----------------|-----------------|
| subjects affected / exposed | 1 / 826 (0.12%) | 0 / 822 (0.00%) | 0 / 824 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Device related sepsis | | | |
| subjects affected / exposed | 0 / 826 (0.00%) | 0 / 822 (0.00%) | 1 / 824 (0.12%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Diabetic foot infection | | | |
| subjects affected / exposed | 0 / 826 (0.00%) | 1 / 822 (0.12%) | 1 / 824 (0.12%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Diverticulitis | | | |
| subjects affected / exposed | 1 / 826 (0.12%) | 2 / 822 (0.24%) | 2 / 824 (0.24%) |
| occurrences causally related to treatment / all | 0 / 1 | 1 / 2 | 1 / 2 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Endocarditis | | | |
| subjects affected / exposed | 1 / 826 (0.12%) | 0 / 822 (0.00%) | 1 / 824 (0.12%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Enteritis infectious | | | |
| subjects affected / exposed | 0 / 826 (0.00%) | 0 / 822 (0.00%) | 1 / 824 (0.12%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Enterococcal infection | | | |
| subjects affected / exposed | 1 / 826 (0.12%) | 0 / 822 (0.00%) | 0 / 824 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| Epididymitis | | | |
| subjects affected / exposed | 0 / 826 (0.00%) | 0 / 822 (0.00%) | 0 / 824 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Escherichia infection | | | |

| | | | |
|---|-----------------|-----------------|-----------------|
| subjects affected / exposed | 0 / 826 (0.00%) | 0 / 822 (0.00%) | 0 / 824 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Escherichia sepsis | | | |
| subjects affected / exposed | 1 / 826 (0.12%) | 2 / 822 (0.24%) | 0 / 824 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 2 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Gangrene | | | |
| subjects affected / exposed | 2 / 826 (0.24%) | 1 / 822 (0.12%) | 4 / 824 (0.49%) |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 1 | 0 / 4 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Gastritis viral | | | |
| subjects affected / exposed | 0 / 826 (0.00%) | 0 / 822 (0.00%) | 1 / 824 (0.12%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Gastroenteritis | | | |
| subjects affected / exposed | 0 / 826 (0.00%) | 2 / 822 (0.24%) | 4 / 824 (0.49%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 2 | 0 / 4 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Gastroenteritis rotavirus | | | |
| subjects affected / exposed | 0 / 826 (0.00%) | 0 / 822 (0.00%) | 1 / 824 (0.12%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 2 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Gastroenteritis salmonella | | | |
| subjects affected / exposed | 0 / 826 (0.00%) | 1 / 822 (0.12%) | 0 / 824 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Gastroenteritis viral | | | |
| subjects affected / exposed | 1 / 826 (0.12%) | 1 / 822 (0.12%) | 1 / 824 (0.12%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 1 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Groin abscess | | | |

| | | | |
|---|-----------------|-----------------|-----------------|
| subjects affected / exposed | 0 / 826 (0.00%) | 0 / 822 (0.00%) | 0 / 824 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Herpes zoster | | | |
| subjects affected / exposed | 1 / 826 (0.12%) | 0 / 822 (0.00%) | 0 / 824 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Implant site infection | | | |
| subjects affected / exposed | 0 / 826 (0.00%) | 0 / 822 (0.00%) | 1 / 824 (0.12%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Incision site infection | | | |
| subjects affected / exposed | 1 / 826 (0.12%) | 1 / 822 (0.12%) | 1 / 824 (0.12%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 1 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Infected skin ulcer | | | |
| subjects affected / exposed | 0 / 826 (0.00%) | 1 / 822 (0.12%) | 0 / 824 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Infectious colitis | | | |
| subjects affected / exposed | 0 / 826 (0.00%) | 1 / 822 (0.12%) | 1 / 824 (0.12%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Infective exacerbation of chronic obstructive airways disease | | | |
| subjects affected / exposed | 1 / 826 (0.12%) | 0 / 822 (0.00%) | 0 / 824 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Influenza | | | |
| subjects affected / exposed | 1 / 826 (0.12%) | 1 / 822 (0.12%) | 2 / 824 (0.24%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 1 | 0 / 2 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Labyrinthitis | | | |

| | | | |
|---|-----------------|-----------------|-----------------|
| subjects affected / exposed | 1 / 826 (0.12%) | 0 / 822 (0.00%) | 0 / 824 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Laryngitis | | | |
| subjects affected / exposed | 0 / 826 (0.00%) | 0 / 822 (0.00%) | 0 / 824 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Liver abscess | | | |
| subjects affected / exposed | 1 / 826 (0.12%) | 0 / 822 (0.00%) | 0 / 824 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Lobar pneumonia | | | |
| subjects affected / exposed | 1 / 826 (0.12%) | 0 / 822 (0.00%) | 1 / 824 (0.12%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Localised infection | | | |
| subjects affected / exposed | 1 / 826 (0.12%) | 2 / 822 (0.24%) | 2 / 824 (0.24%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 2 | 0 / 2 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Lower respiratory tract infection | | | |
| subjects affected / exposed | 0 / 826 (0.00%) | 0 / 822 (0.00%) | 1 / 824 (0.12%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Meningitis bacterial | | | |
| subjects affected / exposed | 0 / 826 (0.00%) | 1 / 822 (0.12%) | 0 / 824 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Necrotising fasciitis | | | |
| subjects affected / exposed | 0 / 826 (0.00%) | 0 / 822 (0.00%) | 1 / 824 (0.12%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Oesophageal candidiasis | | | |

| | | | |
|---|-----------------|-----------------|-----------------|
| subjects affected / exposed | 0 / 826 (0.00%) | 1 / 822 (0.12%) | 1 / 824 (0.12%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Osteomyelitis | | | |
| subjects affected / exposed | 5 / 826 (0.61%) | 1 / 822 (0.12%) | 2 / 824 (0.24%) |
| occurrences causally related to treatment / all | 0 / 5 | 0 / 1 | 1 / 2 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Otitis externa | | | |
| subjects affected / exposed | 1 / 826 (0.12%) | 0 / 822 (0.00%) | 0 / 824 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Paronychia | | | |
| subjects affected / exposed | 1 / 826 (0.12%) | 1 / 822 (0.12%) | 0 / 824 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Perirectal abscess | | | |
| subjects affected / exposed | 0 / 826 (0.00%) | 1 / 822 (0.12%) | 0 / 824 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Peritonitis | | | |
| subjects affected / exposed | 1 / 826 (0.12%) | 1 / 822 (0.12%) | 0 / 824 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| Peritonsillar abscess | | | |
| subjects affected / exposed | 0 / 826 (0.00%) | 1 / 822 (0.12%) | 0 / 824 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Periumbilical abscess | | | |
| subjects affected / exposed | 0 / 826 (0.00%) | 0 / 822 (0.00%) | 0 / 824 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Pharyngitis | | | |

| | | | |
|---|------------------|------------------|------------------|
| subjects affected / exposed | 1 / 826 (0.12%) | 2 / 822 (0.24%) | 0 / 824 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 1 / 2 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Pneumonia | | | |
| subjects affected / exposed | 18 / 826 (2.18%) | 15 / 822 (1.82%) | 22 / 824 (2.67%) |
| occurrences causally related to treatment / all | 2 / 19 | 0 / 16 | 0 / 26 |
| deaths causally related to treatment / all | 0 / 1 | 0 / 3 | 0 / 1 |
| Pneumonia pneumococcal | | | |
| subjects affected / exposed | 0 / 826 (0.00%) | 0 / 822 (0.00%) | 1 / 824 (0.12%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| Pneumonia respiratory syncytial viral | | | |
| subjects affected / exposed | 0 / 826 (0.00%) | 0 / 822 (0.00%) | 1 / 824 (0.12%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Post procedural infection | | | |
| subjects affected / exposed | 0 / 826 (0.00%) | 1 / 822 (0.12%) | 1 / 824 (0.12%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Post procedural pneumonia | | | |
| subjects affected / exposed | 1 / 826 (0.12%) | 0 / 822 (0.00%) | 0 / 824 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Postoperative wound infection | | | |
| subjects affected / exposed | 1 / 826 (0.12%) | 1 / 822 (0.12%) | 1 / 824 (0.12%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 1 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Pseudomembranous colitis | | | |
| subjects affected / exposed | 0 / 826 (0.00%) | 0 / 822 (0.00%) | 1 / 824 (0.12%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Pulmonary sepsis | | | |

| | | | |
|---|-----------------|-----------------|-----------------|
| subjects affected / exposed | 1 / 826 (0.12%) | 0 / 822 (0.00%) | 0 / 824 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Pyelonephritis | | | |
| subjects affected / exposed | 1 / 826 (0.12%) | 1 / 822 (0.12%) | 0 / 824 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 1 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Pyelonephritis acute | | | |
| subjects affected / exposed | 1 / 826 (0.12%) | 0 / 822 (0.00%) | 0 / 824 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Pyelonephritis chronic | | | |
| subjects affected / exposed | 1 / 826 (0.12%) | 0 / 822 (0.00%) | 1 / 824 (0.12%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Respiratory tract infection | | | |
| subjects affected / exposed | 1 / 826 (0.12%) | 0 / 822 (0.00%) | 0 / 824 (0.00%) |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Respiratory tract infection viral | | | |
| subjects affected / exposed | 1 / 826 (0.12%) | 0 / 822 (0.00%) | 0 / 824 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Sepsis | | | |
| subjects affected / exposed | 7 / 826 (0.85%) | 4 / 822 (0.49%) | 3 / 824 (0.36%) |
| occurrences causally related to treatment / all | 1 / 7 | 1 / 4 | 0 / 3 |
| deaths causally related to treatment / all | 0 / 2 | 0 / 0 | 0 / 1 |
| Septic encephalopathy | | | |
| subjects affected / exposed | 1 / 826 (0.12%) | 0 / 822 (0.00%) | 0 / 824 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| Septic shock | | | |

| | | | |
|---|-----------------|-----------------|-----------------|
| subjects affected / exposed | 1 / 826 (0.12%) | 0 / 822 (0.00%) | 4 / 824 (0.49%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 4 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 3 |
| Sinusitis | | | |
| subjects affected / exposed | 0 / 826 (0.00%) | 1 / 822 (0.12%) | 2 / 824 (0.24%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 2 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Soft tissue infection | | | |
| subjects affected / exposed | 0 / 826 (0.00%) | 0 / 822 (0.00%) | 0 / 824 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Splenic abscess | | | |
| subjects affected / exposed | 0 / 826 (0.00%) | 0 / 822 (0.00%) | 0 / 824 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Staphylococcal bacteraemia | | | |
| subjects affected / exposed | 0 / 826 (0.00%) | 0 / 822 (0.00%) | 1 / 824 (0.12%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Staphylococcal infection | | | |
| subjects affected / exposed | 2 / 826 (0.24%) | 0 / 822 (0.00%) | 0 / 824 (0.00%) |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| Staphylococcal osteomyelitis | | | |
| subjects affected / exposed | 0 / 826 (0.00%) | 0 / 822 (0.00%) | 1 / 824 (0.12%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Staphylococcal sepsis | | | |
| subjects affected / exposed | 1 / 826 (0.12%) | 1 / 822 (0.12%) | 0 / 824 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| Subcutaneous abscess | | | |

| | | | |
|---|-----------------|-----------------|------------------|
| subjects affected / exposed | 0 / 826 (0.00%) | 0 / 822 (0.00%) | 1 / 824 (0.12%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Tooth abscess | | | |
| subjects affected / exposed | 1 / 826 (0.12%) | 0 / 822 (0.00%) | 0 / 824 (0.00%) |
| occurrences causally related to treatment / all | 1 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Tuberculosis | | | |
| subjects affected / exposed | 0 / 826 (0.00%) | 0 / 822 (0.00%) | 0 / 824 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Upper respiratory tract infection | | | |
| subjects affected / exposed | 0 / 826 (0.00%) | 0 / 822 (0.00%) | 2 / 824 (0.24%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 2 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Urinary tract infection | | | |
| subjects affected / exposed | 9 / 826 (1.09%) | 2 / 822 (0.24%) | 10 / 824 (1.21%) |
| occurrences causally related to treatment / all | 0 / 9 | 0 / 2 | 0 / 10 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Urinary tract infection pseudomonal | | | |
| subjects affected / exposed | 0 / 826 (0.00%) | 1 / 822 (0.12%) | 0 / 824 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 1 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Urinary tract infection staphylococcal | | | |
| subjects affected / exposed | 0 / 826 (0.00%) | 0 / 822 (0.00%) | 0 / 824 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Urosepsis | | | |
| subjects affected / exposed | 2 / 826 (0.24%) | 1 / 822 (0.12%) | 2 / 824 (0.24%) |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 1 | 0 / 2 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| Vestibular neuronitis | | | |

| | | | |
|---|-----------------|-----------------|-----------------|
| subjects affected / exposed | 1 / 826 (0.12%) | 0 / 822 (0.00%) | 0 / 824 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Viral infection | | | |
| subjects affected / exposed | 2 / 826 (0.24%) | 1 / 822 (0.12%) | 0 / 824 (0.00%) |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Wound infection bacterial | | | |
| subjects affected / exposed | 0 / 826 (0.00%) | 0 / 822 (0.00%) | 1 / 824 (0.12%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Metabolism and nutrition disorders | | | |
| Acidosis | | | |
| subjects affected / exposed | 1 / 826 (0.12%) | 0 / 822 (0.00%) | 0 / 824 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| Dehydration | | | |
| subjects affected / exposed | 3 / 826 (0.36%) | 5 / 822 (0.61%) | 2 / 824 (0.24%) |
| occurrences causally related to treatment / all | 0 / 3 | 1 / 5 | 1 / 2 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Diabetes mellitus | | | |
| subjects affected / exposed | 2 / 826 (0.24%) | 1 / 822 (0.12%) | 1 / 824 (0.12%) |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 1 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| Diabetes mellitus inadequate control | | | |
| subjects affected / exposed | 4 / 826 (0.48%) | 1 / 822 (0.12%) | 5 / 824 (0.61%) |
| occurrences causally related to treatment / all | 0 / 4 | 0 / 1 | 1 / 7 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Diabetic ketoacidosis | | | |
| subjects affected / exposed | 1 / 826 (0.12%) | 0 / 822 (0.00%) | 2 / 824 (0.24%) |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 0 | 0 / 2 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Electrolyte imbalance | | | |

| | | | |
|---|-----------------|-----------------|-----------------|
| subjects affected / exposed | 0 / 826 (0.00%) | 0 / 822 (0.00%) | 1 / 824 (0.12%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Failure to thrive | | | |
| subjects affected / exposed | 0 / 826 (0.00%) | 0 / 822 (0.00%) | 0 / 824 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Fluid overload | | | |
| subjects affected / exposed | 2 / 826 (0.24%) | 1 / 822 (0.12%) | 1 / 824 (0.12%) |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 1 | 0 / 2 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Gout | | | |
| subjects affected / exposed | 1 / 826 (0.12%) | 0 / 822 (0.00%) | 0 / 824 (0.00%) |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Hyperglycaemia | | | |
| subjects affected / exposed | 3 / 826 (0.36%) | 2 / 822 (0.24%) | 4 / 824 (0.49%) |
| occurrences causally related to treatment / all | 0 / 3 | 0 / 2 | 0 / 4 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Hyperkalaemia | | | |
| subjects affected / exposed | 0 / 826 (0.00%) | 1 / 822 (0.12%) | 3 / 824 (0.36%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 1 / 4 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 1 / 1 |
| Hypocalcaemia | | | |
| subjects affected / exposed | 0 / 826 (0.00%) | 1 / 822 (0.12%) | 0 / 824 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Hypoglycaemia | | | |
| subjects affected / exposed | 7 / 826 (0.85%) | 2 / 822 (0.24%) | 5 / 824 (0.61%) |
| occurrences causally related to treatment / all | 5 / 8 | 1 / 2 | 5 / 7 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Hypokalaemia | | | |

| | | | |
|---|-----------------|-----------------|-----------------|
| subjects affected / exposed | 0 / 826 (0.00%) | 1 / 822 (0.12%) | 0 / 824 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 1 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Hypomagnesaemia | | | |
| subjects affected / exposed | 1 / 826 (0.12%) | 1 / 822 (0.12%) | 0 / 824 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Hyponatraemia | | | |
| subjects affected / exposed | 1 / 826 (0.12%) | 0 / 822 (0.00%) | 4 / 824 (0.49%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 1 / 4 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Hypovolaemia | | | |
| subjects affected / exposed | 1 / 826 (0.12%) | 0 / 822 (0.00%) | 0 / 824 (0.00%) |
| occurrences causally related to treatment / all | 1 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Lactic acidosis | | | |
| subjects affected / exposed | 1 / 826 (0.12%) | 1 / 822 (0.12%) | 1 / 824 (0.12%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 1 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| Metabolic acidosis | | | |
| subjects affected / exposed | 0 / 826 (0.00%) | 0 / 822 (0.00%) | 0 / 824 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Metabolic disorder | | | |
| subjects affected / exposed | 0 / 826 (0.00%) | 0 / 822 (0.00%) | 1 / 824 (0.12%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Obesity | | | |
| subjects affected / exposed | 0 / 826 (0.00%) | 0 / 822 (0.00%) | 1 / 824 (0.12%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |

| | | | |
|------------------------------------|----------------|--|--|
| Serious adverse events | Placebo 1.0 mg | | |
| Total subjects affected by serious | | | |

| | | | |
|---|--------------------|--|--|
| adverse events | | | |
| subjects affected / exposed | 298 / 825 (36.12%) | | |
| number of deaths (all causes) | 28 | | |
| number of deaths resulting from adverse events | 2 | | |
| Neoplasms benign, malignant and unspecified (incl cysts and polyps) | | | |
| Acute lymphocytic leukaemia | | | |
| subjects affected / exposed | 1 / 825 (0.12%) | | |
| occurrences causally related to treatment / all | 0 / 1 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Acute myeloid leukaemia | | | |
| subjects affected / exposed | 0 / 825 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Adenocarcinoma gastric | | | |
| subjects affected / exposed | 0 / 825 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Adenocarcinoma of colon | | | |
| subjects affected / exposed | 1 / 825 (0.12%) | | |
| occurrences causally related to treatment / all | 0 / 1 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Adenocarcinoma pancreas | | | |
| subjects affected / exposed | 0 / 825 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Anaplastic astrocytoma | | | |
| subjects affected / exposed | 1 / 825 (0.12%) | | |
| occurrences causally related to treatment / all | 0 / 1 | | |
| deaths causally related to treatment / all | 0 / 1 | | |
| B-cell lymphoma | | | |
| subjects affected / exposed | 2 / 825 (0.24%) | | |
| occurrences causally related to treatment / all | 0 / 2 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| B-cell small lymphocytic lymphoma | | | |

| | | | | |
|---|-----------------|--|--|--|
| subjects affected / exposed | 0 / 825 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Basal cell carcinoma | | | | |
| subjects affected / exposed | 0 / 825 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Benign lymph node neoplasm | | | | |
| subjects affected / exposed | 0 / 825 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Benign neoplasm of thyroid gland | | | | |
| subjects affected / exposed | 1 / 825 (0.12%) | | | |
| occurrences causally related to treatment / all | 0 / 1 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Bladder neoplasm | | | | |
| subjects affected / exposed | 1 / 825 (0.12%) | | | |
| occurrences causally related to treatment / all | 0 / 1 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Bladder papilloma | | | | |
| subjects affected / exposed | 0 / 825 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Bladder transitional cell carcinoma | | | | |
| subjects affected / exposed | 1 / 825 (0.12%) | | | |
| occurrences causally related to treatment / all | 0 / 1 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Bladder transitional cell carcinoma recurrent | | | | |
| subjects affected / exposed | 1 / 825 (0.12%) | | | |
| occurrences causally related to treatment / all | 0 / 1 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Bladder transitional cell carcinoma stage II | | | | |

| | | | |
|---|-----------------|--|--|
| subjects affected / exposed | 0 / 825 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Bone cancer metastatic | | | |
| subjects affected / exposed | 0 / 825 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Brain neoplasm | | | |
| subjects affected / exposed | 0 / 825 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Breast cancer | | | |
| subjects affected / exposed | 0 / 825 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Breast cancer in situ | | | |
| subjects affected / exposed | 0 / 825 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Breast cancer stage III | | | |
| subjects affected / exposed | 1 / 825 (0.12%) | | |
| occurrences causally related to treatment / all | 0 / 1 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Bronchial carcinoma | | | |
| subjects affected / exposed | 1 / 825 (0.12%) | | |
| occurrences causally related to treatment / all | 0 / 1 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Cholangiocarcinoma | | | |
| subjects affected / exposed | 0 / 825 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Cholesteatoma | | | |

| | | | |
|---|-----------------|--|--|
| subjects affected / exposed | 1 / 825 (0.12%) | | |
| occurrences causally related to treatment / all | 0 / 1 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Chondroma | | | |
| subjects affected / exposed | 0 / 825 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Choroid melanoma | | | |
| subjects affected / exposed | 0 / 825 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Chronic lymphocytic leukaemia | | | |
| subjects affected / exposed | 0 / 825 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Clear cell renal cell carcinoma | | | |
| subjects affected / exposed | 1 / 825 (0.12%) | | |
| occurrences causally related to treatment / all | 0 / 1 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Colon adenoma | | | |
| subjects affected / exposed | 0 / 825 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Colon cancer | | | |
| subjects affected / exposed | 0 / 825 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Colon cancer metastatic | | | |
| subjects affected / exposed | 1 / 825 (0.12%) | | |
| occurrences causally related to treatment / all | 0 / 1 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Colon neoplasm | | | |

| | | | | |
|--|-----------------|--|--|--|
| subjects affected / exposed | 0 / 825 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Colorectal cancer | | | | |
| subjects affected / exposed | 0 / 825 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Endometrial adenocarcinoma | | | | |
| subjects affected / exposed | 0 / 825 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Endometrial sarcoma | | | | |
| subjects affected / exposed | 1 / 825 (0.12%) | | | |
| occurrences causally related to treatment / all | 0 / 1 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Extranodal marginal zone B-cell lymphoma (MALT type) | | | | |
| subjects affected / exposed | 0 / 825 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Gallbladder adenocarcinoma | | | | |
| subjects affected / exposed | 0 / 825 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Gastric cancer | | | | |
| subjects affected / exposed | 0 / 825 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Glomus tumour | | | | |
| subjects affected / exposed | 0 / 825 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Growth hormone-producing pituitary tumour | | | | |

| | | | | |
|---|-----------------|--|--|--|
| subjects affected / exposed | 1 / 825 (0.12%) | | | |
| occurrences causally related to treatment / all | 0 / 1 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Hepatic adenoma | | | | |
| subjects affected / exposed | 0 / 825 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Hepatic cancer | | | | |
| subjects affected / exposed | 0 / 825 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Invasive breast carcinoma | | | | |
| subjects affected / exposed | 0 / 825 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Invasive ductal breast carcinoma | | | | |
| subjects affected / exposed | 0 / 825 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Laryngeal squamous cell carcinoma | | | | |
| subjects affected / exposed | 1 / 825 (0.12%) | | | |
| occurrences causally related to treatment / all | 0 / 1 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Lip neoplasm malignant stage unspecified | | | | |
| subjects affected / exposed | 0 / 825 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Lung adenocarcinoma | | | | |
| subjects affected / exposed | 0 / 825 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Lung adenocarcinoma stage 0 | | | | |

| | | | | |
|---|-----------------|--|--|--|
| subjects affected / exposed | 0 / 825 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Lung adenocarcinoma stage IV | | | | |
| subjects affected / exposed | 0 / 825 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Lung carcinoma cell type unspecified stage IV | | | | |
| subjects affected / exposed | 0 / 825 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Lung neoplasm | | | | |
| subjects affected / exposed | 0 / 825 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Lung neoplasm malignant | | | | |
| subjects affected / exposed | 0 / 825 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Malignant melanoma | | | | |
| subjects affected / exposed | 0 / 825 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Metastases to bone | | | | |
| subjects affected / exposed | 0 / 825 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Metastases to central nervous system | | | | |
| subjects affected / exposed | 0 / 825 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Metastases to liver | | | | |

| | | | | |
|---|-----------------|--|--|--|
| subjects affected / exposed | 1 / 825 (0.12%) | | | |
| occurrences causally related to treatment / all | 0 / 1 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Metastases to lung | | | | |
| subjects affected / exposed | 0 / 825 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Metastases to lymph nodes | | | | |
| subjects affected / exposed | 0 / 825 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Metastatic gastric cancer | | | | |
| subjects affected / exposed | 0 / 825 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Neoplasm of appendix | | | | |
| subjects affected / exposed | 0 / 825 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Non-small cell lung cancer | | | | |
| subjects affected / exposed | 1 / 825 (0.12%) | | | |
| occurrences causally related to treatment / all | 0 / 1 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Ovarian epithelial cancer | | | | |
| subjects affected / exposed | 0 / 825 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Ovarian germ cell teratoma benign | | | | |
| subjects affected / exposed | 0 / 825 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Pancreatic carcinoma | | | | |

| | | | | |
|---|-----------------|--|--|--|
| subjects affected / exposed | 1 / 825 (0.12%) | | | |
| occurrences causally related to treatment / all | 1 / 1 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Pancreatic carcinoma metastatic | | | | |
| subjects affected / exposed | 1 / 825 (0.12%) | | | |
| occurrences causally related to treatment / all | 0 / 1 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Pancreatic carcinoma stage IV | | | | |
| subjects affected / exposed | 0 / 825 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Papillary thyroid cancer | | | | |
| subjects affected / exposed | 0 / 825 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Paraganglion neoplasm | | | | |
| subjects affected / exposed | 0 / 825 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Parathyroid tumour benign | | | | |
| subjects affected / exposed | 2 / 825 (0.24%) | | | |
| occurrences causally related to treatment / all | 0 / 2 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Phaeochromocytoma | | | | |
| subjects affected / exposed | 0 / 825 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Plasma cell myeloma | | | | |
| subjects affected / exposed | 1 / 825 (0.12%) | | | |
| occurrences causally related to treatment / all | 0 / 1 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Prostate cancer | | | | |

| | | | | |
|---|-----------------|--|--|--|
| subjects affected / exposed | 1 / 825 (0.12%) | | | |
| occurrences causally related to treatment / all | 0 / 1 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Prostate cancer metastatic | | | | |
| subjects affected / exposed | 0 / 825 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Prostate cancer recurrent | | | | |
| subjects affected / exposed | 1 / 825 (0.12%) | | | |
| occurrences causally related to treatment / all | 0 / 1 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Prostate cancer stage I | | | | |
| subjects affected / exposed | 1 / 825 (0.12%) | | | |
| occurrences causally related to treatment / all | 0 / 1 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Prostate cancer stage III | | | | |
| subjects affected / exposed | 1 / 825 (0.12%) | | | |
| occurrences causally related to treatment / all | 0 / 1 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Rectal cancer | | | | |
| subjects affected / exposed | 0 / 825 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Renal cancer metastatic | | | | |
| subjects affected / exposed | 0 / 825 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Renal cancer stage I | | | | |
| subjects affected / exposed | 1 / 825 (0.12%) | | | |
| occurrences causally related to treatment / all | 0 / 1 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Renal cell carcinoma | | | | |

| | | | | |
|---|-----------------|--|--|--|
| subjects affected / exposed | 0 / 825 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Small cell lung cancer | | | | |
| subjects affected / exposed | 0 / 825 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Squamous cell carcinoma | | | | |
| subjects affected / exposed | 0 / 825 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Squamous cell carcinoma of lung | | | | |
| subjects affected / exposed | 1 / 825 (0.12%) | | | |
| occurrences causally related to treatment / all | 0 / 1 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Squamous cell carcinoma of skin | | | | |
| subjects affected / exposed | 0 / 825 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Thyroid cancer metastatic | | | | |
| subjects affected / exposed | 0 / 825 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Thyroid neoplasm | | | | |
| subjects affected / exposed | 0 / 825 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Transitional cell carcinoma | | | | |
| subjects affected / exposed | 0 / 825 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Ureteric cancer | | | | |

| | | | |
|---|-----------------|--|--|
| subjects affected / exposed | 0 / 825 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Uterine leiomyoma | | | |
| subjects affected / exposed | 1 / 825 (0.12%) | | |
| occurrences causally related to treatment / all | 0 / 1 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Vascular disorders | | | |
| Aortic aneurysm | | | |
| subjects affected / exposed | 0 / 825 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Aortic dissection | | | |
| subjects affected / exposed | 1 / 825 (0.12%) | | |
| occurrences causally related to treatment / all | 0 / 1 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Aortic stenosis | | | |
| subjects affected / exposed | 0 / 825 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Arterial insufficiency | | | |
| subjects affected / exposed | 0 / 825 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Circulatory collapse | | | |
| subjects affected / exposed | 0 / 825 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Deep vein thrombosis | | | |
| subjects affected / exposed | 0 / 825 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Extremity necrosis | | | |

| | | | |
|---|-----------------|--|--|
| subjects affected / exposed | 1 / 825 (0.12%) | | |
| occurrences causally related to treatment / all | 0 / 1 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Femoral artery aneurysm | | | |
| subjects affected / exposed | 0 / 825 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Femoral artery occlusion | | | |
| subjects affected / exposed | 0 / 825 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Haematoma | | | |
| subjects affected / exposed | 0 / 825 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Hypertension | | | |
| subjects affected / exposed | 3 / 825 (0.36%) | | |
| occurrences causally related to treatment / all | 0 / 3 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Hypertensive crisis | | | |
| subjects affected / exposed | 2 / 825 (0.24%) | | |
| occurrences causally related to treatment / all | 0 / 2 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Hypertensive emergency | | | |
| subjects affected / exposed | 0 / 825 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Hypotension | | | |
| subjects affected / exposed | 3 / 825 (0.36%) | | |
| occurrences causally related to treatment / all | 0 / 3 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Intra-abdominal haematoma | | | |

| | | | |
|---|-----------------|--|--|
| subjects affected / exposed | 0 / 825 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Leriche syndrome | | | |
| subjects affected / exposed | 0 / 825 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Orthostatic hypotension | | | |
| subjects affected / exposed | 1 / 825 (0.12%) | | |
| occurrences causally related to treatment / all | 0 / 1 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Peripheral arterial occlusive disease | | | |
| subjects affected / exposed | 3 / 825 (0.36%) | | |
| occurrences causally related to treatment / all | 0 / 3 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Peripheral artery aneurysm | | | |
| subjects affected / exposed | 0 / 825 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Peripheral artery stenosis | | | |
| subjects affected / exposed | 1 / 825 (0.12%) | | |
| occurrences causally related to treatment / all | 0 / 1 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Peripheral artery thrombosis | | | |
| subjects affected / exposed | 0 / 825 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Peripheral ischaemia | | | |
| subjects affected / exposed | 0 / 825 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Peripheral vascular disorder | | | |

| | | | |
|---|-----------------|--|--|
| subjects affected / exposed | 3 / 825 (0.36%) | | |
| occurrences causally related to treatment / all | 0 / 3 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Shock haemorrhagic | | | |
| subjects affected / exposed | 0 / 825 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Temporal arteritis | | | |
| subjects affected / exposed | 0 / 825 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Varicose vein | | | |
| subjects affected / exposed | 0 / 825 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Vasculitis | | | |
| subjects affected / exposed | 0 / 825 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Surgical and medical procedures | | | |
| Abdominal hernia repair | | | |
| subjects affected / exposed | 0 / 825 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Angioplasty | | | |
| subjects affected / exposed | 1 / 825 (0.12%) | | |
| occurrences causally related to treatment / all | 0 / 1 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Brachytherapy | | | |
| subjects affected / exposed | 1 / 825 (0.12%) | | |
| occurrences causally related to treatment / all | 0 / 1 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Carotid angioplasty | | | |

| | | | | |
|---|------------------|--|--|--|
| subjects affected / exposed | 1 / 825 (0.12%) | | | |
| occurrences causally related to treatment / all | 0 / 1 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Carotid artery stent insertion | | | | |
| subjects affected / exposed | 0 / 825 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Carotid endarterectomy | | | | |
| subjects affected / exposed | 4 / 825 (0.48%) | | | |
| occurrences causally related to treatment / all | 0 / 4 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Carotid revascularisation | | | | |
| subjects affected / exposed | 1 / 825 (0.12%) | | | |
| occurrences causally related to treatment / all | 0 / 1 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Cataract operation | | | | |
| subjects affected / exposed | 2 / 825 (0.24%) | | | |
| occurrences causally related to treatment / all | 0 / 2 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Coronary angioplasty | | | | |
| subjects affected / exposed | 5 / 825 (0.61%) | | | |
| occurrences causally related to treatment / all | 1 / 5 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Coronary arterial stent insertion | | | | |
| subjects affected / exposed | 17 / 825 (2.06%) | | | |
| occurrences causally related to treatment / all | 2 / 19 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Coronary artery bypass | | | | |
| subjects affected / exposed | 10 / 825 (1.21%) | | | |
| occurrences causally related to treatment / all | 1 / 10 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Coronary revascularisation | | | | |

| | | | | |
|---|-----------------|--|--|--|
| subjects affected / exposed | 9 / 825 (1.09%) | | | |
| occurrences causally related to treatment / all | 0 / 10 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Hospitalisation | | | | |
| subjects affected / exposed | 0 / 825 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Laparotomy | | | | |
| subjects affected / exposed | 0 / 825 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Mechanical ventilation | | | | |
| subjects affected / exposed | 0 / 825 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Nasal polypectomy | | | | |
| subjects affected / exposed | 1 / 825 (0.12%) | | | |
| occurrences causally related to treatment / all | 0 / 1 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Percutaneous coronary intervention | | | | |
| subjects affected / exposed | 6 / 825 (0.73%) | | | |
| occurrences causally related to treatment / all | 0 / 7 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Peripheral artery angioplasty | | | | |
| subjects affected / exposed | 2 / 825 (0.24%) | | | |
| occurrences causally related to treatment / all | 0 / 2 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Peripheral artery bypass | | | | |
| subjects affected / exposed | 0 / 825 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Peripheral artery stent insertion | | | | |

| | | | | |
|---|-----------------|--|--|--|
| subjects affected / exposed | 0 / 825 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Peripheral endarterectomy | | | | |
| subjects affected / exposed | 0 / 825 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Peripheral revascularisation | | | | |
| subjects affected / exposed | 9 / 825 (1.09%) | | | |
| occurrences causally related to treatment / all | 0 / 9 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Pterygium operation | | | | |
| subjects affected / exposed | 0 / 825 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Removal of internal fixation | | | | |
| subjects affected / exposed | 0 / 825 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Renal artery stent placement | | | | |
| subjects affected / exposed | 0 / 825 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Stent placement | | | | |
| subjects affected / exposed | 1 / 825 (0.12%) | | | |
| occurrences causally related to treatment / all | 0 / 2 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Tendon sheath incision | | | | |
| subjects affected / exposed | 0 / 825 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Umbilical hernia repair | | | | |

| | | | |
|--|-----------------|--|--|
| subjects affected / exposed | 0 / 825 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| General disorders and administration site conditions | | | |
| Asthenia | | | |
| subjects affected / exposed | 2 / 825 (0.24%) | | |
| occurrences causally related to treatment / all | 1 / 2 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Chest discomfort | | | |
| subjects affected / exposed | 1 / 825 (0.12%) | | |
| occurrences causally related to treatment / all | 0 / 1 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Chest pain | | | |
| subjects affected / exposed | 3 / 825 (0.36%) | | |
| occurrences causally related to treatment / all | 0 / 3 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Death | | | |
| subjects affected / exposed | 2 / 825 (0.24%) | | |
| occurrences causally related to treatment / all | 0 / 2 | | |
| deaths causally related to treatment / all | 0 / 2 | | |
| Device malfunction | | | |
| subjects affected / exposed | 0 / 825 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Drug intolerance | | | |
| subjects affected / exposed | 0 / 825 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Gait disturbance | | | |
| subjects affected / exposed | 2 / 825 (0.24%) | | |
| occurrences causally related to treatment / all | 0 / 2 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Generalised oedema | | | |

| | | | | |
|---|-----------------|--|--|--|
| subjects affected / exposed | 0 / 825 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Hyperthermia malignant | | | | |
| subjects affected / exposed | 0 / 825 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Impaired healing | | | | |
| subjects affected / exposed | 0 / 825 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Metaplasia | | | | |
| subjects affected / exposed | 0 / 825 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Microlithiasis | | | | |
| subjects affected / exposed | 0 / 825 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Multi-organ failure | | | | |
| subjects affected / exposed | 2 / 825 (0.24%) | | | |
| occurrences causally related to treatment / all | 0 / 2 | | | |
| deaths causally related to treatment / all | 0 / 1 | | | |
| Necrosis | | | | |
| subjects affected / exposed | 0 / 825 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Non-cardiac chest pain | | | | |
| subjects affected / exposed | 4 / 825 (0.48%) | | | |
| occurrences causally related to treatment / all | 0 / 5 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Oedema | | | | |

| | | | |
|---|-----------------|--|--|
| subjects affected / exposed | 0 / 825 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Oedema peripheral | | | |
| subjects affected / exposed | 1 / 825 (0.12%) | | |
| occurrences causally related to treatment / all | 0 / 1 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Pyrexia | | | |
| subjects affected / exposed | 0 / 825 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Sudden cardiac death | | | |
| subjects affected / exposed | 0 / 825 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Sudden death | | | |
| subjects affected / exposed | 0 / 825 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Immune system disorders | | | |
| Anaphylactic shock | | | |
| subjects affected / exposed | 0 / 825 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Drug hypersensitivity | | | |
| subjects affected / exposed | 1 / 825 (0.12%) | | |
| occurrences causally related to treatment / all | 0 / 1 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Hypersensitivity | | | |
| subjects affected / exposed | 0 / 825 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Sarcoidosis | | | |

| | | | |
|---|-----------------|--|--|
| subjects affected / exposed | 0 / 825 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Reproductive system and breast disorders | | | |
| Benign prostatic hyperplasia | | | |
| subjects affected / exposed | 0 / 825 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Breast cyst | | | |
| subjects affected / exposed | 0 / 825 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Cystocele | | | |
| subjects affected / exposed | 1 / 825 (0.12%) | | |
| occurrences causally related to treatment / all | 0 / 1 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Endometrial hyperplasia | | | |
| subjects affected / exposed | 0 / 825 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Epididymal tenderness | | | |
| subjects affected / exposed | 0 / 825 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Erectile dysfunction | | | |
| subjects affected / exposed | 0 / 825 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Genital haemorrhage | | | |
| subjects affected / exposed | 0 / 825 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Menorrhagia | | | |

| | | | |
|---|-----------------|--|--|
| subjects affected / exposed | 0 / 825 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Ovarian cyst | | | |
| subjects affected / exposed | 1 / 825 (0.12%) | | |
| occurrences causally related to treatment / all | 0 / 1 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Prostatic obstruction | | | |
| subjects affected / exposed | 0 / 825 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Prostatomegaly | | | |
| subjects affected / exposed | 1 / 825 (0.12%) | | |
| occurrences causally related to treatment / all | 0 / 1 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Testicular cyst | | | |
| subjects affected / exposed | 0 / 825 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Uterine polyp | | | |
| subjects affected / exposed | 0 / 825 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Vaginal prolapse | | | |
| subjects affected / exposed | 0 / 825 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Respiratory, thoracic and mediastinal disorders | | | |
| Acquired diaphragmatic eventration | | | |
| subjects affected / exposed | 0 / 825 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Acute pulmonary oedema | | | |

| | | | | |
|---|-----------------|--|--|--|
| subjects affected / exposed | 2 / 825 (0.24%) | | | |
| occurrences causally related to treatment / all | 0 / 2 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Acute respiratory failure | | | | |
| subjects affected / exposed | 1 / 825 (0.12%) | | | |
| occurrences causally related to treatment / all | 0 / 1 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Asthma | | | | |
| subjects affected / exposed | 1 / 825 (0.12%) | | | |
| occurrences causally related to treatment / all | 0 / 1 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Atelectasis | | | | |
| subjects affected / exposed | 0 / 825 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Bronchitis chronic | | | | |
| subjects affected / exposed | 0 / 825 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Bronchospasm | | | | |
| subjects affected / exposed | 0 / 825 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Chronic obstructive pulmonary disease | | | | |
| subjects affected / exposed | 7 / 825 (0.85%) | | | |
| occurrences causally related to treatment / all | 0 / 9 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Dyspnoea | | | | |
| subjects affected / exposed | 4 / 825 (0.48%) | | | |
| occurrences causally related to treatment / all | 0 / 4 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Dyspnoea at rest | | | | |

| | | | | |
|---|-----------------|--|--|--|
| subjects affected / exposed | 0 / 825 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Epistaxis | | | | |
| subjects affected / exposed | 0 / 825 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Haemoptysis | | | | |
| subjects affected / exposed | 0 / 825 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Hydrothorax | | | | |
| subjects affected / exposed | 0 / 825 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Hyperventilation | | | | |
| subjects affected / exposed | 0 / 825 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Hypoxia | | | | |
| subjects affected / exposed | 0 / 825 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Idiopathic pulmonary fibrosis | | | | |
| subjects affected / exposed | 0 / 825 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Laryngeal stenosis | | | | |
| subjects affected / exposed | 0 / 825 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Lung cyst | | | | |

| | | | |
|---|-----------------|--|--|
| subjects affected / exposed | 0 / 825 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Pleural effusion | | | |
| subjects affected / exposed | 0 / 825 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Pleurisy | | | |
| subjects affected / exposed | 1 / 825 (0.12%) | | |
| occurrences causally related to treatment / all | 0 / 1 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Pneumonia aspiration | | | |
| subjects affected / exposed | 0 / 825 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Pneumothorax | | | |
| subjects affected / exposed | 1 / 825 (0.12%) | | |
| occurrences causally related to treatment / all | 0 / 1 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Pulmonary congestion | | | |
| subjects affected / exposed | 1 / 825 (0.12%) | | |
| occurrences causally related to treatment / all | 0 / 1 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Pulmonary embolism | | | |
| subjects affected / exposed | 4 / 825 (0.48%) | | |
| occurrences causally related to treatment / all | 0 / 4 | | |
| deaths causally related to treatment / all | 0 / 1 | | |
| Pulmonary hypertension | | | |
| subjects affected / exposed | 1 / 825 (0.12%) | | |
| occurrences causally related to treatment / all | 0 / 1 | | |
| deaths causally related to treatment / all | 0 / 1 | | |
| Pulmonary mass | | | |

| | | | |
|---|-----------------|--|--|
| subjects affected / exposed | 0 / 825 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Pulmonary oedema | | | |
| subjects affected / exposed | 5 / 825 (0.61%) | | |
| occurrences causally related to treatment / all | 0 / 6 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Respiratory arrest | | | |
| subjects affected / exposed | 0 / 825 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Respiratory distress | | | |
| subjects affected / exposed | 0 / 825 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Respiratory failure | | | |
| subjects affected / exposed | 3 / 825 (0.36%) | | |
| occurrences causally related to treatment / all | 0 / 3 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Psychiatric disorders | | | |
| Anxiety | | | |
| subjects affected / exposed | 0 / 825 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Confusional state | | | |
| subjects affected / exposed | 0 / 825 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Delirium | | | |
| subjects affected / exposed | 1 / 825 (0.12%) | | |
| occurrences causally related to treatment / all | 0 / 1 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Depression | | | |

| | | | |
|---|-----------------|--|--|
| subjects affected / exposed | 0 / 825 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Homicidal ideation | | | |
| subjects affected / exposed | 0 / 825 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Mental status changes | | | |
| subjects affected / exposed | 3 / 825 (0.36%) | | |
| occurrences causally related to treatment / all | 0 / 3 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Post-traumatic stress disorder | | | |
| subjects affected / exposed | 0 / 825 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Schizoaffective disorder | | | |
| subjects affected / exposed | 0 / 825 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Sleep terror | | | |
| subjects affected / exposed | 0 / 825 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Investigations | | | |
| Amylase increased | | | |
| subjects affected / exposed | 0 / 825 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Arteriogram coronary | | | |
| subjects affected / exposed | 1 / 825 (0.12%) | | |
| occurrences causally related to treatment / all | 0 / 1 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Bacterial test positive | | | |

| | | | | |
|---|-----------------|--|--|--|
| subjects affected / exposed | 1 / 825 (0.12%) | | | |
| occurrences causally related to treatment / all | 0 / 1 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Blood alkaline phosphatase increased | | | | |
| subjects affected / exposed | 0 / 825 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Blood bilirubin increased | | | | |
| subjects affected / exposed | 0 / 825 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Blood creatinine increased | | | | |
| subjects affected / exposed | 0 / 825 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Blood glucose fluctuation | | | | |
| subjects affected / exposed | 1 / 825 (0.12%) | | | |
| occurrences causally related to treatment / all | 0 / 1 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Blood glucose increased | | | | |
| subjects affected / exposed | 1 / 825 (0.12%) | | | |
| occurrences causally related to treatment / all | 0 / 1 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Blood urea increased | | | | |
| subjects affected / exposed | 0 / 825 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Catheterisation cardiac | | | | |
| subjects affected / exposed | 0 / 825 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Coagulation time prolonged | | | | |

| | | | | |
|---|-----------------|--|--|--|
| subjects affected / exposed | 0 / 825 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Ejection fraction decreased | | | | |
| subjects affected / exposed | 0 / 825 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Electrocardiogram QT prolonged | | | | |
| subjects affected / exposed | 0 / 825 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Electrocardiogram ST segment abnormal | | | | |
| subjects affected / exposed | 0 / 825 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Electrocardiogram T wave inversion | | | | |
| subjects affected / exposed | 0 / 825 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Electrocardiogram change | | | | |
| subjects affected / exposed | 1 / 825 (0.12%) | | | |
| occurrences causally related to treatment / all | 0 / 1 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Lipase increased | | | | |
| subjects affected / exposed | 0 / 825 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Liver function test abnormal | | | | |
| subjects affected / exposed | 0 / 825 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Pancreatic enzymes increased | | | | |

| | | | |
|---|-----------------|--|--|
| subjects affected / exposed | 0 / 825 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Transaminases increased | | | |
| subjects affected / exposed | 0 / 825 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Troponin increased | | | |
| subjects affected / exposed | 2 / 825 (0.24%) | | |
| occurrences causally related to treatment / all | 0 / 2 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Weight decreased | | | |
| subjects affected / exposed | 0 / 825 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Injury, poisoning and procedural complications | | | |
| Accident at work | | | |
| subjects affected / exposed | 0 / 825 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Alcohol poisoning | | | |
| subjects affected / exposed | 0 / 825 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Anaemia postoperative | | | |
| subjects affected / exposed | 0 / 825 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Animal bite | | | |
| subjects affected / exposed | 0 / 825 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Ankle fracture | | | |

| | | | | |
|---|-----------------|--|--|--|
| subjects affected / exposed | 0 / 825 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Burns third degree | | | | |
| subjects affected / exposed | 0 / 825 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Cervical vertebral fracture | | | | |
| subjects affected / exposed | 0 / 825 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Contusion | | | | |
| subjects affected / exposed | 0 / 825 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Dural tear | | | | |
| subjects affected / exposed | 0 / 825 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Failure to anastomose | | | | |
| subjects affected / exposed | 1 / 825 (0.12%) | | | |
| occurrences causally related to treatment / all | 0 / 1 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Fall | | | | |
| subjects affected / exposed | 8 / 825 (0.97%) | | | |
| occurrences causally related to treatment / all | 0 / 8 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Femur fracture | | | | |
| subjects affected / exposed | 0 / 825 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Foot fracture | | | | |

| | | | | |
|---|-----------------|--|--|--|
| subjects affected / exposed | 1 / 825 (0.12%) | | | |
| occurrences causally related to treatment / all | 0 / 1 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Hand fracture | | | | |
| subjects affected / exposed | 1 / 825 (0.12%) | | | |
| occurrences causally related to treatment / all | 0 / 1 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Head injury | | | | |
| subjects affected / exposed | 1 / 825 (0.12%) | | | |
| occurrences causally related to treatment / all | 0 / 1 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Hip fracture | | | | |
| subjects affected / exposed | 0 / 825 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Humerus fracture | | | | |
| subjects affected / exposed | 1 / 825 (0.12%) | | | |
| occurrences causally related to treatment / all | 0 / 1 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Incisional hernia | | | | |
| subjects affected / exposed | 1 / 825 (0.12%) | | | |
| occurrences causally related to treatment / all | 0 / 1 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Incorrect dose administered | | | | |
| subjects affected / exposed | 0 / 825 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Injury | | | | |
| subjects affected / exposed | 0 / 825 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Intentional overdose | | | | |

| | | | |
|---|-----------------|--|--|
| subjects affected / exposed | 1 / 825 (0.12%) | | |
| occurrences causally related to treatment / all | 0 / 1 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Laceration | | | |
| subjects affected / exposed | 0 / 825 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Limb injury | | | |
| subjects affected / exposed | 0 / 825 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Lumbar vertebral fracture | | | |
| subjects affected / exposed | 0 / 825 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Meniscus injury | | | |
| subjects affected / exposed | 1 / 825 (0.12%) | | |
| occurrences causally related to treatment / all | 0 / 1 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Muscle strain | | | |
| subjects affected / exposed | 1 / 825 (0.12%) | | |
| occurrences causally related to treatment / all | 0 / 1 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Near drowning | | | |
| subjects affected / exposed | 0 / 825 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Overdose | | | |
| subjects affected / exposed | 1 / 825 (0.12%) | | |
| occurrences causally related to treatment / all | 0 / 1 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Post procedural haematoma | | | |

| | | | | |
|---|-----------------|--|--|--|
| subjects affected / exposed | 1 / 825 (0.12%) | | | |
| occurrences causally related to treatment / all | 0 / 1 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Postoperative ileus | | | | |
| subjects affected / exposed | 0 / 825 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Postoperative respiratory failure | | | | |
| subjects affected / exposed | 0 / 825 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Radius fracture | | | | |
| subjects affected / exposed | 0 / 825 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Rib fracture | | | | |
| subjects affected / exposed | 1 / 825 (0.12%) | | | |
| occurrences causally related to treatment / all | 0 / 1 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Road traffic accident | | | | |
| subjects affected / exposed | 4 / 825 (0.48%) | | | |
| occurrences causally related to treatment / all | 0 / 5 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Scapula fracture | | | | |
| subjects affected / exposed | 1 / 825 (0.12%) | | | |
| occurrences causally related to treatment / all | 0 / 1 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Seroma | | | | |
| subjects affected / exposed | 0 / 825 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Skin abrasion | | | | |

| | | | | |
|---|-----------------|--|--|--|
| subjects affected / exposed | 1 / 825 (0.12%) | | | |
| occurrences causally related to treatment / all | 0 / 1 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Skull fracture | | | | |
| subjects affected / exposed | 1 / 825 (0.12%) | | | |
| occurrences causally related to treatment / all | 0 / 1 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Spinal compression fracture | | | | |
| subjects affected / exposed | 0 / 825 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Subdural haematoma | | | | |
| subjects affected / exposed | 0 / 825 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Tendon rupture | | | | |
| subjects affected / exposed | 1 / 825 (0.12%) | | | |
| occurrences causally related to treatment / all | 0 / 1 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Thermal burn | | | | |
| subjects affected / exposed | 0 / 825 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Toxicity to various agents | | | | |
| subjects affected / exposed | 1 / 825 (0.12%) | | | |
| occurrences causally related to treatment / all | 0 / 1 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Traumatic fracture | | | | |
| subjects affected / exposed | 0 / 825 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Traumatic haemothorax | | | | |

| | | | |
|---|-----------------|--|--|
| subjects affected / exposed | 0 / 825 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Traumatic ulcer | | | |
| subjects affected / exposed | 0 / 825 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Vascular graft complication | | | |
| subjects affected / exposed | 0 / 825 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Vascular graft occlusion | | | |
| subjects affected / exposed | 0 / 825 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Vascular pseudoaneurysm | | | |
| subjects affected / exposed | 0 / 825 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Wound | | | |
| subjects affected / exposed | 0 / 825 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Wound necrosis | | | |
| subjects affected / exposed | 0 / 825 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Wrong drug administered | | | |
| subjects affected / exposed | 0 / 825 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Congenital, familial and genetic disorders | | | |
| Phimosis | | | |

| | | | |
|---|------------------|--|--|
| subjects affected / exposed | 0 / 825 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Cardiac disorders | | | |
| Acute coronary syndrome | | | |
| subjects affected / exposed | 2 / 825 (0.24%) | | |
| occurrences causally related to treatment / all | 0 / 2 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Acute left ventricular failure | | | |
| subjects affected / exposed | 1 / 825 (0.12%) | | |
| occurrences causally related to treatment / all | 0 / 1 | | |
| deaths causally related to treatment / all | 0 / 1 | | |
| Acute myocardial infarction | | | |
| subjects affected / exposed | 27 / 825 (3.27%) | | |
| occurrences causally related to treatment / all | 2 / 28 | | |
| deaths causally related to treatment / all | 0 / 2 | | |
| Angina pectoris | | | |
| subjects affected / exposed | 12 / 825 (1.45%) | | |
| occurrences causally related to treatment / all | 2 / 12 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Angina unstable | | | |
| subjects affected / exposed | 22 / 825 (2.67%) | | |
| occurrences causally related to treatment / all | 0 / 23 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Aortic valve disease | | | |
| subjects affected / exposed | 0 / 825 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Aortic valve stenosis | | | |
| subjects affected / exposed | 0 / 825 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Arrhythmia | | | |

| | | | | |
|---|------------------|--|--|--|
| subjects affected / exposed | 3 / 825 (0.36%) | | | |
| occurrences causally related to treatment / all | 0 / 3 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Arteriosclerosis coronary artery | | | | |
| subjects affected / exposed | 3 / 825 (0.36%) | | | |
| occurrences causally related to treatment / all | 0 / 3 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Atrial fibrillation | | | | |
| subjects affected / exposed | 18 / 825 (2.18%) | | | |
| occurrences causally related to treatment / all | 3 / 19 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Atrial flutter | | | | |
| subjects affected / exposed | 1 / 825 (0.12%) | | | |
| occurrences causally related to treatment / all | 0 / 1 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Atrial thrombosis | | | | |
| subjects affected / exposed | 0 / 825 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Atrioventricular block | | | | |
| subjects affected / exposed | 0 / 825 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Atrioventricular block complete | | | | |
| subjects affected / exposed | 3 / 825 (0.36%) | | | |
| occurrences causally related to treatment / all | 0 / 3 | | | |
| deaths causally related to treatment / all | 0 / 1 | | | |
| Atrioventricular block first degree | | | | |
| subjects affected / exposed | 0 / 825 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Atrioventricular block second degree | | | | |

| | | | | |
|---|-----------------|--|--|--|
| subjects affected / exposed | 1 / 825 (0.12%) | | | |
| occurrences causally related to treatment / all | 0 / 1 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Bradyarrhythmia | | | | |
| subjects affected / exposed | 0 / 825 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Bradycardia | | | | |
| subjects affected / exposed | 2 / 825 (0.24%) | | | |
| occurrences causally related to treatment / all | 0 / 2 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Bundle branch block left | | | | |
| subjects affected / exposed | 3 / 825 (0.36%) | | | |
| occurrences causally related to treatment / all | 0 / 3 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Bundle branch block right | | | | |
| subjects affected / exposed | 0 / 825 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Cardiac arrest | | | | |
| subjects affected / exposed | 2 / 825 (0.24%) | | | |
| occurrences causally related to treatment / all | 1 / 3 | | | |
| deaths causally related to treatment / all | 1 / 2 | | | |
| Cardiac asthma | | | | |
| subjects affected / exposed | 0 / 825 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Cardiac failure | | | | |
| subjects affected / exposed | 3 / 825 (0.36%) | | | |
| occurrences causally related to treatment / all | 1 / 4 | | | |
| deaths causally related to treatment / all | 0 / 1 | | | |
| Cardiac failure acute | | | | |

| | | | |
|---|------------------|--|--|
| subjects affected / exposed | 1 / 825 (0.12%) | | |
| occurrences causally related to treatment / all | 0 / 2 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Cardiac failure chronic | | | |
| subjects affected / exposed | 3 / 825 (0.36%) | | |
| occurrences causally related to treatment / all | 0 / 3 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Cardiac failure congestive | | | |
| subjects affected / exposed | 18 / 825 (2.18%) | | |
| occurrences causally related to treatment / all | 1 / 21 | | |
| deaths causally related to treatment / all | 0 / 1 | | |
| Cardiac tamponade | | | |
| subjects affected / exposed | 0 / 825 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Cardiac ventricular thrombosis | | | |
| subjects affected / exposed | 1 / 825 (0.12%) | | |
| occurrences causally related to treatment / all | 0 / 1 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Cardio-respiratory arrest | | | |
| subjects affected / exposed | 0 / 825 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Cardiogenic shock | | | |
| subjects affected / exposed | 1 / 825 (0.12%) | | |
| occurrences causally related to treatment / all | 0 / 1 | | |
| deaths causally related to treatment / all | 0 / 1 | | |
| Cardiomyopathy | | | |
| subjects affected / exposed | 0 / 825 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Cardiopulmonary failure | | | |

| | | | |
|---|-----------------|--|--|
| subjects affected / exposed | 0 / 825 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Cardiovascular insufficiency | | | |
| subjects affected / exposed | 0 / 825 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Congestive cardiomyopathy | | | |
| subjects affected / exposed | 0 / 825 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Cor pulmonale acute | | | |
| subjects affected / exposed | 0 / 825 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Coronary artery disease | | | |
| subjects affected / exposed | 2 / 825 (0.24%) | | |
| occurrences causally related to treatment / all | 0 / 3 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Coronary artery insufficiency | | | |
| subjects affected / exposed | 0 / 825 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Coronary artery occlusion | | | |
| subjects affected / exposed | 1 / 825 (0.12%) | | |
| occurrences causally related to treatment / all | 0 / 1 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Coronary artery stenosis | | | |
| subjects affected / exposed | 1 / 825 (0.12%) | | |
| occurrences causally related to treatment / all | 0 / 1 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Diabetic cardiomyopathy | | | |

| | | | |
|---|------------------|--|--|
| subjects affected / exposed | 1 / 825 (0.12%) | | |
| occurrences causally related to treatment / all | 0 / 1 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Hypertensive cardiomyopathy | | | |
| subjects affected / exposed | 1 / 825 (0.12%) | | |
| occurrences causally related to treatment / all | 0 / 1 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Ischaemic cardiomyopathy | | | |
| subjects affected / exposed | 1 / 825 (0.12%) | | |
| occurrences causally related to treatment / all | 0 / 1 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Left ventricular failure | | | |
| subjects affected / exposed | 1 / 825 (0.12%) | | |
| occurrences causally related to treatment / all | 1 / 1 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Mitral valve incompetence | | | |
| subjects affected / exposed | 0 / 825 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Myocardial infarction | | | |
| subjects affected / exposed | 12 / 825 (1.45%) | | |
| occurrences causally related to treatment / all | 4 / 14 | | |
| deaths causally related to treatment / all | 1 / 4 | | |
| Myocardial ischaemia | | | |
| subjects affected / exposed | 2 / 825 (0.24%) | | |
| occurrences causally related to treatment / all | 0 / 2 | | |
| deaths causally related to treatment / all | 0 / 1 | | |
| Myocarditis | | | |
| subjects affected / exposed | 0 / 825 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Nodal arrhythmia | | | |

| | | | |
|---|-----------------|--|--|
| subjects affected / exposed | 0 / 825 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Pericardial effusion | | | |
| subjects affected / exposed | 0 / 825 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Pulmonary valve stenosis | | | |
| subjects affected / exposed | 0 / 825 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Right ventricular failure | | | |
| subjects affected / exposed | 1 / 825 (0.12%) | | |
| occurrences causally related to treatment / all | 0 / 1 | | |
| deaths causally related to treatment / all | 0 / 1 | | |
| Silent myocardial infarction | | | |
| subjects affected / exposed | 0 / 825 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Sinus bradycardia | | | |
| subjects affected / exposed | 1 / 825 (0.12%) | | |
| occurrences causally related to treatment / all | 0 / 1 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Sinus node dysfunction | | | |
| subjects affected / exposed | 0 / 825 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Stress cardiomyopathy | | | |
| subjects affected / exposed | 0 / 825 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Supraventricular extrasystoles | | | |

| | | | |
|---|-----------------|--|--|
| subjects affected / exposed | 0 / 825 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Supraventricular tachycardia | | | |
| subjects affected / exposed | 1 / 825 (0.12%) | | |
| occurrences causally related to treatment / all | 0 / 1 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Tachycardia | | | |
| subjects affected / exposed | 0 / 825 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Tricuspid valve incompetence | | | |
| subjects affected / exposed | 0 / 825 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Ventricular arrhythmia | | | |
| subjects affected / exposed | 0 / 825 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Ventricular asystole | | | |
| subjects affected / exposed | 1 / 825 (0.12%) | | |
| occurrences causally related to treatment / all | 0 / 1 | | |
| deaths causally related to treatment / all | 0 / 1 | | |
| Ventricular extrasystoles | | | |
| subjects affected / exposed | 1 / 825 (0.12%) | | |
| occurrences causally related to treatment / all | 0 / 1 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Ventricular fibrillation | | | |
| subjects affected / exposed | 2 / 825 (0.24%) | | |
| occurrences causally related to treatment / all | 0 / 2 | | |
| deaths causally related to treatment / all | 0 / 2 | | |
| Ventricular hypokinesia | | | |

| | | | |
|---|-----------------|--|--|
| subjects affected / exposed | 0 / 825 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Ventricular tachyarrhythmia | | | |
| subjects affected / exposed | 0 / 825 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Ventricular tachycardia | | | |
| subjects affected / exposed | 2 / 825 (0.24%) | | |
| occurrences causally related to treatment / all | 0 / 2 | | |
| deaths causally related to treatment / all | 0 / 1 | | |
| Nervous system disorders | | | |
| Brain oedema | | | |
| subjects affected / exposed | 1 / 825 (0.12%) | | |
| occurrences causally related to treatment / all | 0 / 1 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Brain stem infarction | | | |
| subjects affected / exposed | 0 / 825 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Carotid artery occlusion | | | |
| subjects affected / exposed | 1 / 825 (0.12%) | | |
| occurrences causally related to treatment / all | 0 / 1 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Carotid artery stenosis | | | |
| subjects affected / exposed | 3 / 825 (0.36%) | | |
| occurrences causally related to treatment / all | 0 / 3 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Cerebellar haemorrhage | | | |
| subjects affected / exposed | 0 / 825 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Cerebellar syndrome | | | |

| | | | |
|---|-----------------|--|--|
| subjects affected / exposed | 0 / 825 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Cerebral haemorrhage | | | |
| subjects affected / exposed | 0 / 825 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Cerebral infarction | | | |
| subjects affected / exposed | 0 / 825 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Cerebral ischaemia | | | |
| subjects affected / exposed | 1 / 825 (0.12%) | | |
| occurrences causally related to treatment / all | 0 / 1 | | |
| deaths causally related to treatment / all | 0 / 1 | | |
| Cerebrospinal fluid leakage | | | |
| subjects affected / exposed | 0 / 825 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Cerebrovascular accident | | | |
| subjects affected / exposed | 6 / 825 (0.73%) | | |
| occurrences causally related to treatment / all | 1 / 8 | | |
| deaths causally related to treatment / all | 0 / 2 | | |
| Cerebrovascular disorder | | | |
| subjects affected / exposed | 0 / 825 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Cervical myelopathy | | | |
| subjects affected / exposed | 1 / 825 (0.12%) | | |
| occurrences causally related to treatment / all | 0 / 1 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Cervical radiculopathy | | | |

| | | | | |
|---|-----------------|--|--|--|
| subjects affected / exposed | 0 / 825 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Chronic inflammatory demyelinating polyradiculoneuropathy | | | | |
| subjects affected / exposed | 0 / 825 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Coma | | | | |
| subjects affected / exposed | 0 / 825 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Coordination abnormal | | | | |
| subjects affected / exposed | 1 / 825 (0.12%) | | | |
| occurrences causally related to treatment / all | 0 / 1 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Cranial nerve disorder | | | | |
| subjects affected / exposed | 0 / 825 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Diabetic mononeuropathy | | | | |
| subjects affected / exposed | 0 / 825 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Dizziness | | | | |
| subjects affected / exposed | 1 / 825 (0.12%) | | | |
| occurrences causally related to treatment / all | 0 / 1 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Embolic stroke | | | | |
| subjects affected / exposed | 1 / 825 (0.12%) | | | |
| occurrences causally related to treatment / all | 0 / 1 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Epilepsy | | | | |

| | | | |
|---|-----------------|--|--|
| subjects affected / exposed | 0 / 825 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Haemorrhage intracranial | | | |
| subjects affected / exposed | 1 / 825 (0.12%) | | |
| occurrences causally related to treatment / all | 0 / 1 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Haemorrhagic stroke | | | |
| subjects affected / exposed | 1 / 825 (0.12%) | | |
| occurrences causally related to treatment / all | 0 / 1 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Headache | | | |
| subjects affected / exposed | 0 / 825 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Hepatic encephalopathy | | | |
| subjects affected / exposed | 0 / 825 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Hydrocephalus | | | |
| subjects affected / exposed | 1 / 825 (0.12%) | | |
| occurrences causally related to treatment / all | 0 / 1 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Hypertensive encephalopathy | | | |
| subjects affected / exposed | 1 / 825 (0.12%) | | |
| occurrences causally related to treatment / all | 1 / 1 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Hypoaesthesia | | | |
| subjects affected / exposed | 0 / 825 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Hypoglycaemic coma | | | |

| | | | |
|---|-----------------|--|--|
| subjects affected / exposed | 0 / 825 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Hypoglycaemic unconsciousness | | | |
| subjects affected / exposed | 3 / 825 (0.36%) | | |
| occurrences causally related to treatment / all | 2 / 6 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Hypoxic-ischaemic encephalopathy | | | |
| subjects affected / exposed | 0 / 825 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Intracranial aneurysm | | | |
| subjects affected / exposed | 1 / 825 (0.12%) | | |
| occurrences causally related to treatment / all | 0 / 1 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Intracranial hypotension | | | |
| subjects affected / exposed | 0 / 825 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Intraventricular haemorrhage | | | |
| subjects affected / exposed | 1 / 825 (0.12%) | | |
| occurrences causally related to treatment / all | 0 / 1 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Ischaemic cerebral infarction | | | |
| subjects affected / exposed | 1 / 825 (0.12%) | | |
| occurrences causally related to treatment / all | 0 / 1 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Ischaemic stroke | | | |
| subjects affected / exposed | 4 / 825 (0.48%) | | |
| occurrences causally related to treatment / all | 0 / 4 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Lacunar infarction | | | |

| | | | | |
|---|-----------------|--|--|--|
| subjects affected / exposed | 1 / 825 (0.12%) | | | |
| occurrences causally related to treatment / all | 0 / 1 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Loss of consciousness | | | | |
| subjects affected / exposed | 0 / 825 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Metabolic encephalopathy | | | | |
| subjects affected / exposed | 0 / 825 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Migraine | | | | |
| subjects affected / exposed | 0 / 825 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Movement disorder | | | | |
| subjects affected / exposed | 0 / 825 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Multiple sclerosis | | | | |
| subjects affected / exposed | 0 / 825 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Myelitis transverse | | | | |
| subjects affected / exposed | 0 / 825 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Neuralgia | | | | |
| subjects affected / exposed | 0 / 825 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Parkinsonism | | | | |

| | | | | |
|---|-----------------|--|--|--|
| subjects affected / exposed | 0 / 825 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Presyncope | | | | |
| subjects affected / exposed | 1 / 825 (0.12%) | | | |
| occurrences causally related to treatment / all | 0 / 1 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Radiculitis lumbosacral | | | | |
| subjects affected / exposed | 0 / 825 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Radiculopathy | | | | |
| subjects affected / exposed | 0 / 825 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Seizure | | | | |
| subjects affected / exposed | 3 / 825 (0.36%) | | | |
| occurrences causally related to treatment / all | 0 / 3 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Speech disorder | | | | |
| subjects affected / exposed | 0 / 825 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Syncope | | | | |
| subjects affected / exposed | 3 / 825 (0.36%) | | | |
| occurrences causally related to treatment / all | 0 / 3 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Thalamic infarction | | | | |
| subjects affected / exposed | 0 / 825 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Transient ischaemic attack | | | | |

| | | | |
|---|-----------------|--|--|
| subjects affected / exposed | 7 / 825 (0.85%) | | |
| occurrences causally related to treatment / all | 0 / 7 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| VIIth nerve paralysis | | | |
| subjects affected / exposed | 1 / 825 (0.12%) | | |
| occurrences causally related to treatment / all | 0 / 1 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| VIth nerve disorder | | | |
| subjects affected / exposed | 0 / 825 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Vascular parkinsonism | | | |
| subjects affected / exposed | 0 / 825 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Visual field defect | | | |
| subjects affected / exposed | 0 / 825 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Blood and lymphatic system disorders | | | |
| Anaemia | | | |
| subjects affected / exposed | 2 / 825 (0.24%) | | |
| occurrences causally related to treatment / all | 0 / 2 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Haemorrhagic anaemia | | | |
| subjects affected / exposed | 1 / 825 (0.12%) | | |
| occurrences causally related to treatment / all | 0 / 1 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Iron deficiency anaemia | | | |
| subjects affected / exposed | 0 / 825 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Leukocytosis | | | |

| | | | |
|---|-----------------|--|--|
| subjects affected / exposed | 0 / 825 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Lymphadenopathy | | | |
| subjects affected / exposed | 0 / 825 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Lymphadenopathy mediastinal | | | |
| subjects affected / exposed | 0 / 825 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Microcytic anaemia | | | |
| subjects affected / exposed | 1 / 825 (0.12%) | | |
| occurrences causally related to treatment / all | 0 / 1 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Splenic vein thrombosis | | | |
| subjects affected / exposed | 1 / 825 (0.12%) | | |
| occurrences causally related to treatment / all | 0 / 1 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Splenomegaly | | | |
| subjects affected / exposed | 1 / 825 (0.12%) | | |
| occurrences causally related to treatment / all | 0 / 1 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Thrombocytopenia | | | |
| subjects affected / exposed | 1 / 825 (0.12%) | | |
| occurrences causally related to treatment / all | 0 / 1 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Ear and labyrinth disorders | | | |
| Deafness neurosensory | | | |
| subjects affected / exposed | 0 / 825 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Otosclerosis | | | |

| | | | |
|---|-----------------|--|--|
| subjects affected / exposed | 0 / 825 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Tympanic membrane perforation | | | |
| subjects affected / exposed | 0 / 825 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Vertigo | | | |
| subjects affected / exposed | 0 / 825 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Eye disorders | | | |
| Amaurosis fugax | | | |
| subjects affected / exposed | 0 / 825 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Blindness | | | |
| subjects affected / exposed | 0 / 825 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Cataract | | | |
| subjects affected / exposed | 5 / 825 (0.61%) | | |
| occurrences causally related to treatment / all | 0 / 6 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Cataract cortical | | | |
| subjects affected / exposed | 1 / 825 (0.12%) | | |
| occurrences causally related to treatment / all | 0 / 1 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Cataract nuclear | | | |
| subjects affected / exposed | 0 / 825 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Cystoid macular oedema | | | |

| | | | |
|---|-----------------|--|--|
| subjects affected / exposed | 0 / 825 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Diabetic retinopathy | | | |
| subjects affected / exposed | 4 / 825 (0.48%) | | |
| occurrences causally related to treatment / all | 0 / 4 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Diplopia | | | |
| subjects affected / exposed | 0 / 825 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Eyelid dermatochalasis | | | |
| subjects affected / exposed | 0 / 825 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Eyelid ptosis | | | |
| subjects affected / exposed | 0 / 825 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Glaucoma | | | |
| subjects affected / exposed | 1 / 825 (0.12%) | | |
| occurrences causally related to treatment / all | 0 / 1 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Iridocyclitis | | | |
| subjects affected / exposed | 1 / 825 (0.12%) | | |
| occurrences causally related to treatment / all | 0 / 1 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Macular fibrosis | | | |
| subjects affected / exposed | 0 / 825 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Macular oedema | | | |

| | | | |
|---|-----------------|--|--|
| subjects affected / exposed | 0 / 825 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Open angle glaucoma | | | |
| subjects affected / exposed | 1 / 825 (0.12%) | | |
| occurrences causally related to treatment / all | 0 / 1 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Optic ischaemic neuropathy | | | |
| subjects affected / exposed | 0 / 825 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Retinal artery occlusion | | | |
| subjects affected / exposed | 0 / 825 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Retinal degeneration | | | |
| subjects affected / exposed | 0 / 825 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Retinal detachment | | | |
| subjects affected / exposed | 2 / 825 (0.24%) | | |
| occurrences causally related to treatment / all | 0 / 2 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Retinopathy haemorrhagic | | | |
| subjects affected / exposed | 0 / 825 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Vitreous haemorrhage | | | |
| subjects affected / exposed | 0 / 825 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Gastrointestinal disorders | | | |
| Abdominal mass | | | |

| | | | | |
|---|-----------------|--|--|--|
| subjects affected / exposed | 0 / 825 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Abdominal pain | | | | |
| subjects affected / exposed | 2 / 825 (0.24%) | | | |
| occurrences causally related to treatment / all | 0 / 2 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Abdominal pain lower | | | | |
| subjects affected / exposed | 0 / 825 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Abdominal pain upper | | | | |
| subjects affected / exposed | 0 / 825 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Ascites | | | | |
| subjects affected / exposed | 1 / 825 (0.12%) | | | |
| occurrences causally related to treatment / all | 0 / 1 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Change of bowel habit | | | | |
| subjects affected / exposed | 0 / 825 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Chronic gastritis | | | | |
| subjects affected / exposed | 0 / 825 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Colitis | | | | |
| subjects affected / exposed | 0 / 825 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Colitis ischaemic | | | | |

| | | | |
|---|-----------------|--|--|
| subjects affected / exposed | 1 / 825 (0.12%) | | |
| occurrences causally related to treatment / all | 0 / 1 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Colitis ulcerative | | | |
| subjects affected / exposed | 0 / 825 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Constipation | | | |
| subjects affected / exposed | 0 / 825 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Diaphragmatic hernia | | | |
| subjects affected / exposed | 1 / 825 (0.12%) | | |
| occurrences causally related to treatment / all | 0 / 1 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Diarrhoea | | | |
| subjects affected / exposed | 1 / 825 (0.12%) | | |
| occurrences causally related to treatment / all | 0 / 1 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Diverticulum | | | |
| subjects affected / exposed | 0 / 825 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Diverticulum intestinal | | | |
| subjects affected / exposed | 0 / 825 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Duodenal ulcer | | | |
| subjects affected / exposed | 1 / 825 (0.12%) | | |
| occurrences causally related to treatment / all | 0 / 1 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Duodenal ulcer haemorrhage | | | |

| | | | | |
|---|-----------------|--|--|--|
| subjects affected / exposed | 0 / 825 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Duodenitis | | | | |
| subjects affected / exposed | 1 / 825 (0.12%) | | | |
| occurrences causally related to treatment / all | 0 / 1 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Enterocolitis haemorrhagic | | | | |
| subjects affected / exposed | 1 / 825 (0.12%) | | | |
| occurrences causally related to treatment / all | 0 / 1 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Epigastric discomfort | | | | |
| subjects affected / exposed | 0 / 825 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Faeces discoloured | | | | |
| subjects affected / exposed | 1 / 825 (0.12%) | | | |
| occurrences causally related to treatment / all | 0 / 1 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Gastric disorder | | | | |
| subjects affected / exposed | 0 / 825 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Gastric ileus | | | | |
| subjects affected / exposed | 1 / 825 (0.12%) | | | |
| occurrences causally related to treatment / all | 0 / 1 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Gastric polyps | | | | |
| subjects affected / exposed | 1 / 825 (0.12%) | | | |
| occurrences causally related to treatment / all | 0 / 1 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Gastric ulcer | | | | |

| | | | |
|---|-----------------|--|--|
| subjects affected / exposed | 1 / 825 (0.12%) | | |
| occurrences causally related to treatment / all | 0 / 1 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Gastric ulcer haemorrhage | | | |
| subjects affected / exposed | 0 / 825 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Gastritis | | | |
| subjects affected / exposed | 1 / 825 (0.12%) | | |
| occurrences causally related to treatment / all | 0 / 1 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Gastritis haemorrhagic | | | |
| subjects affected / exposed | 0 / 825 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Gastroduodenitis | | | |
| subjects affected / exposed | 1 / 825 (0.12%) | | |
| occurrences causally related to treatment / all | 0 / 1 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Gastrointestinal haemorrhage | | | |
| subjects affected / exposed | 4 / 825 (0.48%) | | |
| occurrences causally related to treatment / all | 0 / 4 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Gastrointestinal ischaemia | | | |
| subjects affected / exposed | 1 / 825 (0.12%) | | |
| occurrences causally related to treatment / all | 0 / 1 | | |
| deaths causally related to treatment / all | 0 / 1 | | |
| Gastrooesophageal reflux disease | | | |
| subjects affected / exposed | 1 / 825 (0.12%) | | |
| occurrences causally related to treatment / all | 0 / 1 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Haematemesis | | | |

| | | | |
|---|-----------------|--|--|
| subjects affected / exposed | 0 / 825 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Hiatus hernia | | | |
| subjects affected / exposed | 0 / 825 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Impaired gastric emptying | | | |
| subjects affected / exposed | 0 / 825 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Inguinal hernia | | | |
| subjects affected / exposed | 1 / 825 (0.12%) | | |
| occurrences causally related to treatment / all | 0 / 1 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Intestinal haemorrhage | | | |
| subjects affected / exposed | 1 / 825 (0.12%) | | |
| occurrences causally related to treatment / all | 0 / 1 | | |
| deaths causally related to treatment / all | 0 / 1 | | |
| Intestinal ischaemia | | | |
| subjects affected / exposed | 0 / 825 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Intestinal obstruction | | | |
| subjects affected / exposed | 0 / 825 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Intestinal perforation | | | |
| subjects affected / exposed | 0 / 825 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Large intestinal haemorrhage | | | |

| | | | |
|---|-----------------|--|--|
| subjects affected / exposed | 0 / 825 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Large intestine polyp | | | |
| subjects affected / exposed | 0 / 825 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Lower gastrointestinal haemorrhage | | | |
| subjects affected / exposed | 0 / 825 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Melaena | | | |
| subjects affected / exposed | 0 / 825 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Mouth ulceration | | | |
| subjects affected / exposed | 0 / 825 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Nausea | | | |
| subjects affected / exposed | 1 / 825 (0.12%) | | |
| occurrences causally related to treatment / all | 0 / 1 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Oesophageal spasm | | | |
| subjects affected / exposed | 1 / 825 (0.12%) | | |
| occurrences causally related to treatment / all | 0 / 1 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Pancreatic cyst | | | |
| subjects affected / exposed | 0 / 825 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Pancreatitis | | | |

| | | | | |
|---|-----------------|--|--|--|
| subjects affected / exposed | 4 / 825 (0.48%) | | | |
| occurrences causally related to treatment / all | 2 / 4 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Pancreatitis acute | | | | |
| subjects affected / exposed | 2 / 825 (0.24%) | | | |
| occurrences causally related to treatment / all | 1 / 2 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Peptic ulcer | | | | |
| subjects affected / exposed | 0 / 825 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Peritoneal haemorrhage | | | | |
| subjects affected / exposed | 0 / 825 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Pneumoperitoneum | | | | |
| subjects affected / exposed | 0 / 825 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Proctitis haemorrhagic | | | | |
| subjects affected / exposed | 0 / 825 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Rectal prolapse | | | | |
| subjects affected / exposed | 0 / 825 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Small intestinal obstruction | | | | |
| subjects affected / exposed | 2 / 825 (0.24%) | | | |
| occurrences causally related to treatment / all | 0 / 2 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Umbilical hernia | | | | |

| | | | |
|---|-----------------|--|--|
| subjects affected / exposed | 2 / 825 (0.24%) | | |
| occurrences causally related to treatment / all | 0 / 2 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Upper gastrointestinal haemorrhage | | | |
| subjects affected / exposed | 1 / 825 (0.12%) | | |
| occurrences causally related to treatment / all | 0 / 1 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Volvulus of small bowel | | | |
| subjects affected / exposed | 0 / 825 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Vomiting | | | |
| subjects affected / exposed | 2 / 825 (0.24%) | | |
| occurrences causally related to treatment / all | 0 / 2 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Hepatobiliary disorders | | | |
| Bile duct stone | | | |
| subjects affected / exposed | 1 / 825 (0.12%) | | |
| occurrences causally related to treatment / all | 0 / 1 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Biliary colic | | | |
| subjects affected / exposed | 0 / 825 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Cholangitis | | | |
| subjects affected / exposed | 0 / 825 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Cholecystitis | | | |
| subjects affected / exposed | 2 / 825 (0.24%) | | |
| occurrences causally related to treatment / all | 1 / 2 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Cholecystitis acute | | | |

| | | | | |
|---|-----------------|--|--|--|
| subjects affected / exposed | 2 / 825 (0.24%) | | | |
| occurrences causally related to treatment / all | 0 / 2 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Cholecystitis chronic | | | | |
| subjects affected / exposed | 1 / 825 (0.12%) | | | |
| occurrences causally related to treatment / all | 0 / 1 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Cholelithiasis | | | | |
| subjects affected / exposed | 1 / 825 (0.12%) | | | |
| occurrences causally related to treatment / all | 0 / 1 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Cholelithiasis obstructive | | | | |
| subjects affected / exposed | 0 / 825 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Cholestasis | | | | |
| subjects affected / exposed | 0 / 825 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Gallbladder necrosis | | | | |
| subjects affected / exposed | 0 / 825 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Gallbladder polyp | | | | |
| subjects affected / exposed | 0 / 825 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Hepatic cirrhosis | | | | |
| subjects affected / exposed | 1 / 825 (0.12%) | | | |
| occurrences causally related to treatment / all | 0 / 1 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Hepatic congestion | | | | |

| | | | |
|---|-----------------|--|--|
| subjects affected / exposed | 1 / 825 (0.12%) | | |
| occurrences causally related to treatment / all | 0 / 1 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Hepatic failure | | | |
| subjects affected / exposed | 0 / 825 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Hydrocholecystis | | | |
| subjects affected / exposed | 0 / 825 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Ischaemic hepatitis | | | |
| subjects affected / exposed | 0 / 825 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Jaundice | | | |
| subjects affected / exposed | 0 / 825 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Pneumobilia | | | |
| subjects affected / exposed | 1 / 825 (0.12%) | | |
| occurrences causally related to treatment / all | 0 / 1 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Skin and subcutaneous tissue disorders | | | |
| Actinic keratosis | | | |
| subjects affected / exposed | 0 / 825 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Angioedema | | | |
| subjects affected / exposed | 0 / 825 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Decubitus ulcer | | | |

| | | | | |
|---|-----------------|--|--|--|
| subjects affected / exposed | 0 / 825 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Diabetic foot | | | | |
| subjects affected / exposed | 5 / 825 (0.61%) | | | |
| occurrences causally related to treatment / all | 0 / 8 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Hyperkeratosis | | | | |
| subjects affected / exposed | 0 / 825 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Pruritus | | | | |
| subjects affected / exposed | 0 / 825 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Psoriasis | | | | |
| subjects affected / exposed | 0 / 825 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Rash papular | | | | |
| subjects affected / exposed | 0 / 825 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Skin necrosis | | | | |
| subjects affected / exposed | 0 / 825 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Skin ulcer | | | | |
| subjects affected / exposed | 1 / 825 (0.12%) | | | |
| occurrences causally related to treatment / all | 0 / 2 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Stevens-Johnson syndrome | | | | |

| | | | |
|---|------------------|--|--|
| subjects affected / exposed | 0 / 825 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Renal and urinary disorders | | | |
| Acute kidney injury | | | |
| subjects affected / exposed | 22 / 825 (2.67%) | | |
| occurrences causally related to treatment / all | 5 / 24 | | |
| deaths causally related to treatment / all | 0 / 2 | | |
| Acute prerenal failure | | | |
| subjects affected / exposed | 0 / 825 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Anuria | | | |
| subjects affected / exposed | 0 / 825 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Azotaemia | | | |
| subjects affected / exposed | 0 / 825 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Bladder trabeculation | | | |
| subjects affected / exposed | 0 / 825 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Calculus ureteric | | | |
| subjects affected / exposed | 1 / 825 (0.12%) | | |
| occurrences causally related to treatment / all | 0 / 1 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Calculus urinary | | | |
| subjects affected / exposed | 1 / 825 (0.12%) | | |
| occurrences causally related to treatment / all | 0 / 1 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Chronic kidney disease | | | |

| | | | | |
|---|-----------------|--|--|--|
| subjects affected / exposed | 5 / 825 (0.61%) | | | |
| occurrences causally related to treatment / all | 0 / 5 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Diabetic end stage renal disease | | | | |
| subjects affected / exposed | 0 / 825 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Dysuria | | | | |
| subjects affected / exposed | 0 / 825 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Glomerulonephritis chronic | | | | |
| subjects affected / exposed | 0 / 825 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Haematuria | | | | |
| subjects affected / exposed | 1 / 825 (0.12%) | | | |
| occurrences causally related to treatment / all | 0 / 1 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Hydronephrosis | | | | |
| subjects affected / exposed | 1 / 825 (0.12%) | | | |
| occurrences causally related to treatment / all | 0 / 1 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Nephrolithiasis | | | | |
| subjects affected / exposed | 3 / 825 (0.36%) | | | |
| occurrences causally related to treatment / all | 0 / 3 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Nephropathy | | | | |
| subjects affected / exposed | 1 / 825 (0.12%) | | | |
| occurrences causally related to treatment / all | 0 / 1 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Nephrotic syndrome | | | | |

| | | | |
|---|-----------------|--|--|
| subjects affected / exposed | 0 / 825 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Proteinuria | | | |
| subjects affected / exposed | 0 / 825 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Renal artery arteriosclerosis | | | |
| subjects affected / exposed | 0 / 825 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Renal artery stenosis | | | |
| subjects affected / exposed | 0 / 825 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Renal colic | | | |
| subjects affected / exposed | 1 / 825 (0.12%) | | |
| occurrences causally related to treatment / all | 0 / 1 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Renal cyst | | | |
| subjects affected / exposed | 1 / 825 (0.12%) | | |
| occurrences causally related to treatment / all | 0 / 1 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Renal failure | | | |
| subjects affected / exposed | 1 / 825 (0.12%) | | |
| occurrences causally related to treatment / all | 0 / 1 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Renal impairment | | | |
| subjects affected / exposed | 1 / 825 (0.12%) | | |
| occurrences causally related to treatment / all | 0 / 1 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Stag horn calculus | | | |

| | | | |
|---|-----------------|--|--|
| subjects affected / exposed | 0 / 825 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Urethral stenosis | | | |
| subjects affected / exposed | 1 / 825 (0.12%) | | |
| occurrences causally related to treatment / all | 0 / 1 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Urinary bladder polyp | | | |
| subjects affected / exposed | 1 / 825 (0.12%) | | |
| occurrences causally related to treatment / all | 0 / 1 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Urinary incontinence | | | |
| subjects affected / exposed | 0 / 825 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Urinary retention | | | |
| subjects affected / exposed | 0 / 825 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Endocrine disorders | | | |
| Goitre | | | |
| subjects affected / exposed | 2 / 825 (0.24%) | | |
| occurrences causally related to treatment / all | 0 / 2 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Hyperthyroidism | | | |
| subjects affected / exposed | 0 / 825 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Inappropriate antidiuretic hormone secretion | | | |
| subjects affected / exposed | 0 / 825 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Thyroid mass | | | |

| | | | |
|---|-----------------|--|--|
| subjects affected / exposed | 0 / 825 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Musculoskeletal and connective tissue disorders | | | |
| Arthralgia | | | |
| subjects affected / exposed | 1 / 825 (0.12%) | | |
| occurrences causally related to treatment / all | 0 / 1 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Arthritis | | | |
| subjects affected / exposed | 2 / 825 (0.24%) | | |
| occurrences causally related to treatment / all | 0 / 2 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Back pain | | | |
| subjects affected / exposed | 6 / 825 (0.73%) | | |
| occurrences causally related to treatment / all | 0 / 6 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Chondrolysis | | | |
| subjects affected / exposed | 0 / 825 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Costochondritis | | | |
| subjects affected / exposed | 0 / 825 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Diabetic arthropathy | | | |
| subjects affected / exposed | 0 / 825 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Fibromyalgia | | | |
| subjects affected / exposed | 0 / 825 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Flank pain | | | |

| | | | | |
|---|-----------------|--|--|--|
| subjects affected / exposed | 0 / 825 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Foot deformity | | | | |
| subjects affected / exposed | 0 / 825 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Intervertebral disc disorder | | | | |
| subjects affected / exposed | 0 / 825 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Intervertebral disc protrusion | | | | |
| subjects affected / exposed | 0 / 825 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Lumbar spinal stenosis | | | | |
| subjects affected / exposed | 1 / 825 (0.12%) | | | |
| occurrences causally related to treatment / all | 0 / 1 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Mobility decreased | | | | |
| subjects affected / exposed | 1 / 825 (0.12%) | | | |
| occurrences causally related to treatment / all | 0 / 1 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Muscle spasms | | | | |
| subjects affected / exposed | 0 / 825 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Muscular weakness | | | | |
| subjects affected / exposed | 1 / 825 (0.12%) | | | |
| occurrences causally related to treatment / all | 0 / 1 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Musculoskeletal chest pain | | | | |

| | | | | |
|---|------------------|--|--|--|
| subjects affected / exposed | 3 / 825 (0.36%) | | | |
| occurrences causally related to treatment / all | 0 / 3 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Musculoskeletal pain | | | | |
| subjects affected / exposed | 1 / 825 (0.12%) | | | |
| occurrences causally related to treatment / all | 0 / 1 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Neck pain | | | | |
| subjects affected / exposed | 0 / 825 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Osteoarthritis | | | | |
| subjects affected / exposed | 10 / 825 (1.21%) | | | |
| occurrences causally related to treatment / all | 0 / 10 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Osteonecrosis | | | | |
| subjects affected / exposed | 0 / 825 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Pain in extremity | | | | |
| subjects affected / exposed | 0 / 825 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Rheumatoid arthritis | | | | |
| subjects affected / exposed | 0 / 825 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Soft tissue disorder | | | | |
| subjects affected / exposed | 0 / 825 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Spinal column stenosis | | | | |

| | | | |
|---|-----------------|--|--|
| subjects affected / exposed | 0 / 825 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Spinal osteoarthritis | | | |
| subjects affected / exposed | 0 / 825 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Synovial cyst | | | |
| subjects affected / exposed | 0 / 825 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Infections and infestations | | | |
| Abdominal sepsis | | | |
| subjects affected / exposed | 0 / 825 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Abscess | | | |
| subjects affected / exposed | 0 / 825 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Abscess limb | | | |
| subjects affected / exposed | 0 / 825 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Acute hepatitis B | | | |
| subjects affected / exposed | 0 / 825 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Appendicitis | | | |
| subjects affected / exposed | 2 / 825 (0.24%) | | |
| occurrences causally related to treatment / all | 0 / 2 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Aspergilloma | | | |

| | | | | |
|---|-----------------|--|--|--|
| subjects affected / exposed | 0 / 825 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Bacteraemia | | | | |
| subjects affected / exposed | 1 / 825 (0.12%) | | | |
| occurrences causally related to treatment / all | 0 / 1 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Boutonneuse fever | | | | |
| subjects affected / exposed | 0 / 825 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Bronchitis | | | | |
| subjects affected / exposed | 2 / 825 (0.24%) | | | |
| occurrences causally related to treatment / all | 0 / 2 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Bronchitis bacterial | | | | |
| subjects affected / exposed | 0 / 825 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Bronchopneumonia | | | | |
| subjects affected / exposed | 1 / 825 (0.12%) | | | |
| occurrences causally related to treatment / all | 1 / 1 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Campylobacter gastroenteritis | | | | |
| subjects affected / exposed | 0 / 825 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Campylobacter infection | | | | |
| subjects affected / exposed | 0 / 825 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Cellulitis | | | | |

| | | | | |
|---|-----------------|--|--|--|
| subjects affected / exposed | 9 / 825 (1.09%) | | | |
| occurrences causally related to treatment / all | 0 / 10 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Clostridium difficile colitis | | | | |
| subjects affected / exposed | 0 / 825 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Cystitis | | | | |
| subjects affected / exposed | 2 / 825 (0.24%) | | | |
| occurrences causally related to treatment / all | 0 / 2 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Dengue fever | | | | |
| subjects affected / exposed | 0 / 825 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Device related sepsis | | | | |
| subjects affected / exposed | 0 / 825 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Diabetic foot infection | | | | |
| subjects affected / exposed | 1 / 825 (0.12%) | | | |
| occurrences causally related to treatment / all | 0 / 1 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Diverticulitis | | | | |
| subjects affected / exposed | 1 / 825 (0.12%) | | | |
| occurrences causally related to treatment / all | 0 / 1 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Endocarditis | | | | |
| subjects affected / exposed | 0 / 825 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Enteritis infectious | | | | |

| | | | | |
|---|-----------------|--|--|--|
| subjects affected / exposed | 0 / 825 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Enterococcal infection | | | | |
| subjects affected / exposed | 0 / 825 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Epididymitis | | | | |
| subjects affected / exposed | 1 / 825 (0.12%) | | | |
| occurrences causally related to treatment / all | 0 / 1 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Escherichia infection | | | | |
| subjects affected / exposed | 1 / 825 (0.12%) | | | |
| occurrences causally related to treatment / all | 0 / 1 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Escherichia sepsis | | | | |
| subjects affected / exposed | 0 / 825 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Gangrene | | | | |
| subjects affected / exposed | 2 / 825 (0.24%) | | | |
| occurrences causally related to treatment / all | 0 / 2 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Gastritis viral | | | | |
| subjects affected / exposed | 0 / 825 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Gastroenteritis | | | | |
| subjects affected / exposed | 2 / 825 (0.24%) | | | |
| occurrences causally related to treatment / all | 0 / 2 | | | |
| deaths causally related to treatment / all | 0 / 1 | | | |
| Gastroenteritis rotavirus | | | | |

| | | | |
|---|-----------------|--|--|
| subjects affected / exposed | 0 / 825 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Gastroenteritis salmonella | | | |
| subjects affected / exposed | 0 / 825 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Gastroenteritis viral | | | |
| subjects affected / exposed | 0 / 825 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Groin abscess | | | |
| subjects affected / exposed | 1 / 825 (0.12%) | | |
| occurrences causally related to treatment / all | 0 / 1 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Herpes zoster | | | |
| subjects affected / exposed | 1 / 825 (0.12%) | | |
| occurrences causally related to treatment / all | 0 / 1 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Implant site infection | | | |
| subjects affected / exposed | 0 / 825 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Incision site infection | | | |
| subjects affected / exposed | 0 / 825 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Infected skin ulcer | | | |
| subjects affected / exposed | 0 / 825 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Infectious colitis | | | |

| | | | | |
|---|-----------------|--|--|--|
| subjects affected / exposed | 0 / 825 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Infective exacerbation of chronic obstructive airways disease | | | | |
| subjects affected / exposed | 0 / 825 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Influenza | | | | |
| subjects affected / exposed | 2 / 825 (0.24%) | | | |
| occurrences causally related to treatment / all | 0 / 2 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Labyrinthitis | | | | |
| subjects affected / exposed | 0 / 825 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Laryngitis | | | | |
| subjects affected / exposed | 1 / 825 (0.12%) | | | |
| occurrences causally related to treatment / all | 0 / 1 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Liver abscess | | | | |
| subjects affected / exposed | 0 / 825 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Lobar pneumonia | | | | |
| subjects affected / exposed | 0 / 825 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Localised infection | | | | |
| subjects affected / exposed | 1 / 825 (0.12%) | | | |
| occurrences causally related to treatment / all | 0 / 2 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Lower respiratory tract infection | | | | |

| | | | | |
|---|-----------------|--|--|--|
| subjects affected / exposed | 1 / 825 (0.12%) | | | |
| occurrences causally related to treatment / all | 0 / 1 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Meningitis bacterial | | | | |
| subjects affected / exposed | 0 / 825 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Necrotising fasciitis | | | | |
| subjects affected / exposed | 0 / 825 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Oesophageal candidiasis | | | | |
| subjects affected / exposed | 0 / 825 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Osteomyelitis | | | | |
| subjects affected / exposed | 3 / 825 (0.36%) | | | |
| occurrences causally related to treatment / all | 0 / 3 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Otitis externa | | | | |
| subjects affected / exposed | 0 / 825 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Paronychia | | | | |
| subjects affected / exposed | 0 / 825 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Perirectal abscess | | | | |
| subjects affected / exposed | 0 / 825 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Peritonitis | | | | |

| | | | | |
|---|------------------|--|--|--|
| subjects affected / exposed | 1 / 825 (0.12%) | | | |
| occurrences causally related to treatment / all | 0 / 1 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Peritonsillar abscess | | | | |
| subjects affected / exposed | 1 / 825 (0.12%) | | | |
| occurrences causally related to treatment / all | 0 / 1 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Periumbilical abscess | | | | |
| subjects affected / exposed | 1 / 825 (0.12%) | | | |
| occurrences causally related to treatment / all | 0 / 1 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Pharyngitis | | | | |
| subjects affected / exposed | 0 / 825 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Pneumonia | | | | |
| subjects affected / exposed | 14 / 825 (1.70%) | | | |
| occurrences causally related to treatment / all | 0 / 14 | | | |
| deaths causally related to treatment / all | 0 / 1 | | | |
| Pneumonia pneumococcal | | | | |
| subjects affected / exposed | 0 / 825 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Pneumonia respiratory syncytial viral | | | | |
| subjects affected / exposed | 0 / 825 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Post procedural infection | | | | |
| subjects affected / exposed | 1 / 825 (0.12%) | | | |
| occurrences causally related to treatment / all | 0 / 1 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Post procedural pneumonia | | | | |

| | | | |
|---|-----------------|--|--|
| subjects affected / exposed | 0 / 825 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Postoperative wound infection | | | |
| subjects affected / exposed | 2 / 825 (0.24%) | | |
| occurrences causally related to treatment / all | 0 / 2 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Pseudomembranous colitis | | | |
| subjects affected / exposed | 0 / 825 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Pulmonary sepsis | | | |
| subjects affected / exposed | 0 / 825 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Pyelonephritis | | | |
| subjects affected / exposed | 1 / 825 (0.12%) | | |
| occurrences causally related to treatment / all | 0 / 1 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Pyelonephritis acute | | | |
| subjects affected / exposed | 1 / 825 (0.12%) | | |
| occurrences causally related to treatment / all | 0 / 1 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Pyelonephritis chronic | | | |
| subjects affected / exposed | 1 / 825 (0.12%) | | |
| occurrences causally related to treatment / all | 0 / 1 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Respiratory tract infection | | | |
| subjects affected / exposed | 0 / 825 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Respiratory tract infection viral | | | |

| | | | |
|---|-----------------|--|--|
| subjects affected / exposed | 0 / 825 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Sepsis | | | |
| subjects affected / exposed | 7 / 825 (0.85%) | | |
| occurrences causally related to treatment / all | 0 / 7 | | |
| deaths causally related to treatment / all | 0 / 1 | | |
| Septic encephalopathy | | | |
| subjects affected / exposed | 0 / 825 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Septic shock | | | |
| subjects affected / exposed | 3 / 825 (0.36%) | | |
| occurrences causally related to treatment / all | 0 / 3 | | |
| deaths causally related to treatment / all | 0 / 3 | | |
| Sinusitis | | | |
| subjects affected / exposed | 1 / 825 (0.12%) | | |
| occurrences causally related to treatment / all | 0 / 2 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Soft tissue infection | | | |
| subjects affected / exposed | 1 / 825 (0.12%) | | |
| occurrences causally related to treatment / all | 0 / 1 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Splenic abscess | | | |
| subjects affected / exposed | 1 / 825 (0.12%) | | |
| occurrences causally related to treatment / all | 0 / 1 | | |
| deaths causally related to treatment / all | 0 / 1 | | |
| Staphylococcal bacteraemia | | | |
| subjects affected / exposed | 0 / 825 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Staphylococcal infection | | | |

| | | | |
|---|-----------------|--|--|
| subjects affected / exposed | 0 / 825 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Staphylococcal osteomyelitis | | | |
| subjects affected / exposed | 0 / 825 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Staphylococcal sepsis | | | |
| subjects affected / exposed | 1 / 825 (0.12%) | | |
| occurrences causally related to treatment / all | 0 / 1 | | |
| deaths causally related to treatment / all | 0 / 1 | | |
| Subcutaneous abscess | | | |
| subjects affected / exposed | 0 / 825 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Tooth abscess | | | |
| subjects affected / exposed | 0 / 825 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Tuberculosis | | | |
| subjects affected / exposed | 1 / 825 (0.12%) | | |
| occurrences causally related to treatment / all | 0 / 1 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Upper respiratory tract infection | | | |
| subjects affected / exposed | 0 / 825 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Urinary tract infection | | | |
| subjects affected / exposed | 6 / 825 (0.73%) | | |
| occurrences causally related to treatment / all | 0 / 6 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Urinary tract infection pseudomonal | | | |

| | | | |
|---|-----------------|--|--|
| subjects affected / exposed | 0 / 825 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Urinary tract infection staphylococcal | | | |
| subjects affected / exposed | 1 / 825 (0.12%) | | |
| occurrences causally related to treatment / all | 0 / 1 | | |
| deaths causally related to treatment / all | 0 / 1 | | |
| Urosepsis | | | |
| subjects affected / exposed | 1 / 825 (0.12%) | | |
| occurrences causally related to treatment / all | 0 / 1 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Vestibular neuronitis | | | |
| subjects affected / exposed | 0 / 825 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Viral infection | | | |
| subjects affected / exposed | 0 / 825 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Wound infection bacterial | | | |
| subjects affected / exposed | 0 / 825 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Metabolism and nutrition disorders | | | |
| Acidosis | | | |
| subjects affected / exposed | 0 / 825 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Dehydration | | | |
| subjects affected / exposed | 0 / 825 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Diabetes mellitus | | | |

| | | | |
|---|-----------------|--|--|
| subjects affected / exposed | 0 / 825 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Diabetes mellitus inadequate control | | | |
| subjects affected / exposed | 4 / 825 (0.48%) | | |
| occurrences causally related to treatment / all | 0 / 5 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Diabetic ketoacidosis | | | |
| subjects affected / exposed | 1 / 825 (0.12%) | | |
| occurrences causally related to treatment / all | 0 / 1 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Electrolyte imbalance | | | |
| subjects affected / exposed | 0 / 825 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Failure to thrive | | | |
| subjects affected / exposed | 1 / 825 (0.12%) | | |
| occurrences causally related to treatment / all | 0 / 1 | | |
| deaths causally related to treatment / all | 0 / 1 | | |
| Fluid overload | | | |
| subjects affected / exposed | 0 / 825 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Gout | | | |
| subjects affected / exposed | 2 / 825 (0.24%) | | |
| occurrences causally related to treatment / all | 0 / 2 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Hyperglycaemia | | | |
| subjects affected / exposed | 4 / 825 (0.48%) | | |
| occurrences causally related to treatment / all | 0 / 4 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Hyperkalaemia | | | |

| | | | | |
|---|-----------------|--|--|--|
| subjects affected / exposed | 1 / 825 (0.12%) | | | |
| occurrences causally related to treatment / all | 0 / 1 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Hypocalcaemia | | | | |
| subjects affected / exposed | 0 / 825 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Hypoglycaemia | | | | |
| subjects affected / exposed | 6 / 825 (0.73%) | | | |
| occurrences causally related to treatment / all | 4 / 6 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Hypokalaemia | | | | |
| subjects affected / exposed | 1 / 825 (0.12%) | | | |
| occurrences causally related to treatment / all | 0 / 1 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Hypomagnesaemia | | | | |
| subjects affected / exposed | 0 / 825 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Hyponatraemia | | | | |
| subjects affected / exposed | 0 / 825 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Hypovolaemia | | | | |
| subjects affected / exposed | 0 / 825 (0.00%) | | | |
| occurrences causally related to treatment / all | 0 / 0 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Lactic acidosis | | | | |
| subjects affected / exposed | 1 / 825 (0.12%) | | | |
| occurrences causally related to treatment / all | 1 / 1 | | | |
| deaths causally related to treatment / all | 0 / 0 | | | |
| Metabolic acidosis | | | | |

| | | | |
|---|-----------------|--|--|
| subjects affected / exposed | 1 / 825 (0.12%) | | |
| occurrences causally related to treatment / all | 0 / 1 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Metabolic disorder | | | |
| subjects affected / exposed | 0 / 825 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Obesity | | | |
| subjects affected / exposed | 1 / 825 (0.12%) | | |
| occurrences causally related to treatment / all | 0 / 1 | | |
| deaths causally related to treatment / all | 0 / 0 | | |

Frequency threshold for reporting non-serious adverse events: 5 %

| Non-serious adverse events | Sema 0.5 mg | Sema 1.0 mg | Placebo 0.5 mg |
|---|--------------------|--------------------|--------------------|
| Total subjects affected by non-serious adverse events | | | |
| subjects affected / exposed | 573 / 826 (69.37%) | 587 / 822 (71.41%) | 547 / 824 (66.38%) |
| Investigations | | | |
| Amylase increased | | | |
| subjects affected / exposed | 31 / 826 (3.75%) | 48 / 822 (5.84%) | 28 / 824 (3.40%) |
| occurrences (all) | 39 | 57 | 33 |
| Lipase increased | | | |
| subjects affected / exposed | 94 / 826 (11.38%) | 90 / 822 (10.95%) | 66 / 824 (8.01%) |
| occurrences (all) | 121 | 123 | 76 |
| Nervous system disorders | | | |
| Dizziness | | | |
| subjects affected / exposed | 53 / 826 (6.42%) | 46 / 822 (5.60%) | 38 / 824 (4.61%) |
| occurrences (all) | 57 | 54 | 53 |
| Headache | | | |
| subjects affected / exposed | 54 / 826 (6.54%) | 58 / 822 (7.06%) | 67 / 824 (8.13%) |
| occurrences (all) | 77 | 89 | 114 |
| Blood and lymphatic system disorders | | | |
| Anaemia | | | |
| subjects affected / exposed | 41 / 826 (4.96%) | 33 / 822 (4.01%) | 44 / 824 (5.34%) |
| occurrences (all) | 46 | 34 | 46 |
| General disorders and administration | | | |

| | | | |
|---|--------------------|--------------------|-------------------|
| site conditions | | | |
| Fatigue | | | |
| subjects affected / exposed | 24 / 826 (2.91%) | 42 / 822 (5.11%) | 15 / 824 (1.82%) |
| occurrences (all) | 27 | 48 | 16 |
| Eye disorders | | | |
| Cataract | | | |
| subjects affected / exposed | 55 / 826 (6.66%) | 43 / 822 (5.23%) | 37 / 824 (4.49%) |
| occurrences (all) | 59 | 48 | 38 |
| Diabetic retinopathy | | | |
| subjects affected / exposed | 46 / 826 (5.57%) | 56 / 822 (6.81%) | 39 / 824 (4.73%) |
| occurrences (all) | 50 | 63 | 39 |
| Gastrointestinal disorders | | | |
| Abdominal pain | | | |
| subjects affected / exposed | 45 / 826 (5.45%) | 35 / 822 (4.26%) | 33 / 824 (4.00%) |
| occurrences (all) | 54 | 40 | 37 |
| Abdominal pain upper | | | |
| subjects affected / exposed | 35 / 826 (4.24%) | 42 / 822 (5.11%) | 19 / 824 (2.31%) |
| occurrences (all) | 37 | 53 | 22 |
| Constipation | | | |
| subjects affected / exposed | 46 / 826 (5.57%) | 79 / 822 (9.61%) | 37 / 824 (4.49%) |
| occurrences (all) | 52 | 97 | 42 |
| Diarrhoea | | | |
| subjects affected / exposed | 148 / 826 (17.92%) | 148 / 822 (18.00%) | 97 / 824 (11.77%) |
| occurrences (all) | 277 | 245 | 159 |
| Dyspepsia | | | |
| subjects affected / exposed | 51 / 826 (6.17%) | 63 / 822 (7.66%) | 23 / 824 (2.79%) |
| occurrences (all) | 68 | 88 | 25 |
| Nausea | | | |
| subjects affected / exposed | 143 / 826 (17.31%) | 179 / 822 (21.78%) | 62 / 824 (7.52%) |
| occurrences (all) | 233 | 282 | 78 |
| Vomiting | | | |
| subjects affected / exposed | 87 / 826 (10.53%) | 122 / 822 (14.84%) | 42 / 824 (5.10%) |
| occurrences (all) | 128 | 170 | 51 |
| Respiratory, thoracic and mediastinal disorders | | | |
| Cough | | | |

| | | | |
|---|-------------------------|------------------------|------------------------|
| subjects affected / exposed occurrences (all) | 36 / 826 (4.36%) 41 | 32 / 822 (3.89%) 33 | 40 / 824 (4.85%) 41 |
| Renal and urinary disorders Microalbuminuria subjects affected / exposed occurrences (all) | 27 / 826 (3.27%) 30 | 33 / 822 (4.01%) 35 | 46 / 824 (5.58%) 51 |
| Musculoskeletal and connective tissue disorders Arthralgia subjects affected / exposed occurrences (all) | 41 / 826 (4.96%) 45 | 35 / 822 (4.26%) 40 | 57 / 824 (6.92%) 69 |
| Back pain subjects affected / exposed occurrences (all) | 54 / 826 (6.54%) 54 | 49 / 822 (5.96%) 58 | 49 / 824 (5.95%) 59 |
| Pain in extremity subjects affected / exposed occurrences (all) | 38 / 826 (4.60%) 42 | 29 / 822 (3.53%) 31 | 46 / 824 (5.58%) 51 |
| Infections and infestations Bronchitis subjects affected / exposed occurrences (all) | 46 / 826 (5.57%) 52 | 38 / 822 (4.62%) 43 | 49 / 824 (5.95%) 52 |
| Influenza subjects affected / exposed occurrences (all) | 51 / 826 (6.17%) 60 | 48 / 822 (5.84%) 56 | 48 / 824 (5.83%) 57 |
| Nasopharyngitis subjects affected / exposed occurrences (all) | 66 / 826 (7.99%) 91 | 60 / 822 (7.30%) 77 | 78 / 824 (9.47%) 99 |
| Upper respiratory tract infection subjects affected / exposed occurrences (all) | 53 / 826 (6.42%) 59 | 51 / 822 (6.20%) 64 | 63 / 824 (7.65%) 75 |
| Urinary tract infection subjects affected / exposed occurrences (all) | 78 / 826 (9.44%) 108 | 71 / 822 (8.64%) 93 | 64 / 824 (7.77%) 97 |
| Metabolism and nutrition disorders Decreased appetite subjects affected / exposed occurrences (all) | 86 / 826 (10.41%) 97 | 75 / 822 (9.12%) 88 | 19 / 824 (2.31%) 21 |

| | | | |
|---|--------------------|--|--|
| Non-serious adverse events | Placebo 1.0 mg | | |
| Total subjects affected by non-serious adverse events | | | |
| subjects affected / exposed | 524 / 825 (63.52%) | | |
| Investigations | | | |
| Amylase increased | | | |
| subjects affected / exposed | 28 / 825 (3.39%) | | |
| occurrences (all) | 33 | | |
| Lipase increased | | | |
| subjects affected / exposed | 69 / 825 (8.36%) | | |
| occurrences (all) | 83 | | |
| Nervous system disorders | | | |
| Dizziness | | | |
| subjects affected / exposed | 38 / 825 (4.61%) | | |
| occurrences (all) | 45 | | |
| Headache | | | |
| subjects affected / exposed | 74 / 825 (8.97%) | | |
| occurrences (all) | 110 | | |
| Blood and lymphatic system disorders | | | |
| Anaemia | | | |
| subjects affected / exposed | 48 / 825 (5.82%) | | |
| occurrences (all) | 55 | | |
| General disorders and administration site conditions | | | |
| Fatigue | | | |
| subjects affected / exposed | 26 / 825 (3.15%) | | |
| occurrences (all) | 28 | | |
| Eye disorders | | | |
| Cataract | | | |
| subjects affected / exposed | 45 / 825 (5.45%) | | |
| occurrences (all) | 46 | | |
| Diabetic retinopathy | | | |
| subjects affected / exposed | 38 / 825 (4.61%) | | |
| occurrences (all) | 43 | | |
| Gastrointestinal disorders | | | |
| Abdominal pain | | | |
| subjects affected / exposed | 31 / 825 (3.76%) | | |
| occurrences (all) | 36 | | |
| Abdominal pain upper | | | |

| | | | |
|---|-------------------|--|--|
| subjects affected / exposed | 19 / 825 (2.30%) | | |
| occurrences (all) | 33 | | |
| Constipation | | | |
| subjects affected / exposed | 36 / 825 (4.36%) | | |
| occurrences (all) | 38 | | |
| Diarrhoea | | | |
| subjects affected / exposed | 87 / 825 (10.55%) | | |
| occurrences (all) | 112 | | |
| Dyspepsia | | | |
| subjects affected / exposed | 18 / 825 (2.18%) | | |
| occurrences (all) | 19 | | |
| Nausea | | | |
| subjects affected / exposed | 66 / 825 (8.00%) | | |
| occurrences (all) | 94 | | |
| Vomiting | | | |
| subjects affected / exposed | 33 / 825 (4.00%) | | |
| occurrences (all) | 41 | | |
| Respiratory, thoracic and mediastinal disorders | | | |
| Cough | | | |
| subjects affected / exposed | 46 / 825 (5.58%) | | |
| occurrences (all) | 48 | | |
| Renal and urinary disorders | | | |
| Microalbuminuria | | | |
| subjects affected / exposed | 42 / 825 (5.09%) | | |
| occurrences (all) | 45 | | |
| Musculoskeletal and connective tissue disorders | | | |
| Arthralgia | | | |
| subjects affected / exposed | 58 / 825 (7.03%) | | |
| occurrences (all) | 70 | | |
| Back pain | | | |
| subjects affected / exposed | 48 / 825 (5.82%) | | |
| occurrences (all) | 50 | | |
| Pain in extremity | | | |
| subjects affected / exposed | 42 / 825 (5.09%) | | |
| occurrences (all) | 45 | | |
| Infections and infestations | | | |

| | | | |
|------------------------------------|------------------|--|--|
| Bronchitis | | | |
| subjects affected / exposed | 51 / 825 (6.18%) | | |
| occurrences (all) | 64 | | |
| Influenza | | | |
| subjects affected / exposed | 46 / 825 (5.58%) | | |
| occurrences (all) | 63 | | |
| Nasopharyngitis | | | |
| subjects affected / exposed | 66 / 825 (8.00%) | | |
| occurrences (all) | 84 | | |
| Upper respiratory tract infection | | | |
| subjects affected / exposed | 65 / 825 (7.88%) | | |
| occurrences (all) | 88 | | |
| Urinary tract infection | | | |
| subjects affected / exposed | 68 / 825 (8.24%) | | |
| occurrences (all) | 87 | | |
| Metabolism and nutrition disorders | | | |
| Decreased appetite | | | |
| subjects affected / exposed | 9 / 825 (1.09%) | | |
| occurrences (all) | 10 | | |

More information

Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

| Date | Amendment |
|--------------|---|
| 29 May 2013 | To accommodate a request from FDA and changes in FDA requirements to the primary objective, the statistical section and other relevant sections were updated accordingly. Additional minor updates were made. |
| 18 June 2014 | The definition of hypoglycaemia was updated including related endpoints, associated statistical analysis and how to report. Additional minor updates for clarification. |

Notes:

Interruptions (globally)

Were there any global interruptions to the trial? No

Limitations and caveats

None reported

Online references

<http://www.ncbi.nlm.nih.gov/pubmed/27633186>